BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1822] [Article Influence: 395.6] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Hu X, Chang J, Chen J, Han X, Zhang T, Shen J, Shang N, Han J, Wang H, Kang W, Meng F. The liver steatosis severity and lipid characteristics in primary biliary cholangitis. BMC Gastroenterol 2021;21:395. [PMID: 34686147 DOI: 10.1186/s12876-021-01974-4] [Reference Citation Analysis]
2 Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-24. [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
3 Zhou H, Luo P, Li P, Wang G, Yi X, Fu Z, Sun X, Cui B, Zhu L, Zhu S. Bariatric Surgery Improves Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Obes Surg 2022. [PMID: 35386040 DOI: 10.1007/s11695-022-06011-1] [Reference Citation Analysis]
4 Yoo ER, Kim D, Vazquez‐montesino LM, Escober JA, Li AA, Tighe SP, Fernandes CT, Cholankeril G, Ahmed A. Diet quality and its association with nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality. Liver Int 2020;40:815-24. [DOI: 10.1111/liv.14374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Gibson PS, Quaglia A, Dhawan A, Wu H, Lanham-New S, Hart KH, Fitzpatrick E, Moore JB. Vitamin D status and associated genetic polymorphisms in a cohort of UK children with non-alcoholic fatty liver disease. Pediatr Obes 2018;13:433-41. [PMID: 29761652 DOI: 10.1111/ijpo.12293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
6 Lu Y, Shao M, Xiang H, Wang J, Ji G, Wu T. Qinggan Huoxue Recipe Alleviates Alcoholic Liver Injury by Suppressing Endoplasmic Reticulum Stress Through LXR-LPCAT3. Front Pharmacol 2022;13:824185. [DOI: 10.3389/fphar.2022.824185] [Reference Citation Analysis]
7 Santos-Baez LS, Ginsberg HN. Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. Curr Opin Lipidol 2021;32:200-6. [PMID: 33883445 DOI: 10.1097/MOL.0000000000000756] [Reference Citation Analysis]
8 Neuschwander-Tetri BA. Therapeutic Landscape for NAFLD in 2020. Gastroenterology 2020;158:1984-1998.e3. [PMID: 32061596 DOI: 10.1053/j.gastro.2020.01.051] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
9 Smith AD, Porter KK, Elkassem AA, Sanyal R, Lockhart ME. Current Imaging Techniques for Noninvasive Staging of Hepatic Fibrosis. American Journal of Roentgenology 2019;213:77-89. [DOI: 10.2214/ajr.19.21144] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
10 Noureddin M, Zelber-Sagi S, Wilkens LR, Porcel J, Boushey CJ, Le Marchand L, Rosen HR, Setiawan VW. Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse Population: The Multiethnic Cohort. Hepatology 2020;71:1940-52. [PMID: 31553803 DOI: 10.1002/hep.30967] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
11 Goldoni MB, Fontes PRO, GuimarÃes MM, Diedrich-Neto JA, Nogueira T, Teixeira UF, Giacomazzi CB, Kiss G, Pioner SR, Rodrigues PD. BYPASS VS. SLEEVE AND ITS EFFECTS IN NON-ALCOHOLIC FATTY LIVER DISEASE: WHAT IS THE BEST TECHNIQUE? Arq Bras Cir Dig 2021;33:e1549. [PMID: 33470379 DOI: 10.1590/0102-672020200003e1549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wen X, Zhou X, Chen D, Cheng J, Ji L. Association between non-alcoholic fatty liver disease and diabetes-related microvascular complications: A retrospective cross-sectional study of hospitalized patients. Endocr Pract 2021:S1530-891X(21)00046-X. [PMID: 33601024 DOI: 10.1016/j.eprac.2021.02.004] [Reference Citation Analysis]
13 Yoon JS, Lee HY, Chung SW, Kim SW, Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim H, Yoon JH, Kim YJ. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1960-8. [PMID: 32128882 DOI: 10.1111/jgh.15026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Liu W, Zheng KI, Pan X, Ma H, Zhu P, Wu X, Rios RS, Targher G, Byrne CD, Wang X, Chen Y, Zheng M. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2020;35:1057-64. [DOI: 10.1111/jgh.14894] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
15 Dharmalingam M, Yamasandhi PG. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J Endocrinol Metab. 2018;22:421-428. [PMID: 30090738 DOI: 10.4103/ijem.ijem_585_17] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
16 Yanavich C, Pacheco AG, Cardoso SW, Nunes EP, Chaves U, Freitas G, Santos R, Morata M, Veloso VG, Grinsztejn B, Perazzo H. Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV. HIV Med 2021;22:445-56. [PMID: 33529485 DOI: 10.1111/hiv.13060] [Reference Citation Analysis]
17 Pan M, Deng Y, Zheng C, Nie H, Tang K, Zhang Y, Yang Q. Chinese Herbal Medicine Formula Shenling Baizhu San Ameliorates High-Fat Diet-Induced NAFLD in Rats by Modulating Hepatic MicroRNA Expression Profiles. Evid Based Complement Alternat Med 2019;2019:8479680. [PMID: 31915454 DOI: 10.1155/2019/8479680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Reig M, Gambato M, Man NK, Roberts JP, Victor D, Orci LA, Toso C. Should Patients With NAFLD/NASH Be Surveyed for HCC? Transplantation 2019;103:39-44. [DOI: 10.1097/tp.0000000000002361] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 8.7] [Reference Citation Analysis]
19 Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52. [PMID: 33270482 DOI: 10.1080/17474124.2021.1860019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
20 Åberg F, Färkkilä M, Männistö V. Interaction Between Alcohol Use and Metabolic Risk Factors for Liver Disease: A Critical Review of Epidemiological Studies. Alcohol Clin Exp Res 2020;44:384-403. [DOI: 10.1111/acer.14271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
21 Germani G, Laryea M, Rubbia-Brandt L, Egawa H, Burra P, OʼGrady J, Watt KD. Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. Transplantation 2019;103:57-67. [PMID: 30335694 DOI: 10.1097/TP.0000000000002485] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 7.7] [Reference Citation Analysis]
22 Armstrong MJ, Marchesini G. Referral pathways for NAFLD fibrosis in primary care - No longer a 'needle in a haystack'. J Hepatol 2019;71:246-8. [PMID: 31229270 DOI: 10.1016/j.jhep.2019.05.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
23 Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications 2021;:108101. [PMID: 34922811 DOI: 10.1016/j.jdiacomp.2021.108101] [Reference Citation Analysis]
24 Yoshio S, Kanto T. Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. Immunol Med 2021;44:175-86. [PMID: 33444517 DOI: 10.1080/25785826.2020.1868664] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, Brosnan MJ, Böcskei Z, Anstee QM, Bossuyt PM, Zafarmand MH, Pavlides M, Levick C, Duffin K, Hyde C, Bauer T, Bedossa P, Leeming D, Daly A, Hanf R, Ortiz P, Oresic M, Schuppan D, Hanauer G, Chen Y, Shumbayawonda E, Bjerring PN, Zwinderman K. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology 2020;73:252-62. [DOI: 10.1016/j.jhep.2020.03.036] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 16.0] [Reference Citation Analysis]
26 Zhao M, Song C, Luo T, Huang T, Lin S. Fatty Liver Disease Prediction Model Based on Big Data of Electronic Physical Examination Records. Front Public Health 2021;9:668351. [PMID: 33912534 DOI: 10.3389/fpubh.2021.668351] [Reference Citation Analysis]
27 Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39:328-348. [PMID: 29846945 DOI: 10.1002/med.21515] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
28 Schröder B, Kahl S, Roden M. Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity? Liver Int 2021;41 Suppl 1:105-11. [PMID: 34155798 DOI: 10.1111/liv.14846] [Reference Citation Analysis]
29 Zarei A, Stasi C, Mahmoodi M, Masoumi SJ, Zare M, Jalali M. Effect of soy consumption on liver enzymes, lipid profile, anthropometry indices, and oxidative stress in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. Iran J Basic Med Sci 2020;23:1245-50. [PMID: 33149855 DOI: 10.22038/ijbms.2020.46854.10797] [Reference Citation Analysis]
30 Kardashian A, Wilder J, Terrault NA, Price JC. Addressing Social Determinants of Liver Disease During the COVID-19 Pandemic and Beyond: A Call to Action. Hepatology 2021;73:811-20. [PMID: 33150599 DOI: 10.1002/hep.31605] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
31 Chalasani N, Abdelmalek MF, Loomba R, Kowdley KV, McCullough AJ, Dasarathy S, Neuschwander-Tetri BA, Terrault N, Ferguson B, Shringarpure R, Shapiro D, Sanyal AJ. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver Int 2019;39:924-32. [PMID: 30253043 DOI: 10.1111/liv.13974] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
32 Fujii H, Enomoto M, Fukumoto S, Kimura T, Nadatani Y, Takashima S, Hagihara A, Uchida-Kobayashi S, Tamori A, Nishimoto N, Kawada N. Validation of a two-step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis. JGH Open 2021;5:801-8. [PMID: 34263075 DOI: 10.1002/jgh3.12590] [Reference Citation Analysis]
33 El-Aziz RA, Alnaggar ARLR, Mohamed Nabih MI, Ali SM, Khattab H, El-Atty SA. Mac-2 binding protein in non-alcoholic fatty liver disease: Is it a reliable diagnostic biomarker? A pilot study. Clin Exp Hepatol 2020;6:28-34. [PMID: 32166121 DOI: 10.5114/ceh.2020.93053] [Reference Citation Analysis]
34 Rosato V, Masarone M, Aglitti A, Persico M. The diagnostic conundrum in non-alcoholic fatty liver disease. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00018] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Labenz C, Huber Y, Kalliga E, Nagel M, Ruckes C, Straub BK, Galle PR, Wörns MA, Anstee QM, Schuppan D, Schattenberg JM. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther 2018;48:1109-16. [PMID: 30288767 DOI: 10.1111/apt.14976] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 12.0] [Reference Citation Analysis]
36 Kim SH, Park HY, Lee HS, Jung KS, Lee MH, Jhee JH, Kim TH, Lee JE, Kim HJ, Kim BS, Park HC, Lee BK, Choi HY. Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity. Sci Rep 2020;10:1025. [PMID: 31974458 DOI: 10.1038/s41598-020-57894-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
38 Danford CJ, Jiang ZG, Salomaa V, Färkkilä M, Jula A, Männistö S, Lundqvist A, Valsta L, Perola M, Åberg F. Insulin Resistance and Genetic Risk Predict Liver-Related Outcomes and Death in Nonalcoholic Fatty Liver Disease. Hepatol Commun 2019;3:1704-5. [PMID: 31832576 DOI: 10.1002/hep4.1437] [Reference Citation Analysis]
39 Ma J, Nano J, Ding J, Zheng Y, Hennein R, Liu C, Speliotes EK, Huan T, Song C, Mendelson MM, Joehanes R, Long MT, Liang L, Smith JA, Reynolds LM, Ghanbari M, Muka T, van Meurs JBJ, Alferink LJM, Franco OH, Dehghan A, Ratliff S, Zhao W, Bielak L, Kardia SLR, Peyser PA, Ning H, VanWagner LB, Lloyd-Jones DM, Carr JJ, Greenland P, Lichtenstein AH, Hu FB, Liu Y, Hou L, Darwish Murad S, Levy D. A Peripheral Blood DNA Methylation Signature of Hepatic Fat Reveals a Potential Causal Pathway for Nonalcoholic Fatty Liver Disease. Diabetes 2019;68:1073-83. [PMID: 30936141 DOI: 10.2337/DB18-1193] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
40 Shetty A, Giron F, Divatia MK, Ahmad MI, Kodali S, Victor D. Nonalcoholic Fatty Liver Disease after Liver Transplant. J Clin Transl Hepatol 2021;9:428-35. [PMID: 34221929 DOI: 10.14218/JCTH.2020.00072] [Reference Citation Analysis]
41 Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JYH, Tan NS. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. Int J Mol Sci. 2019;20. [PMID: 31614690 DOI: 10.3390/ijms20205055] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 15.3] [Reference Citation Analysis]
42 Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. World J Hepatol 2021; 13(11): 1688-1698 [PMID: 34904038 DOI: 10.4254/wjh.v13.i11.1688] [Reference Citation Analysis]
43 Eskridge W, Vierling JM, Gosbee W, Wan GA, Hyunh ML, Chang HE. Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE). PLoS One 2021;16:e0260320. [PMID: 34847156 DOI: 10.1371/journal.pone.0260320] [Reference Citation Analysis]
44 Boursier J, Shreay S, Fabron C, Torreton E, Fraysse J. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database. EClinicalMedicine 2020;25:100445. [PMID: 32775971 DOI: 10.1016/j.eclinm.2020.100445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
45 Haghbin H, Gangwani MK, Ravi SJK, Perisetti A, Aziz M, Goyal H, Nawras A, Sodeman T. Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. Ann Gastroenterol 2020;33:603-14. [PMID: 33162737 DOI: 10.20524/aog.2020.0550] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Neilson LJ, Macdougall L, Lee PS, Hardy T, Beaton D, Chandrapalan S, Ebraheem A, Hussien M, Galbraith S, Looi S, Oxenburgh S, Phaw NA, Taylor W, Haigh L, Hallsworth K, Mansour D, Dyson JK, Masson S, Anstee Q, McPherson S. Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease. Frontline Gastroenterol 2021;12:578-85. [PMID: 34917315 DOI: 10.1136/flgastro-2020-101480] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Herrero-Aguayo V, Sáez-Martínez P, López-Cánovas JL, Prados-Carmona JJ, Alcántara-Laguna MD, López FL, Molina-Puerta MJ, Calañas-Continente A, Membrives A, Castilla J, Ruiz-Ravelo J, Alonso-Echague R, Yubero-Serrano EM, Castaño JP, Gahete MD, Gálvez-Moreno MA, Luque RM, Herrera-Martínez AD. Dysregulation of Components of the Inflammasome Machinery After Bariatric Surgery: Novel Targets for a Chronic Disease. J Clin Endocrinol Metab 2021;106:e4917-34. [PMID: 34363480 DOI: 10.1210/clinem/dgab586] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;. [PMID: 32997882 DOI: 10.1111/liv.14675] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 46.0] [Reference Citation Analysis]
49 Huang X, Chen W, Yan C, Yang R, Chen Q, Xu H, Huang Y. Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression. Biomedicine & Pharmacotherapy 2019;118:109258. [DOI: 10.1016/j.biopha.2019.109258] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
50 Hempel F, Roderfeld M, Müntnich LJ, Albrecht J, Oruc Z, Arneth B, Karrasch T, Pons-Kühnemann J, Padberg W, Renz H, Schäffler A, Roeb E. Caspase-Cleaved Keratin 18 Measurements Identified Ongoing Liver Injury after Bariatric Surgery. J Clin Med 2021;10:1233. [PMID: 33809676 DOI: 10.3390/jcm10061233] [Reference Citation Analysis]
51 Charles-messance H, Mitchelson KA, De Marco Castro E, Sheedy FJ, Roche HM. Regulating metabolic inflammation by nutritional modulation. Journal of Allergy and Clinical Immunology 2020;146:706-20. [DOI: 10.1016/j.jaci.2020.08.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
52 Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021;54:1013-25. [PMID: 34416040 DOI: 10.1111/apt.16575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Morgan A, Hartmanis S, Tsochatzis E, Newsome PN, Ryder SD, Elliott R, Floros L, Hall R, Higgins V, Stanley G, Cure S, Vasudevan S, Pezzullo L. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. Eur J Health Econ 2021;22:505-18. [PMID: 33751289 DOI: 10.1007/s10198-020-01256-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Miralles-Pérez B, Méndez L, Nogués MR, Sánchez-Martos V, Fortuño-Mar À, Ramos-Romero S, Hereu M, Medina I, Romeu M. Effects of a Fish Oil Rich in Docosahexaenoic Acid on Cardiometabolic Risk Factors and Oxidative Stress in Healthy Rats. Mar Drugs 2021;19:555. [PMID: 34677454 DOI: 10.3390/md19100555] [Reference Citation Analysis]
55 Yoo JJ, Lim YS, Kim MS, Lee B, Kim BY, Kim Z, Lee JE, Lee MH, Kim SG, Kim YS. Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer. PLoS One 2020;15:e0236506. [PMID: 32730287 DOI: 10.1371/journal.pone.0236506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Bonomini F, Borsani E, Favero G, Rodella LF, Rezzani R. Dietary Melatonin Supplementation Could Be a Promising Preventing/Therapeutic Approach for a Variety of Liver Diseases. Nutrients 2018;10:E1135. [PMID: 30134592 DOI: 10.3390/nu10091135] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
57 Gim JA, Bang SM, Lee YS, Lee Y, Yim SY, Jung YK, Kim H, Kim BH, Kim JH, Seo YS, Yim HJ, Yeon JE, Um SH, Byun KS. Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression. PLoS One 2021;16:e0255822. [PMID: 34358264 DOI: 10.1371/journal.pone.0255822] [Reference Citation Analysis]
58 Ozturk A, Grajo JR, Gee MS, Benjamin A, Zubajlo RE, Thomenius KE, Anthony BW, Samir AE, Dhyani M. Quantitative Hepatic Fat Quantification in Non-alcoholic Fatty Liver Disease Using Ultrasound-Based Techniques: A Review of Literature and Their Diagnostic Performance. Ultrasound Med Biol 2018;44:2461-75. [PMID: 30232020 DOI: 10.1016/j.ultrasmedbio.2018.07.019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
59 Wang J, Ye C, Fei S. Association between APOC3 polymorphisms and non-alcoholic fatty liver disease risk: a meta-analysis. Afr Health Sci 2020;20:1800-8. [PMID: 34394242 DOI: 10.4314/ahs.v20i4.34] [Reference Citation Analysis]
60 Lisboa QC, Nardelli MJ, Pereira PA, Miranda DM, Ribeiro SN, Costa RSN, Versiani CA, Vidigal PVT, Ferrari TCA, Couto CA. PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. World J Hepatol 2020; 12(10): 792-806 [PMID: 33200017 DOI: 10.4254/wjh.v12.i10.792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
61 Hupfeld S, Pischel D, Jechorek D, Janicová A, Pech M, Fischbach F. MRI-based fat quantification of the liver: Is it time for commercially available products? Eur J Radiol 2021;144:109993. [PMID: 34656047 DOI: 10.1016/j.ejrad.2021.109993] [Reference Citation Analysis]
62 Kasia C, Scaglione SJ. Patients With Chronic Liver Disease/Cirrhosis Should Not Take Statin Medications. Clin Liver Dis (Hoboken). 2019;13:106-110. [PMID: 31061703 DOI: 10.1002/cld.788] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
63 Tawfiq RA, Nassar NN, Hammam OA, Allam RM, Elmazar MM, Abdallah DM, Attia YM. Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4/TGF-β1 axis. Chemico-Biological Interactions 2022. [DOI: 10.1016/j.cbi.2022.109953] [Reference Citation Analysis]
64 Asai A, Yasuoka H, Matsui M, Okamoto N, Fukunishi S, Higuchi K. Exacerbation of liver dysfunction in non-alcoholic steatohepatitis patients during the coronavirus disease 2019 (COVID-19) pandemic. J Clin Biochem Nutr 2021;68:243-5. [PMID: 34025027 DOI: 10.3164/jcbn.20-136] [Reference Citation Analysis]
65 Leivas G, Maraschin CK, Blume CA, Telo GH, Trindade MRM, Trindade EN, Diemen VV, Cerski CTS, Schaan BD. Accuracy of ultrasound diagnosis of nonalcoholic fatty liver disease in patients with classes II and III obesity: A pathological image study. Obes Res Clin Pract 2021;15:461-5. [PMID: 34511367 DOI: 10.1016/j.orcp.2021.09.002] [Reference Citation Analysis]
66 Maier S, Wieland A, Cree-Green M, Nadeau K, Sullivan S, Lanaspa MA, Johnson RJ, Jensen T. Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord 2021;22:351-66. [PMID: 33389543 DOI: 10.1007/s11154-020-09621-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP. Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. J Clin Transl Hepatol 2021;9:40-50. [PMID: 33604254 DOI: 10.14218/JCTH.2020.00055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Li X, Wang H. Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. Cell Biosci 2020;10:140. [PMID: 33372630 DOI: 10.1186/s13578-020-00507-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
69 Yoo J, Lee JM, Joo I, Yoon JH. Assessment of liver fibrosis using 2-dimensional shear wave elastography: a prospective study of intra- and inter-observer repeatability and comparison with point shear wave elastography. Ultrasonography. 2020;39:52-59. [PMID: 31623416 DOI: 10.14366/usg.19013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
70 Caussy C, Hsu C, Singh S, Bassirian S, Kolar J, Faulkner C, Sinha N, Bettencourt R, Gara N, Valasek MA, Schnabl B, Richards L, Brenner DA, Hofmann AF, Loomba R. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Aliment Pharmacol Ther 2019;49:183-93. [PMID: 30506692 DOI: 10.1111/apt.15035] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
71 Lam S, Doran S, Yuksel HH, Altay O, Turkez H, Nielsen J, Boren J, Uhlen M, Mardinoglu A. Addressing the heterogeneity in liver diseases using biological networks. Brief Bioinform 2021;22:1751-66. [PMID: 32201876 DOI: 10.1093/bib/bbaa002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
72 Tan EX, Lee JW, Jumat NH, Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Lesmana LA, Zheng KI, Zheng MH, Koh CJ, Ho KY, Goh KL, Wong VW, Dan YY. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism 2021;126:154911. [PMID: 34648769 DOI: 10.1016/j.metabol.2021.154911] [Reference Citation Analysis]
73 Tsochatzis EA, Newsome PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care. Lancet Gastroenterol Hepatol 2018;3:509-17. [PMID: 29893235 DOI: 10.1016/S2468-1253(18)30077-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 22] [Article Influence: 16.7] [Reference Citation Analysis]
74 Suwa K, Yamaguchi T, Yoshida K, Murata M, Ichimura M, Tsuneyama K, Seki T, Okazaki K. Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis. Cancers (Basel) 2020;12:E286. [PMID: 31991602 DOI: 10.3390/cancers12020286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. Clin Diabetes. 2019;37:65-72. [PMID: 30705499 DOI: 10.2337/cd18-0026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
76 Toppo E, Sylvester Darvin S, Esakkimuthu S, Buvanesvaragurunathan K, Ajeesh Krishna T, Antony Caesar S, Stalin A, Balakrishna K, Pandikumar P, Ignacimuthu S, Al-dhabi N. Curative effect of arjunolic acid from Terminalia arjuna in non-alcoholic fatty liver disease models. Biomedicine & Pharmacotherapy 2018;107:979-88. [DOI: 10.1016/j.biopha.2018.08.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
77 Kalogirou M, Sinakos E. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle? World J Hepatol 2018; 10(11): 790-794 [PMID: 30533179 DOI: 10.4254/wjh.v10.i11.790] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
78 Alsaqal S, Hockings P, Ahlström H, Gummesson A, Hedström A, Hulthe J, Johansson L, Niessen HG, Schoelch C, Schultheis C, Vessby J, Wanders A, Rorsman F, Ebeling Barbier C. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis. J Magn Reson Imaging 2021. [PMID: 34953171 DOI: 10.1002/jmri.28040] [Reference Citation Analysis]
79 Lu FB, Hu ED, Xu LM, Chen L, Wu JL, Li H, Chen DZ, Chen YP. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2018;12:491-502. [PMID: 29609501 DOI: 10.1080/17474124.2018.1460202] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
80 Sarkar S, Tsuchida Y, Diab R, Xu C, Yermalitsky V, Davies SS, Ikizler TA, Hung AM, Kon V, Flynn CR. Pro-inflammatory HDL in women with obesity and nonalcoholic steatohepatitis. Obes Res Clin Pract 2020;14:333-8. [PMID: 32595023 DOI: 10.1016/j.orcp.2020.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Chen YC, Jeng WJ, Hsu CW, Lin CY. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. BMC Gastroenterol 2020;20:146. [PMID: 32397963 DOI: 10.1186/s12876-020-01289-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Zhu M, Chen H, Zhou S, Zheng L, Li X, Chu R, Chen W, Wang B, Wang M, Chai Z, Feng W. Iron oxide nanoparticles aggravate hepatic steatosis and liver injury in nonalcoholic fatty liver disease through BMP-SMAD-mediated hepatic iron overload. Nanotoxicology 2021;15:761-78. [PMID: 33961538 DOI: 10.1080/17435390.2021.1919329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
83 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
84 Kim D, Hanzawa F, Sun S, Laurent T, Ikeda S, Umeki M, Mochizuki S, Oda H. Delayed Meal Timing, a Breakfast Skipping Model, Increased Hepatic Lipid Accumulation and Adipose Tissue Weight by Disintegrating Circadian Oscillation in Rats Fed a High-Cholesterol Diet. Front Nutr 2021;8:681436. [PMID: 34277681 DOI: 10.3389/fnut.2021.681436] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal NH, Lai M. Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD. Hepatol Commun 2021. [PMID: 34970870 DOI: 10.1002/hep4.1841] [Reference Citation Analysis]
86 Schnurr TM, Katz SF, Justesen JM, O'Sullivan JW, Saliba-Gustafsson P, Assimes TL, Carcamo-Orive I, Ahmed A, Ashley EA, Hansen T, Knowles JW. Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD. Hepatol Commun 2022. [PMID: 35293152 DOI: 10.1002/hep4.1932] [Reference Citation Analysis]
87 Zhang S, Gan S, Zhang Q, Liu L, Meng G, Yao Z, Wu H, Gu Y, Wang Y, Zhang T, Wang X, Sun S, Wang X, Zhou M, Jia Q, Song K, Qi L, Niu K. Ultra-processed food consumption and the risk of non-alcoholic fatty liver disease in the Tianjin Chronic Low-grade Systemic Inflammation and Health Cohort Study. Int J Epidemiol 2021:dyab174. [PMID: 34528679 DOI: 10.1093/ije/dyab174] [Reference Citation Analysis]
88 Dakhoul L, Gawrieh S, Jones KR, Ghabril M, McShane C, Orman E, Vilar-Gomez E, Chalasani N, Nephew L. Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden. Hepatol Commun 2019;3:52-62. [PMID: 30619994 DOI: 10.1002/hep4.1277] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
89 Chang TY, Chang SH, Lin YH, Ho WC, Wang CY, Jeng WJ, Wan YL, Tsui PH. Utility of quantitative ultrasound in community screening for hepatic steatosis. Ultrasonics 2021;111:106329. [PMID: 33338730 DOI: 10.1016/j.ultras.2020.106329] [Reference Citation Analysis]
90 Eriksen PL, Thomsen KL, Sørensen M, Vilstrup H, Hvas A. Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease. Thrombosis Research 2022. [DOI: 10.1016/j.thromres.2022.02.023] [Reference Citation Analysis]
91 De A, Keisham A, Mishra S, Mehta M, Verma N, Premkumar M, Taneja S, Das A, Singh V, Duseja A. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis – Validation in an Indian Cohort. Journal of Clinical and Experimental Hepatology 2022;12:440-7. [DOI: 10.1016/j.jceh.2021.06.008] [Reference Citation Analysis]
92 Austin P, Gerber L, Paik JM, Price JK, Escheik C, Younossi ZM. Aerobic capacity and exercise performance in nonalcoholic fatty liver disease. J Sports Med Phys Fitness 2019;59. [DOI: 10.23736/s0022-4707.19.09231-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
93 Pădureanu V, Dop D, Drăgoescu AN, Pădureanu R, Mușetescu AE, Nedelcu L. Non-alcoholic fatty liver disease and hematologic manifestations (Review). Exp Ther Med 2021;22:1355. [PMID: 34659501 DOI: 10.3892/etm.2021.10790] [Reference Citation Analysis]
94 Finer N. Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. Diabetes Obes Metab 2021. [PMID: 34622555 DOI: 10.1111/dom.14569] [Reference Citation Analysis]
95 Sanches JM, Zhao LN, Salehi A, Wollheim CB, Kaldis P. Pathophysiology of type 2 diabetes and the impact of altered metabolic interorgan crosstalk. FEBS J 2021. [PMID: 34847289 DOI: 10.1111/febs.16306] [Reference Citation Analysis]
96 Omokaro SO, Golden JK. The regulatory state of nonalcoholic steatohepatitis and metabolism. Endocrinol Diabetes Metab 2020;3:e00113. [PMID: 33102795 DOI: 10.1002/edm2.113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Sumida Y, Yoneda M, Seko Y, Takahashi H, Hara N, Fujii H, Itoh Y, Yoneda M, Nakajima A, Okanoue T; Japan Study Group of NAFLD (JSG-NAFLD). Role of vitamin E in the treatment of non-alcoholic steatohepatitis. Free Radic Biol Med 2021;177:391-403. [PMID: 34715296 DOI: 10.1016/j.freeradbiomed.2021.10.017] [Reference Citation Analysis]
98 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
99 El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;20:E2215. [PMID: 31064058 DOI: 10.3390/ijms20092215] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
100 Bavaro DF, Laghetti P, Poliseno M, De Gennaro N, Di Gennaro F, Saracino A. A Step Closer to the "Fourth 90": A Practical Narrative Review of Diagnosis and Management of Nutritional Issues of People Living with HIV. Diagnostics (Basel) 2021;11:2047. [PMID: 34829394 DOI: 10.3390/diagnostics11112047] [Reference Citation Analysis]
101 Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM. Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. Hepatol Commun. [DOI: 10.1002/hep4.1765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Xu F, Guo W. The progress of epigenetics in the development and progression of non-alcoholic fatty liver disease. Liver Research 2020;4:118-23. [DOI: 10.1016/j.livres.2020.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Saneian H, Khalilian L, Heidari-Beni M, Khademian M, Famouri F, Nasri P, Hassanzadeh A, Kelishadi R. Effect of l-carnitine supplementation on children and adolescents with nonalcoholic fatty liver disease (NAFLD): a randomized, triple-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab 2021;34:897-904. [PMID: 33939897 DOI: 10.1515/jpem-2020-0642] [Reference Citation Analysis]
104 Moore JB. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. Proc Nutr Soc. 2019;78:290-304. [PMID: 30924429 DOI: 10.1017/s0029665119000570] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
105 Borges-canha M, Neves JS, Mendonça F, Silva MM, Costa C, Cabral PM, Guerreiro V, Lourenço R, Meira P, Salazar D, Ferreira MJ, Pedro J, Leite A, Viana S, Sande A, Belo S, Lau E, Freitas P, Carvalho D; CRIO group. The Impact of Bariatric Surgery on Hepatic Function and Predictors of Liver Steatosis and Fibrosis. OBES SURG 2020;30:2935-41. [DOI: 10.1007/s11695-020-04622-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
106 Brunner KT, Henneberg CJ, Wilechansky RM, Long MT. Nonalcoholic Fatty Liver Disease and Obesity Treatment. Curr Obes Rep 2019;8:220-8. [PMID: 30945129 DOI: 10.1007/s13679-019-00345-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
107 Chen XY, Cai CZ, Yu ML, Feng ZM, Zhang YW, Liu PH, Zeng H, Yu CH. LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway. World J Gastroenterol 2019; 25(45): 6607-6618 [PMID: 31832001 DOI: 10.3748/wjg.v25.i45.6607] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
108 Chartrand DJ, Larose E, Poirier P, Mathieu P, Alméras N, Pibarot P, Lamarche B, Rhéaume C, Després JP. Visceral adiposity and liver fat as mediators of the association between cardiorespiratory fitness and plasma glucose-insulin homeostasis. Am J Physiol Endocrinol Metab 2020;319:E548-56. [PMID: 32715747 DOI: 10.1152/ajpendo.00251.2020] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
109 Dou X, Ding Q, Lai S, Jiang F, Song Q, Zhao X, Fu A, Moustaid-moussa N, Su D, Li S. Salidroside alleviates lipotoxicity-induced cell death through inhibition of TLR4/MAPKs pathway, and independently of AMPK and autophagy in AML-12 mouse hepatocytes. Journal of Functional Foods 2020;65:103691. [DOI: 10.1016/j.jff.2019.103691] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
110 Asai A, Yokohama K, Ohama H, Tsuchimoto Y, Fukunishi S, Higuchi K. Association between Administration of Antithrombotics and Intraperitoneal Hemorrhage in Patients Undergoing Percutaneous Interventions for Liver Diseases. J Clin Med 2021;10:2527. [PMID: 34200283 DOI: 10.3390/jcm10112527] [Reference Citation Analysis]
111 Eguchi A, Iwasa M, Yamada M, Tamai Y, Shigefuku R, Hasegawa H, Hirokawa Y, Hayashi A, Okuno K, Matsushita Y, Nakatsuka T, Enooku K, Sakaguchi K, Kobayashi Y, Yamaguchi T, Watanabe M, Takei Y, Nakagawa H. A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis. Hepatol Commun 2022. [PMID: 35485207 DOI: 10.1002/hep4.1971] [Reference Citation Analysis]
112 Zhang X, Wu M, Liu Z, Yuan H, Wu X, Shi T, Chen X, Zhang T. Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study. BMJ Open 2021;11:e042843. [PMID: 33947727 DOI: 10.1136/bmjopen-2020-042843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Madkhali A, Alalem F, Aljuhani G, Alsharaabi A, Alsaif F, Hassanain M. Preoperative Selection and Optimization for Liver Resection in Colorectal Cancer Liver Metastases. Curr Colorectal Cancer Rep 2018;14:89-97. [DOI: 10.1007/s11888-018-0405-x] [Reference Citation Analysis]
114 Fetzer DT, Rodgers SK, Seow JH, Dawkins AA, Joshi G, Gabriel H, Kamaya A. Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma. Radiol Clin North Am. 2019;57:563-583. [PMID: 30928078 DOI: 10.1016/j.rcl.2019.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
115 Ciardullo S, Bianconi E, Zerbini F, Perseghin G. Current type 2 diabetes, rather than previous gestational diabetes, is associated with liver disease in U.S. Women. Diabetes Res Clin Pract 2021;177:108879. [PMID: 34058299 DOI: 10.1016/j.diabres.2021.108879] [Reference Citation Analysis]
116 Albhaisi S, Sanyal AJ. Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2021;12:665987. [PMID: 34040583 DOI: 10.3389/fendo.2021.665987] [Reference Citation Analysis]
117 Ahn SY, Kim SB, Song IH. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol 2020;2020:4873875. [PMID: 32566546 DOI: 10.1155/2020/4873875] [Reference Citation Analysis]
118 Karamfilova V, Assyov Y, Nedeva I, Gateva A, Ivanova I, Cherkezov N, Mateva L, Kamenov Z. Increased Serum Pentraxin 3 Is Associated with Prediabetes and Type 2 Diabetes in Obese Patients with Nonalcoholic Fatty Liver Disease. Metab Syndr Relat Disord 2021. [PMID: 34818080 DOI: 10.1089/met.2021.0086] [Reference Citation Analysis]
119 Marciano S, Dirchwolf M, Torres MC, Allevato J, García Dans C, García B, Pollarsky F, Gaite L, Sirotinsky E, Rios B, Anselmo MN, Peche M, Hurtado E, Haddad L, Narvaez A, Mauro E, Martinez A, Bellizzi C, Ratusnu N, D Amico C, Arora S, Gadano A. Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them. Rev Gastroenterol Mex (Engl Ed) 2021:S0375-0906(21)00015-X. [PMID: 33773856 DOI: 10.1016/j.rgmx.2020.08.006] [Reference Citation Analysis]
120 Zhang D, Wu S, Lan Y, Chen S, Wang Y, Sun Y, Liao W, Wang L. Blood manganese and nonalcoholic fatty liver disease: A cohort-based case-control study. Chemosphere 2022;287:132316. [PMID: 34592210 DOI: 10.1016/j.chemosphere.2021.132316] [Reference Citation Analysis]
121 Guirguis E, Grace Y, Bolson A, DellaVecchia MJ, Ruble M. Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review. Pharmacotherapy 2021;41:315-28. [PMID: 33278029 DOI: 10.1002/phar.2489] [Reference Citation Analysis]
122 Ma L, Li H, Hu J, Zheng J, Zhou J, Botchlett R, Matthews D, Zeng T, Chen L, Xiao X, Athrey G, Threadgill DW, Li Q, Glaser S, Francis H, Meng F, Li Q, Alpini G, Wu C. Indole Alleviates Diet-Induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3. Hepatology 2020;72:1191-203. [PMID: 31953865 DOI: 10.1002/hep.31115] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
123 Li B, Zhang C, Zhan YT. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastroenterol Hepatol 2018;2018:2784537. [PMID: 30065915 DOI: 10.1155/2018/2784537] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
124 Sugiyama A, Kurisu A, E B, Ouoba S, Ko K, Rakhimov A, Akita T, Harakawa T, Sako T, Koshiyama M, Kumada T, Tanaka J. Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups. BMC Gastroenterol 2022;22:241. [PMID: 35562658 DOI: 10.1186/s12876-022-02290-1] [Reference Citation Analysis]
125 Cusi K. Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes. Hepatology 2019. [DOI: 10.1002/hep.30670] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
126 Coelho FDS, Borges-Canha M, von Hafe M, Neves JS, Vale C, Leite AR, Carvalho D, Leite-Moreira A. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. Diabetes Metab Res Rev 2021;37:e3413. [PMID: 33010191 DOI: 10.1002/dmrr.3413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
127 Federico A, Rosato V, Masarone M, Torre P, Dallio M, Romeo M, Persico M. The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. Nutrients 2021;13:1314. [PMID: 33923525 DOI: 10.3390/nu13041314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 López-Sánchez GN, Dóminguez-Pérez M, Uribe M, Chávez-Tapia NC, Nuño-Lámbarri N. Non-alcoholic fatty liver disease and microRNAs expression, how it affects the development and progression of the disease. Ann Hepatol 2021;21:100212. [PMID: 32533953 DOI: 10.1016/j.aohep.2020.04.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Westerouen Van Meeteren MJ, Drenth JPH, Tjwa ETTL. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs 2020;29:117-23. [PMID: 31523999 DOI: 10.1080/13543784.2020.1668375] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
130 Poul SS, Parker KJ. Fat and fibrosis as confounding cofactors in viscoelastic measurements of the liver. Phys Med Biol 2021;66:045024. [PMID: 33348325 DOI: 10.1088/1361-6560/abd593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
131 Zhang H, Dong M, Liu X. Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat. Exp Ther Med 2021;22:991. [PMID: 34345273 DOI: 10.3892/etm.2021.10423] [Reference Citation Analysis]
132 Kulkarni AV, Tevethia HV, Arab JP, Candia R, Premkumar M, Kumar P, Sharma M, Reddy DN, Padaki NR. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021;45:101675. [PMID: 33722778 DOI: 10.1016/j.clinre.2021.101675] [Reference Citation Analysis]
133 Choudhary NS, Duseja A. Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How? J Clin Exp Hepatol 2019;9:506-14. [PMID: 31516267 DOI: 10.1016/j.jceh.2019.02.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
134 El-ashmawy HM, Ahmed AM. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. European Journal of Gastroenterology & Hepatology 2019;31:859-64. [DOI: 10.1097/meg.0000000000001354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
135 Hoang SA, Oseini A, Feaver RE, Cole BK, Asgharpour A, Vincent R, Siddiqui M, Lawson MJ, Day NC, Taylor JM, Wamhoff BR, Mirshahi F, Contos MJ, Idowu M, Sanyal AJ. Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease. Sci Rep 2019;9:12541. [PMID: 31467298 DOI: 10.1038/s41598-019-48746-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
136 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 30.5] [Reference Citation Analysis]
137 Saeed N, Glass LM, Habbal H, Mahmood A, Sengstock D, Saini SD, Tincopa MA. Primary care and referring physician perspectives on non-alcoholic fatty liver disease management: a nationwide survey. Therap Adv Gastroenterol 2021;14:17562848211042200. [PMID: 34567270 DOI: 10.1177/17562848211042200] [Reference Citation Analysis]
138 Spooner MH, Jump DB. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand? Curr Opin Clin Nutr Metab Care 2019;22:103-10. [PMID: 30601174 DOI: 10.1097/MCO.0000000000000539] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 9.5] [Reference Citation Analysis]
139 Stofan M, Guo GL. Bile Acids and FXR: Novel Targets for Liver Diseases. Front Med (Lausanne) 2020;7:544. [PMID: 33015098 DOI: 10.3389/fmed.2020.00544] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
140 Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials 2019;84:105803. [PMID: 31260793 DOI: 10.1016/j.cct.2019.06.017] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 18.7] [Reference Citation Analysis]
141 Velarde-Ruiz Velasco JA, García-Jiménez ES, García-Zermeño KR, Morel-Cerda EC, Aldana-Ledesma JM, Castro-Narro GE, Cerpa-Cruz S, Tapia-Calderón DK, Mercado-Jauregui LA, Contreras-Omaña R. Extrahepatic complications of non-alcoholic fatty liver disease: Its impact beyond the liver. Rev Gastroenterol Mex (Engl Ed) 2019;84:472-81. [PMID: 31488310 DOI: 10.1016/j.rgmx.2019.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
142 Jamialahmadi T, Nematy M, Jangjoo A, Goshayeshi L, Abdalla MA, Akhlaghi S, Sathyapalan T, Sahebkar A. The predictive role of parathyroid hormone for non-alcoholic fatty liver disease based on invasive and non-invasive findings in candidates of bariatric surgery. Eat Weight Disord 2021. [PMID: 33999371 DOI: 10.1007/s40519-021-01151-2] [Reference Citation Analysis]
143 Lee JI, Lee HW, Lee KS, Lee HS, Park JY. Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. Am J Gastroenterol 2021;116:116-24. [PMID: 33027082 DOI: 10.14309/ajg.0000000000000845] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
144 Svop Jensen V, Fledelius C, Max Wulff E, Lykkesfeldt J, Hvid H. Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet. Nutrients 2021;13:604. [PMID: 33673227 DOI: 10.3390/nu13020604] [Reference Citation Analysis]
145 Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 2020;69:1877-84. [PMID: 32381514 DOI: 10.1136/gutjnl-2019-319104] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 17.0] [Reference Citation Analysis]
146 Christensen K, Lawler T, Mares J. Dietary Carotenoids and Non-Alcoholic Fatty Liver Disease among US Adults, NHANES 2003⁻2014. Nutrients 2019;11:E1101. [PMID: 31108934 DOI: 10.3390/nu11051101] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
147 Fernández-Mincone T, Contreras-Briceño F, Espinosa-Ramírez M, García-Valdés P, López-Fuenzalida A, Riquelme A, Arab JP, Cabrera D, Arrese M, Barrera F. Nonalcoholic fatty liver disease and sarcopenia: pathophysiological connections and therapeutic implications. Expert Rev Gastroenterol Hepatol 2020;14:1141-57. [PMID: 32811209 DOI: 10.1080/17474124.2020.1810563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
148 Velarde-ruiz Velasco J, García-jiménez E, García-zermeño K, Morel-cerda E, Aldana-ledesma J, Castro-narro G, Cerpa-cruz S, Tapia-calderón D, Mercado-jauregui L, Contreras-omaña R. Extrahepatic complications of non-alcoholic fatty liver disease. Revista de Gastroenterología de México (English Edition) 2019;84:472-81. [DOI: 10.1016/j.rgmxen.2019.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
149 Carr RM. VCAM-1: closing the gap between lipotoxicity and endothelial dysfunction in nonalcoholic steatohepatitis. J Clin Invest 2021;131:147556. [PMID: 33720049 DOI: 10.1172/JCI147556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
150 Vidal-Cevallos P, Ordóñez-Vázquez AL, Procopio-Mosso O, Cardoso-Arias R, Uribe M, Chávez-Tapia NC. Cross-sectional pilot study to assess primary healthcare workers' knowledge of nonalcoholic fatty liver disease in a marginalized community in Mexico. Sci Rep 2021;11:12100. [PMID: 34103552 DOI: 10.1038/s41598-021-91199-y] [Reference Citation Analysis]
151 Veltkamp C, Lan S, Korompoki E, Weiss K, Schmidt H, Seitz HK. Hepatic Steatosis and Fibrosis in Chronic Inflammatory Bowel Disease. JCM 2022;11:2623. [DOI: 10.3390/jcm11092623] [Reference Citation Analysis]
152 Biberci Keskin E, Coban G. Evaluation of Liver Biopsy Findings and Comparison with Noninvasive Fibrosis Scores in Patients with Non-Alcoholic Steatohepatitis. Medeni Med J 2019;34:354-9. [PMID: 32821461 DOI: 10.5222/MMJ.2019.48640] [Reference Citation Analysis]
153 Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00261-2] [Reference Citation Analysis]
154 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
155 Shaheen AA, Riazi K, Medellin A, Bhayana D, Kaplan GG, Jiang J, Park R, Schaufert W, Burak KW, Sargious M, Swain MG. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. CMAJ Open 2020;8:E370-6. [PMID: 32414883 DOI: 10.9778/cmajo.20200009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
156 Zhou H, Zhou Y, Ding J, Chen Y, Wen J, Zhao L, Zhang Q, Jing X. Clinical evaluation of grayscale and linear scale hepatorenal indices for fatty liver quantification: a prospective study of a native Chinese population. Abdom Radiol (NY) 2022. [PMID: 35150314 DOI: 10.1007/s00261-022-03434-3] [Reference Citation Analysis]
157 Besutti G, Valenti L, Ligabue G, Bassi MC, Pattacini P, Guaraldi G, Giorgi Rossi P. Accuracy of imaging methods for steatohepatitis diagnosis in non‐alcoholic fatty liver disease patients: A systematic review. Liver Int 2019;39:1521-34. [DOI: 10.1111/liv.14118] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
158 Vilar-Gomez E, Calzadilla-Bertot L, Wong VW, Castellanos M, Aller-de la Fuente R, Eslam M, Wong GL, George J, Romero-Gomez M, Adams LA. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. Clin Gastroenterol Hepatol 2021;19:136-145.e6. [PMID: 32389886 DOI: 10.1016/j.cgh.2020.04.083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
159 Shaheen AA, Swain MG. Editorial: choosing an appropriate risk stratification tool for nonalcoholic fatty liver disease-one size does not fit all. Aliment Pharmacol Ther 2020;51:661-2. [PMID: 32100347 DOI: 10.1111/apt.15640] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
160 Van Dijk AM, Vali Y, Mak AL, Lee J, Tushuizen ME, Zafarmand MH, Anstee QM, Brosnan MJ, Nieuwdorp M, Bossuyt PM, Holleboom AG. Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease. J Clin Med 2021;10:2910. [PMID: 34209858 DOI: 10.3390/jcm10132910] [Reference Citation Analysis]
161 Russo MF, Lembo E, Mari A, Angelini G, Verrastro O, Nanni G, Pompili M, Raffaelli M, Vecchio FM, Bornstein SR, Mingrone G. Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery. J Clin Endocrinol Metab 2021;106:750-61. [PMID: 33248441 DOI: 10.1210/clinem/dgaa892] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Amor AJ, Perea V. Dyslipidemia in nonalcoholic fatty liver disease: . Current Opinion in Endocrinology & Diabetes and Obesity 2019;26:103-8. [DOI: 10.1097/med.0000000000000464] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 6.7] [Reference Citation Analysis]
163 Mansour D, Grapes A, Herscovitz M, Cassidy P, Vernazza J, Broad A, Anstee QM, McPherson S. Embedding assessment of liver fibrosis into routine diabetic review in primary care. JHEP Rep 2021;3:100293. [PMID: 34179738 DOI: 10.1016/j.jhepr.2021.100293] [Reference Citation Analysis]
164 Doulberis M, Papadimitriou K, Papaefthymiou A, Kountouras J, Polyzos SA. The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. Exploration of Medicine 2020;1:170-83. [DOI: 10.37349/emed.2020.00012] [Reference Citation Analysis]
165 On S, Kim HY, Kim HS, Park J, Kang KW. Involvement of G-Protein-Coupled Receptor 40 in the Inhibitory Effects of Docosahexaenoic Acid on SREBP1-Mediated Lipogenic Enzyme Expression in Primary Hepatocytes. Int J Mol Sci. 2019;20. [PMID: 31142011 DOI: 10.3390/ijms20112625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
166 Singh SP, Anirvan P, Reddy KR, Conjeevaram HS, Marchesini G, Rinella ME, Madan K, Petroni ML, Al-Mahtab M, Caldwell SH, Aithal GP, Hamid SS, Farrell GC, Satapathy SK, Duseja A, Acharya SK, Dassanayake AS, Goh KL. Non-alcoholic fatty liver disease: Not time for an obituary just yet! J Hepatol 2021;74:972-4. [PMID: 33340575 DOI: 10.1016/j.jhep.2020.10.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
167 Cummings D, Ferstenberg R. Recommendations for the Evaluation for Autoimmune Liver Disease in Nonalcoholic Fatty Liver Disease. Hepatology 2018;68:1203. [PMID: 29694671 DOI: 10.1002/hep.30057] [Reference Citation Analysis]
168 Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH — current progress and future promise. Nat Rev Gastroenterol Hepatol 2018;15:461-78. [DOI: 10.1038/s41575-018-0014-9] [Cited by in Crossref: 153] [Cited by in F6Publishing: 144] [Article Influence: 38.3] [Reference Citation Analysis]
169 Cadamuro M, Lasagni A, Sarcognato S, Guido M, Fabris R, Strazzabosco M, Strain AJ, Simioni P, Villa E, Fabris L. The Neglected Role of Bile Duct Epithelial Cells in NASH. Semin Liver Dis 2021. [PMID: 34794182 DOI: 10.1055/s-0041-1739455] [Reference Citation Analysis]
170 Schumacher JD, Guo GL. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis. Handb Exp Pharmacol 2019;256:325-57. [PMID: 31201553 DOI: 10.1007/164_2019_228] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
171 Wang G, Rahmim A, Gunn RN. PET Parametric Imaging: Past, Present, and Future. IEEE Trans Radiat Plasma Med Sci 2020;4:663-75. [PMID: 33763624 DOI: 10.1109/trpms.2020.3025086] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
172 Lee S, Kim KW, Lee J, Park T, Khang S, Jeong H, Song GW, Lee SG. Visceral adiposity as a risk factor for lean non-alcoholic fatty liver disease in potential living liver donors. J Gastroenterol Hepatol 2021. [PMID: 34169561 DOI: 10.1111/jgh.15597] [Reference Citation Analysis]
173 Raschi E, Mazzotti A, Poluzzi E, De Ponti F, Marchesini G. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Expert Opin Pharmacother 2018;19:1903-14. [PMID: 30299993 DOI: 10.1080/14656566.2018.1531126] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
174 Castellana M, Conte E, Cignarelli A, Perrini S, Giustina A, Giovanella L, Giorgino F, Trimboli P. Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis. Rev Endocr Metab Disord 2020;21:5-16. [PMID: 31705259 DOI: 10.1007/s11154-019-09514-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 42.0] [Reference Citation Analysis]
175 Simon TG, Roelstraete B, Khalili H, Hagström H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 2021;70:1375-82. [PMID: 33037056 DOI: 10.1136/gutjnl-2020-322786] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
176 Liu L, Yan H, Xia M, Zhao L, Lv M, Zhao N, Rao S, Yao X, Wu W, Pan B, Bian H, Gao X. Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev 2020;36:e3292. [PMID: 31955491 DOI: 10.1002/dmrr.3292] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
177 Lee YS, Yoo YJ, Jung YK, Kim JH, Seo YS, Yim HJ, Kim IH, Lee SY, Kim BH, Kim JW, Lee CH, Yeon JE, Kwon SY, Um SH, Byun KS. Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2020;11:e00157. [PMID: 32251018 DOI: 10.14309/ctg.0000000000000157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
178 Nichols PH, Pan Y, May B, Pavlicova M, Rausch JC, Mencin AA, Thaker VV. Effect of TSH on Non-Alcoholic Fatty Liver Disease (NAFLD) independent of obesity in children of predominantly Hispanic/Latino ancestry by causal mediation analysis. PLoS One 2020;15:e0234985. [PMID: 32569304 DOI: 10.1371/journal.pone.0234985] [Reference Citation Analysis]
179 Skubic C, Drakulić Ž, Rozman D. Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. Expert Opin Drug Metab Toxicol 2018;14:831-41. [PMID: 29969922 DOI: 10.1080/17425255.2018.1492552] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
180 Zhao YZ, Gan YG, Zhou JL, Liu JQ, Cao WG, Cheng SM, Bai DM, Wang MZ, Gao FQ, Zhou SM. Accuracy of multi-echo Dixon sequence in quantification of hepatic steatosis in Chinese children and adolescents. World J Gastroenterol 2019; 25(12): 1513-1523 [PMID: 30948914 DOI: 10.3748/wjg.v25.i12.1513] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
181 Wong C, Yaow CYL, Ng CH, Chin YH, Low YF, Lim AYL, Muthiah MD, Khoo CM. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis. Front Endocrinol (Lausanne) 2020;11:609135. [PMID: 33643221 DOI: 10.3389/fendo.2020.609135] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
182 Marin-Alejandre BA, Cantero I, Perez-Diaz-Del-Campo N, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano JI, Huarte-Muniesa MP, Tur JA, Martinez JA, Abete I, Zulet MA. Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial. Liver Int 2021;41:1532-44. [PMID: 33550706 DOI: 10.1111/liv.14818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
183 Akahane T, Akahane M, Namisaki T, Kaji K, Moriya K, Kawaratani H, Takaya H, Sawada Y, Shimozato N, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mitoro A, Yoshiji H. Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. J Clin Med 2020;9:E1635. [PMID: 32481684 DOI: 10.3390/jcm9061635] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
184 Patton H, Burchette R, Tovar S, Pio J, Shi J, Nyberg LM. Retrospective analysis of a dedicated care pathway for nonalcoholic fatty liver disease in an integrated US healthcare system demonstrates support of weight management and improved ALT. BMC Gastroenterol 2020;20:362. [PMID: 33129272 DOI: 10.1186/s12876-020-01492-9] [Reference Citation Analysis]
185 Elhence A, Shalimar. Treatment of non-alcoholic fatty liver disease - Current perspectives. Indian J Gastroenterol 2020;39:22-31. [PMID: 32152902 DOI: 10.1007/s12664-020-01021-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
186 Li X, Qin P, Cao L, Lou Y, Shi J, Zhao P, Wang C, Ma J, Xu S, Peng X, Chen H, Zhao D, Hu F, Zhao Y. Dose-response association of the ZJU index and fatty liver disease risk: A large cohort in China. J Gastroenterol Hepatol 2021;36:1326-33. [PMID: 33001484 DOI: 10.1111/jgh.15286] [Reference Citation Analysis]
187 Garcia DO, Morrill KE, Lopez-Pentecost M, Villavicencio EA, Vogel RM, Bell ML, Klimentidis YC, Marrero DG, Thomson CA. Nonalcoholic Fatty Liver Disease and Associated Risk Factors in a Community-Based Sample of Mexican-Origin Adults. Hepatol Commun 2022. [PMID: 35076162 DOI: 10.1002/hep4.1896] [Reference Citation Analysis]
188 Tamaki N, Kurosaki M, Takahashi Y, Itakura Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Izumi N. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. J Gastroenterol Hepatol 2021. [PMID: 34154037 DOI: 10.1111/jgh.15589] [Reference Citation Analysis]
189 Ramkissoon R, Gardner TB. Pancreatic steatosis: an update. Curr Opin Gastroenterol 2019;35:440-7. [PMID: 31343416 DOI: 10.1097/MOG.0000000000000566] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
190 Chongmelaxme B, Phisalprapa P, Sawangjit R, Dilokthornsakul P, Chaiyakunapruk N. Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. Pharmacoeconomics 2019;37:267-78. [PMID: 30430467 DOI: 10.1007/s40273-018-0736-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
191 Ishitobi M, Hosaka T, Morita N, Kondo K, Murashima T, Kitahara A, Takahashi K, Sumitani Y, Tanaka T, Yokoyama T, Kondo T, Ishida H. Serum lactate levels are associated with serum alanine aminotransferase and total bilirubin levels in patients with type 2 diabetes mellitus: A cross-sectional study. Diabetes Res Clin Pract 2019;149:1-8. [PMID: 30711436 DOI: 10.1016/j.diabres.2019.01.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
192 Saiman Y, Hooks R, Carr RM. High-Risk Groups for Non-alcoholic Fatty Liver and Non-alcoholic Steatohepatitis Development and Progression. Curr Hepatology Rep 2020;19:412-9. [DOI: 10.1007/s11901-020-00539-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Lee HH, Cho Y, Choi YJ, Huh BW, Lee BW, Kang ES, Park SW, Cha BS, Lee EJ, Lee YH, Huh KB. Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study. Cardiovasc Diabetol 2020;19:81. [PMID: 32534588 DOI: 10.1186/s12933-020-01064-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
194 Pilling D, Karhadkar TR, Gomer RH. A CD209 ligand and a sialidase inhibitor differentially modulate adipose tissue and liver macrophage populations and steatosis in mice on the Methionine and Choline-Deficient (MCD) diet. PLoS One 2020;15:e0244762. [PMID: 33378413 DOI: 10.1371/journal.pone.0244762] [Reference Citation Analysis]
195 Gleeson MW. Interplay of Liver Disease and Gut Microbiota in the Development of Colorectal Neoplasia. Curr Treat Options Gastro 2019;17:378-93. [DOI: 10.1007/s11938-019-00241-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
196 Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018;24:3361-73. [PMID: 30122876 DOI: 10.3748/wjg.v24.i30.3361] [Cited by in CrossRef: 198] [Cited by in F6Publishing: 168] [Article Influence: 49.5] [Reference Citation Analysis]
197 Abenavoli L, Falalyeyeva T, Boccuto L, Tsyryuk O, Kobyliak N. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease. Pharmaceuticals (Basel) 2018;11:E104. [PMID: 30314377 DOI: 10.3390/ph11040104] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
198 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Reference Citation Analysis]
199 Pfeiffer RM, Rotman Y, O'Brien TR. Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score? Hepatology 2020;72:794-6. [PMID: 32506469 DOI: 10.1002/hep.31413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
200 Mitsinikos T, Mrowczynski-Hernandez P, Kohli R. Pediatric Nonalcoholic Fatty Liver Disease. Pediatr Clin North Am 2021;68:1309-20. [PMID: 34736591 DOI: 10.1016/j.pcl.2021.07.013] [Reference Citation Analysis]
201 Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, Anstee QM, Bossuyt PM, Zafarmand MH, On Behalf Of The Litmus Systematic Review Team. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2415. [PMID: 34072480 DOI: 10.3390/jcm10112415] [Reference Citation Analysis]
202 Lockhart ME, Smith AD. Fatty Liver Disease: Artificial Intelligence Takes on the Challenge. Radiology 2020;295:351-2. [PMID: 32101094 DOI: 10.1148/radiol.2020200058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
203 Yoneda M, Honda Y, Nogami A, Imajo K, Nakajima A. Advances in ultrasound elastography for nonalcoholic fatty liver disease. J Med Ultrason (2001) 2020;47:521-33. [PMID: 32748075 DOI: 10.1007/s10396-020-01040-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
204 Sun X, Harris EN. New aspects of hepatic endothelial cells in physiology and nonalcoholic fatty liver disease. Am J Physiol Cell Physiol 2020;318:C1200-13. [PMID: 32374676 DOI: 10.1152/ajpcell.00062.2020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
205 Emdin CA, Haas M, Ajmera V, Simon TG, Homburger J, Neben C, Jiang L, Wei WQ, Feng Q, Zhou A, Denny J, Corey K, Loomba R, Kathiresan S, Khera AV. Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study. Gastroenterology 2021;160:1620-1633.e13. [PMID: 33310085 DOI: 10.1053/j.gastro.2020.12.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
206 Abdelmalek MF, Charles ED, Sanyal AJ, Harrison SA, Neuschwander-Tetri BA, Goodman Z, Ehman RA, Karsdal M, Nakajima A, Du S, Tirucherai GS, Klinger GH, Mora J, Yamaguchi M, Shevell DE, Loomba R. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Contemp Clin Trials 2021;104:106335. [PMID: 33657443 DOI: 10.1016/j.cct.2021.106335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
207 Kazankov K, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D, Grønbæk H. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2019;16:145-59. [DOI: 10.1038/s41575-018-0082-x] [Cited by in Crossref: 177] [Cited by in F6Publishing: 185] [Article Influence: 44.3] [Reference Citation Analysis]
208 Hasan F, Daher HB. The Burden and Clinical Care Pathways of Nonalcoholic Steatohepatitis in the Middle East. Clin Liver Dis (Hoboken) 2019;14:207-11. [PMID: 32015870 DOI: 10.1002/cld.885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
209 Tsou P, Wu CJ. Serum Vitamin E Levels of Adults with Nonalcoholic Fatty Liver Disease: An Inverse Relationship with All-Cause Mortality in Non-Diabetic but Not in Pre-Diabetic or Diabetic Subjects. J Clin Med 2019;8:E1057. [PMID: 31330971 DOI: 10.3390/jcm8071057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
210 Golabi P, Stepanova M, Pham HT, Cable R, Rafiq N, Bush H, Gogoll T, Younossi ZM. Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). BMJ Open Gastroenterol 2018;5:e000198. [PMID: 29607054 DOI: 10.1136/bmjgast-2018-000198] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
211 Niriella MA, Kasturiratna A, Beddage T, Ediriweera DS, De Silva ST, Perera KR, Subasinghe CE, Kodisinghe SK, Piyaratna TC, Rishikesawan V, Dassanayaka AS, De Silva AP, Pathmeswaran A, Wickramasinghe AR, Kato N, Janaka de Silva H. Non-resolution of non-alcoholic fatty liver disease (NAFLD) among urban, adult Sri Lankans in the general population: A prospective, cohort follow-up study. PLoS One 2019;14:e0224474. [PMID: 31661524 DOI: 10.1371/journal.pone.0224474] [Reference Citation Analysis]
212 Parolin M, Dassie F, Vettor R, Maffei P. Acromegaly and ultrasound: how, when and why? J Endocrinol Invest 2020;43:279-87. [DOI: 10.1007/s40618-019-01111-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
213 Yang HH, Chen GC, Li DM, Lan L, Chen LH, Xu JY, Qin LQ. Serum iron and risk of nonalcoholic fatty liver disease and advanced hepatic fibrosis in US adults. Sci Rep 2021;11:10387. [PMID: 34002001 DOI: 10.1038/s41598-021-89991-x] [Reference Citation Analysis]
214 Noureddin M, Jones C, Alkhouri N, Gomez EV, Dieterich DT, Rinella ME; NASHNET. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.Gastroenterology. 2020;159:1985-1987.e4. [PMID: 32763241 DOI: 10.1053/j.gastro.2020.07.050] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
215 Luo L, An P, Jia X, Yue X, Zheng S, Liu S, Chen Y, An W, Winkler CA, Duan Z. Genetically Regulated Bilirubin and Risk of Non-alcoholic Fatty Liver Disease: A Mendelian Randomization Study. Front Genet 2018;9:662. [PMID: 30619479 DOI: 10.3389/fgene.2018.00662] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
216 Miller E, Schmidberger J, Kratzer W. Focal fatty sparing as an indicator of higher-grade fatty liver assessed by attenuation imaging: a prospective clinical study in NAFLD population. Z Gastroenterol 2021. [PMID: 34905800 DOI: 10.1055/a-1695-3637] [Reference Citation Analysis]
217 Khandelwal R, Dassanayake AS, Conjeevaram HS, Singh SP. Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist? World J Diabetes 2021; 12(9): 1479-1493 [PMID: 34630901 DOI: 10.4239/wjd.v12.i9.1479] [Reference Citation Analysis]
218 Lonardo A, Lugari S, Nascimbeni F. Non-alcoholic fatty liver disease (NAFLD) diagnosis and management-differentiating the essential from the ancillary and the present from the future. Hepatobiliary Surg Nutr 2020;9:374-8. [PMID: 32509834 DOI: 10.21037/hbsn.2019.11.12] [Reference Citation Analysis]
219 Zhao N, Tan H, Wang L, Han L, Cheng Y, Feng Y, Li T, Liu X. Palmitate induces fat accumulation via repressing FoxO1-mediated ATGL-dependent lipolysis in HepG2 hepatocytes. PLoS One 2021;16:e0243938. [PMID: 33449950 DOI: 10.1371/journal.pone.0243938] [Reference Citation Analysis]
220 Lam B, Kurzke K, Younossi Z. The Clinical and Economic Burden of Nonalcoholic Steatohepatitis. Curr Hepatology Rep 2018;17:345-9. [DOI: 10.1007/s11901-018-0423-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
221 Vilar-Gomez E, Chalasani N. Daily Aspirin Use Reduces Risk of Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease, Providing New Uses for an Old Drug. Clin Gastroenterol Hepatol 2019;17:2651-3. [PMID: 31252189 DOI: 10.1016/j.cgh.2019.06.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
222 Ogawa Y, Yoneda M, Kobayashi T, Honda Y, Kessoku T, Imajo K, Saito S, Nakajima A. Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. Expert Opinion on Pharmacotherapy 2018;20:69-82. [DOI: 10.1080/14656566.2018.1543403] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
223 Chang Y, Ryu S, Kim Y, Cho YK, Sung E, Kim H, Ahn J, Jung H, Yun KE, Kim S, Sung K, Sohn CI, Shin H, Wild SH, Byrne CD. Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis. Hepatology 2020;71:861-73. [DOI: 10.1002/hep.30867] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
224 Zhong GC, Liu S, Wu YL, Xia M, Zhu JX, Hao FB, Wan L. ABO blood group and risk of newly diagnosed nonalcoholic fatty liver disease: A case-control study in Han Chinese population. PLoS One 2019;14:e0225792. [PMID: 31800606 DOI: 10.1371/journal.pone.0225792] [Reference Citation Analysis]
225 Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M, Vogl T, Loomba R, Plum-Mörschel L. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2021;54:1150-61. [PMID: 34570916 DOI: 10.1111/apt.16608] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
226 Mostafa F, Hasan E, Williamson M, Khan H. Statistical Machine Learning Approaches to Liver Disease Prediction. Livers 2021;1:294-312. [DOI: 10.3390/livers1040023] [Reference Citation Analysis]
227 Popa A, Bende F, Șirli R, Popescu A, Bâldea V, Lupușoru R, Cotrău R, Fofiu R, Foncea C, Sporea I. Quantification of Liver Fibrosis, Steatosis, and Viscosity Using Multiparametric Ultrasound in Patients with Non-Alcoholic Liver Disease: A "Real-Life" Cohort Study. Diagnostics (Basel) 2021;11:783. [PMID: 33926073 DOI: 10.3390/diagnostics11050783] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
228 Mahabaleshwarkar R, Liu TL, McKillop IH, Spencer M. The Association Between Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease Diagnosis Varies by Race. Metab Syndr Relat Disord 2022. [PMID: 35319282 DOI: 10.1089/met.2021.0108] [Reference Citation Analysis]
229 Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: Facts and figures. JHEP Rep 2019;1:468-79. [PMID: 32039399 DOI: 10.1016/j.jhepr.2019.10.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 11.3] [Reference Citation Analysis]
230 Zhao F, Dong T, Yuan KY, Wang NJ, Xia FZ, Liu D, Wang ZM, Ma R, Lu YL, Huang ZW. Shifts in the Bacterial Community of Supragingival Plaque Associated With Metabolic-Associated Fatty Liver Disease. Front Cell Infect Microbiol 2020;10:581888. [PMID: 33384967 DOI: 10.3389/fcimb.2020.581888] [Reference Citation Analysis]
231 Makker J, Tariq H, Kumar K, Ravi M, Shaikh DH, Leung V, Hayat U, Hassan MT, Patel H, Nayudu S, Chilimuri S. Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study. World J Gastroenterol 2021; 27(6): 523-533 [PMID: 33642826 DOI: 10.3748/wjg.v27.i6.523] [Reference Citation Analysis]
232 Majumdar A, Tsochatzis EA. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. Metabolism 2020;111:154291. [DOI: 10.1016/j.metabol.2020.154291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
233 Loomba R. MRI-Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis. Hepatology 2021;73:881-3. [PMID: 33179266 DOI: 10.1002/hep.31624] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
234 Kreisel W, Lazaro A, Trebicka J, Grosse Perdekamp M, Schmitt-Graeff A, Deibert P. Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. Int J Mol Sci 2021;22:10372. [PMID: 34638713 DOI: 10.3390/ijms221910372] [Reference Citation Analysis]
235 Nastasa R, Stanciu C, Zenovia S, Singeap AM, Cojocariu C, Sfarti C, Girleanu I, Chiriac S, Cuciureanu T, Huiban L, Muzica CM, Trifan A. The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students. Diagnostics (Basel) 2021;11:2341. [PMID: 34943578 DOI: 10.3390/diagnostics11122341] [Reference Citation Analysis]
236 Karamfilova V, Gateva A, Assyov Y, Nedeva I, Velikova T, Cherkezov N, Mateva L, Kamenov Z. Lumican in Obese Patients with Nonalcoholic Fatty Liver Disease With or Without Prediabetes. Metabolic Syndrome and Related Disorders 2020;18:443-8. [DOI: 10.1089/met.2020.0001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
237 Hernandez Roman J, Patel S. Why Do Lifestyle Recommendations Fail in Most Patients with Nonalcoholic Fatty Liver Disease? Gastroenterol Clin North Am 2020;49:95-104. [PMID: 32033766 DOI: 10.1016/j.gtc.2019.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
238 Ishiba H, Sumida Y, Seko Y, Tanaka S, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Suzuki Y, Yoneda M, Takahashi H, Nakahara T, Mori K, Kanemasa K, Shimada K, Imajo K, Yamaguchi K, Kawaguchi T, Nakajima A, Chayama K, Shima T, Fujimoto K, Okanoue T, Itoh Y; Japan Study Group of NAFLD. Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. Hepatol Commun 2021;5:559-72. [PMID: 33860115 DOI: 10.1002/hep4.1637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
239 Duseja A, Acharya SK, Mehta M, Chhabra S, Rana S, Das A, Dattagupta S, Dhiman RK, Chawla YK; Shalimar. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. BMJ Open Gastroenterol 2019;6:e000315. [PMID: 31423319 DOI: 10.1136/bmjgast-2019-000315] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
240 Somda S, Lebrun A, Tranchart H, Lamouri K, Prevot S, Njike-Nakseu M, Gaillard M, Lainas P, Balian A, Dagher I, Perlemuter G, Naveau S, Voican CS. Adaptation of controlled attenuation parameter (CAP) measurement depth in morbidly obese patients addressed for bariatric surgery. PLoS One 2019;14:e0217093. [PMID: 31125357 DOI: 10.1371/journal.pone.0217093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
241 Liu J, Guan L, Zhao M, Li Q, Song A, Gao L, Lin H, Zhao J. Association Between the Triglyceride-Glucose Index and Outcomes of Nonalcoholic Fatty Liver Disease: A Large-Scale Health Management Cohort Study. Diabetes Metab Syndr Obes 2021;14:2829-39. [PMID: 34188506 DOI: 10.2147/DMSO.S316864] [Reference Citation Analysis]
242 Carvajal S, Perramón M, Casals G, Oró D, Ribera J, Morales-Ruiz M, Casals E, Casado P, Melgar-Lesmes P, Fernández-Varo G, Cutillas P, Puntes V, Jiménez W. Cerium Oxide Nanoparticles Protect against Oxidant Injury and Interfere with Oxidative Mediated Kinase Signaling in Human-Derived Hepatocytes. Int J Mol Sci 2019;20:E5959. [PMID: 31783479 DOI: 10.3390/ijms20235959] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
243 Liu S, Wang J, Wu S, Niu J, Zheng R, Bie L, Xin Z, Wang S, Lin H, Zhao Z, Wang T, Xu M, Lu J, Chen Y, Xu Y, Wang W, Ning G, Bi Y, Li M, Xu Y. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis. Metabolism 2021;120:154779. [PMID: 33895182 DOI: 10.1016/j.metabol.2021.154779] [Reference Citation Analysis]
244 Marciano S, Dirchwolf M, Torres MC, Allevato J, García Dans C, García B, Pollarsky F, Gaite L, Sirotinsky E, Rios B, Anselmo MN, Peche M, Hurtado E, Haddad L, Narvaez A, Mauro E, Martinez A, Bellizzi C, Ratusnu N, D'Amico C, Arora S, Gadano A. Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00103-1. [PMID: 34690105 DOI: 10.1016/j.rgmxen.2021.09.002] [Reference Citation Analysis]
245 Ristic-Medic D, Kovacic M, Takic M, Arsic A, Petrovic S, Paunovic M, Jovicic M, Vucic V. Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease.Nutrients. 2020;13:15. [PMID: 33374554 DOI: 10.3390/nu13010015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
246 Qiu S, Cao P, Guo Y, Lu H, Hu Y. Exploring the Causality Between Hypothyroidism and Non-alcoholic Fatty Liver: A Mendelian Randomization Study. Front Cell Dev Biol 2021;9:643582. [PMID: 33791302 DOI: 10.3389/fcell.2021.643582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
247 Park S, Chung MJ, Son JY, Yun HH, Park JM, Yim JH, Jung SJ, Lee SH, Jeong KS. The role of Sirtuin 2 in sustaining functional integrity of the liver. Life Sci 2021;285:119997. [PMID: 34597608 DOI: 10.1016/j.lfs.2021.119997] [Reference Citation Analysis]
248 Tuong TTK, Tran DK, Phu PQT, Hong TND, Dinh TC, Chu DT. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan. Diagnostics (Basel). 2020;10. [PMID: 32183383 DOI: 10.3390/diagnostics10030159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
249 Salva-Pastor N, López-Sánchez GN, Chávez-Tapia NC, Audifred-Salomón JR, Niebla-Cárdenas D, Topete-Estrada R, Pereznuñez-Zamora H, Vidaltamayo-Ramírez R, Báez-Arellano ME, Uribe M, Nuño-Lámbarri N. Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population. Ann Hepatol 2020;19:251-7. [PMID: 32111488 DOI: 10.1016/j.aohep.2020.01.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
250 Colucci A, Rocco MC, De Anseris AGE, Nazzaro L, Vajro P, Mandato C. Pediatric vs. adult NAFLD to MAFLD transition: a welcome but tangled path. Exploration of Medicine. [DOI: 10.37349/emed.2021.00051] [Reference Citation Analysis]
251 Chen Z, Liu J, Zhou F, Li H, Zhang XJ, She ZG, Lu Z, Cai J, Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. Circ Res 2021;128:1747-65. [PMID: 34043417 DOI: 10.1161/CIRCRESAHA.121.319059] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
252 Fitzpatrick E. Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum. Proc Nutr Soc 2019;78:362-71. [DOI: 10.1017/s0029665118002914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
253 Sumida Y, Shima T, Mitsumoto Y, Katayama T, Umemura A, Yamaguchi K, Itoh Y, Yoneda M, Okanoue T. Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan. Int J Mol Sci 2020;21:E4337. [PMID: 32570776 DOI: 10.3390/ijms21124337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
254 Zhang Y, Xu J, Wang X, Ren X, Liu Y. Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. BMC Genomics 2019;20:862. [PMID: 31726978 DOI: 10.1186/s12864-019-6251-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
255 Kuchay MS, Choudhary NS, Mishra SK, Misra A. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes. Diabetes Metab Syndr 2020;14:2233-9. [PMID: 33336648 DOI: 10.1016/j.dsx.2020.11.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
256 Zhou J, Li H, Cai Y, Ma L, Mathews D, Lu B, Zhu B, Chen Y, Qian X, Xiao X, Li Q, Guo S, Huo Y, Zhao L, Tian Y, Li Q, Wu C. Mice lacking adenosine 2A receptor reveal increased severity of MCD-induced NASH. J Endocrinol 2019:JOE-19-0198. [PMID: 31505462 DOI: 10.1530/JOE-19-0198] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
257 Mehta KJ, Farnaud SJ, Sharp PA. Iron and liver fibrosis: Mechanistic and clinical aspects. World J Gastroenterol 2019; 25(5): 521-538 [PMID: 30774269 DOI: 10.3748/wjg.v25.i5.521] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 52] [Article Influence: 19.3] [Reference Citation Analysis]
258 Zhou X, Fouda S, Li D, Zhang K, Ye JM. Involvement of the Autophagy-ER Stress Axis in High Fat/Carbohydrate Diet-Induced Nonalcoholic Fatty Liver Disease. Nutrients 2020;12:E2626. [PMID: 32872238 DOI: 10.3390/nu12092626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
259 Casler K, Trees K, Bosak K. Readiness for the epidemic: The adult nonalcoholic fatty liver disease toolkit for primary care nurse practitioners. J Am Assoc Nurse Pract 2020;32:323-31. [PMID: 31274677 DOI: 10.1097/JXX.0000000000000223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 2021:S0168-8278(21)02037-7. [PMID: 34555422 DOI: 10.1016/j.jhep.2021.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
261 Mantovani A. GLP-1 receptor agonists and reduction of liver fat content in NAFLD patients: Just a question of weight loss? Dig Liver Dis 2021;53:1673-4. [PMID: 34366254 DOI: 10.1016/j.dld.2021.07.013] [Reference Citation Analysis]
262 Lee JH, Lee HS, Lee BK, Kwon YJ, Lee JW. Relationship between Muscle Mass and Non-Alcoholic Fatty Liver Disease. Biology (Basel) 2021;10:122. [PMID: 33562473 DOI: 10.3390/biology10020122] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, Portillo Romero J, Schmidt S, Chang KL, Samraj G, Malaty J, Huber K, Bedossa P, Kalavalapalli S, Marte J, Barb D, Poulton D, Fanous N, Cusi K. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care 2021;44:399-406. [PMID: 33355256 DOI: 10.2337/dc20-1997] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
264 Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol 2021:S0168-8278(21)02026-2. [PMID: 34508791 DOI: 10.1016/j.jhep.2021.08.028] [Reference Citation Analysis]
265 Schreiner AD, Bian J, Zhang J, Kirkland EB, Heincelman ME, Schumann SO 3rd, Mauldin PD, Moran WP, Rockey DC. When Do Clinicians Follow-up Abnormal Liver Tests in Primary Care? Am J Med Sci 2019;358:127-33. [PMID: 31331450 DOI: 10.1016/j.amjms.2019.04.017] [Reference Citation Analysis]
266 Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’amato M, Wang DQ, Di Ciaula A. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines 2022;10:83. [DOI: 10.3390/biomedicines10010083] [Reference Citation Analysis]
267 Hernandez ED, Zheng L, Kim Y, Fang B, Liu B, Valdez RA, Dietrich WF, Rucker PV, Chianelli D, Schmeits J, Bao D, Zoll J, Dubois C, Federe GC, Chen L, Joseph SB, Klickstein LB, Walker J, Molteni V, McNamara P, Meeusen S, Tully DC, Badman MK, Xu J, Laffitte B. Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents. Hepatol Commun. 2019;3:1085-1097. [PMID: 31388629 DOI: 10.1002/hep4.1368] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
268 Wu Q, Liu J, Liu L, Chen Y, Wang J, Leng L, Yu Q, Duan Z, Wang Y. Establishment of an ex Vivo Model of Nonalcoholic Fatty Liver Disease Using a Tissue-Engineered Liver. ACS Biomater Sci Eng 2018;4:3016-26. [DOI: 10.1021/acsbiomaterials.8b00652] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
269 Baik M, Kim SU, Nam HS, Heo JH, Kim YD. The Paradoxical Protective Effect of Liver Steatosis on Severity and Functional Outcome of Ischemic Stroke. Front Neurol 2019;10:375. [PMID: 31031700 DOI: 10.3389/fneur.2019.00375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
270 Olofson AM, Gonzalo DH, Chang M, Liu X. Steatohepatitic Variant of Hepatocellular Carcinoma: A Focused Review. Gastroenterology Res 2018;11:391-6. [PMID: 30627261 DOI: 10.14740/gr1110] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
271 Hyun J, Jung Y. DNA Methylation in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E8138. [PMID: 33143364 DOI: 10.3390/ijms21218138] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
272 Griffin JD, Bejarano E, Wang XD, Greenberg AS. Integrated Action of Autophagy and Adipose Tissue Triglyceride Lipase Ameliorates Diet-Induced Hepatic Steatosis in Liver-Specific PLIN2 Knockout Mice. Cells 2021;10:1016. [PMID: 33923083 DOI: 10.3390/cells10051016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
273 Vuppalanchi R, Weber R, Russell S, Gawrieh S, Samala N, Slaven JE, Harden L, Chalasani N. Is Fasting Necessary for Individuals With Nonalcoholic Fatty Liver Disease to Undergo Vibration-Controlled Transient Elastography? Am J Gastroenterol 2019;114:995-7. [PMID: 30694869 DOI: 10.14309/ajg.0000000000000116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
274 Long MT, Massaro JM, Hoffmann U, Benjamin EJ, Naimi TS. Alcohol Use Is Associated With Hepatic Steatosis Among Persons With Presumed Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020;18:1831-1841.e5. [PMID: 31734449 DOI: 10.1016/j.cgh.2019.11.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
275 Cariello M, Piccinin E, Moschetta A. Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH. Cell Mol Gastroenterol Hepatol 2021;11:1519-39. [PMID: 33545430 DOI: 10.1016/j.jcmgh.2021.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
276 Fabrellas N, Hernández R, Graupera I, Solà E, Ramos P, Martín N, Sáez G, Simón C, Pérez A, Graell T, Larrañaga A, Garcia M, de la Arada A, Juanola A, Coiduras A, Duaso I, Casado A, Martin J, Ginès M, Moreno N, Gema Perez A, Marti L, Bernat M, Sola M, Olivé C, Solé C, Ginès P. Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. PLoS One 2018;13:e0200656. [PMID: 30226889 DOI: 10.1371/journal.pone.0200656] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
277 Erden A, Kuru Öz D, Peker E, Kul M, Özalp Ateş FS, Erden İ, İdilman R. MRI quantification techniques in fatty liver: the diagnostic performance of hepatic T1, T2, and stiffness measurements in relation to the proton density fat fraction. Diagn Interv Radiol 2021;27:7-14. [PMID: 33290237 DOI: 10.5152/dir.2020.19654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
278 Schiavo L, Busetto L, Cesaretti M, Zelber-Sagi S, Deutsch L, Iannelli A. Nutritional issues in patients with obesity and cirrhosis. World J Gastroenterol 2018; 24(30): 3330-3346 [PMID: 30122874 DOI: 10.3748/wjg.v24.i30.3330] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 21] [Article Influence: 7.8] [Reference Citation Analysis]
279 Vernuccio F, Cannella R, Bartolotta TV, Galia M, Tang A, Brancatelli G. Advances in liver US, CT, and MRI: moving toward the future. Eur Radiol Exp 2021;5:52. [PMID: 34873633 DOI: 10.1186/s41747-021-00250-0] [Reference Citation Analysis]
280 Hua YQ, Zeng Y, Xu J, Xu XL. Naringenin alleviates nonalcoholic steatohepatitis in middle-aged Apoe-/-mice: role of SIRT1. Phytomedicine 2021;81:153412. [PMID: 33234364 DOI: 10.1016/j.phymed.2020.153412] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
281 Tran TT, Wei K, Cole S, Mena E, Csete M, King KS. Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis. J Neuroimaging 2020;30:697-703. [PMID: 32705733 DOI: 10.1111/jon.12728] [Reference Citation Analysis]
282 Yoneda M, Imajo K, Takahashi H, Ogawa Y, Eguchi Y, Sumida Y, Yoneda M, Kawanaka M, Saito S, Tokushige K, Nakajima A. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol 2018;53:181-96. [PMID: 29177681 DOI: 10.1007/s00535-017-1414-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 7.6] [Reference Citation Analysis]
283 Yang N, Lu Y, Cao L, Lu M. The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults. J Clin Lab Anal 2022;:e24225. [PMID: 34997649 DOI: 10.1002/jcla.24225] [Reference Citation Analysis]
284 Yousaf MN, Chaudhary FS, Mehal WZ. The impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). GHOA 2019;10:262-6. [DOI: 10.15406/ghoa.2019.10.00392] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
285 Vilar-Gomez E, Lou Z, Kong N, Vuppalanchi R, Imperiale TF, Chalasani N. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System. Clin Gastroenterol Hepatol 2020;18:2305-2314.e12. [PMID: 32289535 DOI: 10.1016/j.cgh.2020.04.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
286 Prasoppokakorn T, Pitisuttithum P, Treeprasertsuk S. Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). J Clin Transl Hepatol 2021;9:939-46. [PMID: 34966657 DOI: 10.14218/JCTH.2021.00189] [Reference Citation Analysis]
287 Albert SG, Wood EM. Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome. Diabetes Metab Syndr 2021;15:102232. [PMID: 34352720 DOI: 10.1016/j.dsx.2021.102232] [Reference Citation Analysis]
288 Johansen P, Howard D, Bishop R, Moreno SI, Buchholtz K. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. Pharmacoeconomics 2020;38:485-97. [PMID: 31919793 DOI: 10.1007/s40273-019-00881-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
289 O'Shea A, Pierce TT. US Elastography in Hepatic Fibrosis-Radiology In Training. Radiology 2021;299:264-71. [PMID: 33754829 DOI: 10.1148/radiol.2021203893] [Reference Citation Analysis]
290 Takahashi H, Kotani K, Tanaka K, Egucih Y, Anzai K. Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms. Front Endocrinol (Lausanne). 2018;9:588. [PMID: 30374329 DOI: 10.3389/fendo.2018.00588] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
291 Ebadi M, Bhanji RA, Tandon P, Mazurak V, Baracos VE, Montano-Loza AJ. Review article: prognostic significance of body composition abnormalities in patients with cirrhosis. Aliment Pharmacol Ther 2020;52:600-18. [PMID: 32621329 DOI: 10.1111/apt.15927] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
292 Younossi ZM, Stepanova M, Ong J, Yilmaz Y, Duseja A, Eguchi Y, El Kassas M, Castellanos-fernandez M, George J, Jacobson IM, Bugianesi E, Wong VW, Arrese M, de Ledinghen V, Romero-gomez M, Mendez-sanchez N, Ahmed A, Wong R, Papatheodoridis G, Serfaty L, Younossi I, Nader F, Ziayee M, Afendy A. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2019;17:1625-1633.e1. [DOI: 10.1016/j.cgh.2018.11.033] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 14.7] [Reference Citation Analysis]
293 Niu L, Sulek K, Vasilopoulou CG, Santos A, Wewer Albrechtsen NJ, Rasmussen S, Meier F, Mann M. Defining NASH from a Multi-Omics Systems Biology Perspective. J Clin Med 2021;10:4673. [PMID: 34682795 DOI: 10.3390/jcm10204673] [Reference Citation Analysis]
294 Ou H, Fu Y, Liao W, Zheng C, Wu X. Association between Smoking and Liver Fibrosis among Patients with Nonalcoholic Fatty Liver Disease. Can J Gastroenterol Hepatol. 2019;2019:6028952. [PMID: 31737583 DOI: 10.1155/2019/6028952] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
295 Bergram M, Nasr P, Iredahl F, Kechagias S, Rådholm K, Ekstedt M. Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. Scand J Gastroenterol 2021;:1-10. [PMID: 34618619 DOI: 10.1080/00365521.2021.1984572] [Reference Citation Analysis]
296 Kosick HM, Keyrouz A, Adeyi O, Sebastiani G, Patel K. A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 33389416 DOI: 10.1007/s10620-020-06748-8] [Reference Citation Analysis]
297 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Metabolism 2021;122:154822. [PMID: 34289945 DOI: 10.1016/j.metabol.2021.154822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
298 Hu C, Zhuang X, Zhang J, Wang T, Du S, Wang J, Peng X, Cao Q, Zhang M, Jiang Y. Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatography-Mass Spectrometry. Lab Med 2022:lmab118. [PMID: 35075477 DOI: 10.1093/labmed/lmab118] [Reference Citation Analysis]
299 Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Jsg-Nafld JSGON. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Int J Mol Sci 2020;21:E1907. [PMID: 32168769 DOI: 10.3390/ijms21061907] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
300 Li H, Wang Q, Chen P, Zhou C, Zhang X, Chen L. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Front Pharmacol 2021;12:788558. [PMID: 34938193 DOI: 10.3389/fphar.2021.788558] [Reference Citation Analysis]
301 Avila MA, Dufour JF, Gerbes AL, Zoulim F, Bataller R, Burra P, Cortez-Pinto H, Gao B, Gilmore I, Mathurin P, Moreno C, Poznyak V, Schnabl B, Szabo G, Thiele M, Thursz MR. Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut 2020;69:764-80. [PMID: 31879281 DOI: 10.1136/gutjnl-2019-319720] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
302 Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis 2019;282:110-20. [PMID: 30731283 DOI: 10.1016/j.atherosclerosis.2019.01.029] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 12.0] [Reference Citation Analysis]
303 Hu L, Shao X, Qiu C, Shao X, Wang X, Niu R, Wang Y. Hepatic steatosis is associated with abnormal hepatic enzymes, visceral adiposity, altered myocardial glucose uptake measured by 18F-FDG PET/CT. BMC Endocr Disord 2020;20:75. [PMID: 32460891 DOI: 10.1186/s12902-020-00556-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
304 Fung A, Shanbhogue KP, Taffel MT, Brinkerhoff BT, Theise ND. Hepatocarcinogenesis: Radiology-Pathology Correlation. Magn Reson Imaging Clin N Am 2021;29:359-74. [PMID: 34243923 DOI: 10.1016/j.mric.2021.05.007] [Reference Citation Analysis]
305 Koo DJ, Lee MY, Jung I, Moon SJ, Kwon H, Park SE, Rhee EJ, Lee WY. Changes in Insulin Resistance Index and the Risk of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease without Diabetes: Kangbuk Samsung Health Study. Endocrinol Metab (Seoul) 2021;36:1016-28. [PMID: 34674510 DOI: 10.3803/EnM.2021.1110] [Reference Citation Analysis]
306 Lv X, Dong Y, Hu L, Lu F, Zhou C, Qin S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. Endocrinol Diabetes Metab 2020;3:e00163. [PMID: 32704576 DOI: 10.1002/edm2.163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
307 Van Haele M, Snoeck J, Roskams T. Human Liver Regeneration: An Etiology Dependent Process. Int J Mol Sci 2019;20:E2332. [PMID: 31083462 DOI: 10.3390/ijms20092332] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
308 Jeong SW. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020;44:640-657. [PMID: 33115209 DOI: 10.4093/dmj.2020.0115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
309 Alves-Bezerra M, Furey N, Johnson CG, Bissig KD. Using CRISPR/Cas9 to model human liver disease. JHEP Rep 2019;1:392-402. [PMID: 32039390 DOI: 10.1016/j.jhepr.2019.09.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
310 Catania R, Furlan A, Smith AD, Behari J, Tublin ME, Borhani AA. Diagnostic value of MRI-derived liver surface nodularity score for the non-invasive quantification of hepatic fibrosis in non-alcoholic fatty liver disease. Eur Radiol 2021;31:256-63. [PMID: 32757050 DOI: 10.1007/s00330-020-07114-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
311 Kozlitina J. Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis. Gastroenterol Clin North Am 2020;49:25-44. [PMID: 32033763 DOI: 10.1016/j.gtc.2019.09.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
312 Bullón-Vela V, Abete I, Tur JA, Konieczna J, Romaguera D, Pintó X, Corbella E, Martínez-González MA, Sayón-Orea C, Toledo E, Corella D, Macías-Gonzalez M, Tinahones FJ, Fitó M, Estruch R, Ros E, Salas-Salvadó J, Daimiel L, Mascaró CM, Zulet MA, Martínez JA. Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. Ther Adv Endocrinol Metab 2020;11:2042018820958298. [PMID: 33149882 DOI: 10.1177/2042018820958298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
313 Meritsi A, Manesis E, Koussis P, Rapti S, Latsou D, Tsitsopoulos E, Moshoyianni H, Manolakopoulos S, Pektasides D, Thanopoulou A. PNPLA3 rs 738409 and Other Nongenetic Factors Associated with Hepatic Steatosis Estimated by Magnetic Resonance Imaging Proton Density Fat Fraction in Adult Greek Subjects with Type 2 Diabetes Mellitus. Metab Syndr Relat Disord 2021. [PMID: 34962148 DOI: 10.1089/met.2021.0098] [Reference Citation Analysis]
314 Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71:1851-1864. [PMID: 32012320 DOI: 10.1002/hep.31150] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 46.0] [Reference Citation Analysis]
315 Akki AS, Chung SM, Rudolph BJ, Ewart MR. Differential Diagnosis of a Patient with Lysosomal Acid Lipase Deficiency: A Case Report. Laboratory Medicine 2018;49:377-84. [DOI: 10.1093/labmed/lmy027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
316 Kuwashiro T, Takahashi H, Hyogo H, Ogawa Y, Imajo K, Yoneda M, Nakahara T, Oeda S, Tanaka K, Amano Y, Ogawa S, Kawaguchi A, Aishima S, Kage M, Chayama K, Nakajima A, Eguchi Y. Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study. JGH Open 2020;4:497-502. [PMID: 32514460 DOI: 10.1002/jgh3.12289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
317 Stine JG, Soriano C, Schreibman I, Rivas G, Hummer B, Yoo E, Schmitz K, Sciamanna C. Breaking Down Barriers to Physical Activity in Patients with Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021;66:3604-11. [DOI: 10.1007/s10620-020-06673-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
318 Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, Henry L. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 2020;69:564-8. [DOI: 10.1136/gutjnl-2019-318813] [Cited by in Crossref: 83] [Cited by in F6Publishing: 69] [Article Influence: 27.7] [Reference Citation Analysis]
319 Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, Setiawan VW, Tran T, Ayoub WS, Lu SC, Klein AS, Sundaram V, Nissen NN. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol. 2018;113:1649-1659. [PMID: 29880964 DOI: 10.1038/s41395-018-0088-6] [Cited by in Crossref: 181] [Cited by in F6Publishing: 167] [Article Influence: 45.3] [Reference Citation Analysis]
320 Ilagan-Ying YC, Xu J, Lim JK, Do A. Low real-world eligibility rates for nonalcoholic steatohepatitis patients for phase 3 clinical trial criteria application in a large academic health system. Eur J Gastroenterol Hepatol 2021;33:424-9. [PMID: 32433419 DOI: 10.1097/MEG.0000000000001758] [Reference Citation Analysis]
321 Wang N, Wang Y, Zhang W, Chen Y, Chen X, Wang C, Li Q, Chen C, Jiang B, Lu Y. C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes. Diabetes Metab Res Rev 2020;36:e3210. [PMID: 31351021 DOI: 10.1002/dmrr.3210] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
322 Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-sun Wong V, Romero-gomez M, Kersey K, Li G, Subramanian GM, Myers RP, Djedjos CS, Okanoue T, Trauner M, Goodman Z, Harrison SA. Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2019;17:2552-2560.e10. [DOI: 10.1016/j.cgh.2019.02.024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
323 Hawa F, Gladshteyn M, Gunaratnam SV, Scheidel C, Corsello PM, Berger SH, Gunaratnam NT. Effective Treatment of Nonalcoholic Fatty Liver Disease Using a Community-Based Weight Management Program. Cureus 2021;13:e16709. [PMID: 34466334 DOI: 10.7759/cureus.16709] [Reference Citation Analysis]
324 Sun L, Deng C, Gu Y, He Y, Yang L, Shi J. Effects of Dapagliflozin in Patients with Nonalcoholic Fatty Liver Disease:A Systematic Review and Meta-Analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 2022;:101876. [PMID: 35321843 DOI: 10.1016/j.clinre.2022.101876] [Reference Citation Analysis]
325 Park JH, Lee JS, Ko YH, Kim YH. Physical activity of Korean cancer survivors is associated with age and sex. Korean J Intern Med 2021;36:S225-34. [PMID: 32375206 DOI: 10.3904/kjim.2019.240] [Reference Citation Analysis]
326 Kulkarni S, Naz N, Gu H, Stoll JM, Thompson MD, DeBosch BJ. A clinical model to predict fibrosis on liver biopsy in paediatric subjects with nonalcoholic fatty liver disease. Clin Obes 2021;:e12472. [PMID: 34106515 DOI: 10.1111/cob.12472] [Reference Citation Analysis]
327 Gawrieh S, Wilson LA, Cummings OW, Clark JM, Loomba R, Hameed B, Abdelmalek MF, Dasarathy S, Neuschwander-Tetri BA, Kowdley K, Kleiner D, Doo E, Tonascia J, Sanyal A, Chalasani N; NASH Clinical Research Network. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. Am J Gastroenterol 2019;114:1626-35. [PMID: 31517638 DOI: 10.14309/ajg.0000000000000388] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
328 Huang KT, Chen KD, Hsu LW, Kung CP, Li SR, Chen CC, Chiu KW, Goto S, Chen CL. Decreased PEDF Promotes Hepatic Fatty Acid Uptake and Lipid Droplet Formation in the Pathogenesis of NAFLD. Nutrients 2020;12:E270. [PMID: 31968655 DOI: 10.3390/nu12010270] [Reference Citation Analysis]
329 Perakakis N, Stefanakis K, Mantzoros CS. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism 2020;111S:154320. [PMID: 32712221 DOI: 10.1016/j.metabol.2020.154320] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
330 Ciardullo S, Muraca E, Zerbini F, Manzoni G, Perseghin G. NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population. J Clin Endocrinol Metab 2021;106:e2856-65. [PMID: 33878156 DOI: 10.1210/clinem/dgab262] [Reference Citation Analysis]
331 Gow P, Spelman T, Gardner S, Hellard M, Howell J. Estimates of the global reduction in liver disease-related mortality with increased coffee consumption: an analysis of the Global Burden of Disease Dataset. Aliment Pharmacol Ther 2020;52:1195-203. [PMID: 32794601 DOI: 10.1111/apt.16020] [Reference Citation Analysis]
332 Taneja S, Roy A. Nonalcoholic steatohepatitis recurrence after liver transplant. Transl Gastroenterol Hepatol 2020;5:24. [PMID: 32258528 DOI: 10.21037/tgh.2019.10.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
333 Sun EJ, Wankell M, Palamuthusingam P, McFarlane C, Hebbard L. Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. Biomedicines 2021;9:1639. [PMID: 34829868 DOI: 10.3390/biomedicines9111639] [Reference Citation Analysis]
334 Duseja A, Singh SP, Mehta M, Shalimar, Venkataraman J, Mehta V, Devadas K, Kar SK, Goyal O, Nagral A, Saigal S, Nijhawan S, Praharaj D, Shukla A, Sharma B, Narayanasamy K, Kumar P, Rao PN, Arora A, Mehta R, Asati P, Ranjan P, Koshy A, Alam S, Mukewar S, Mukewar S, Mohan Prasad VG, Rastogi M, Sanyal AJ. Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease. Metab Syndr Relat Disord 2022. [PMID: 35085026 DOI: 10.1089/met.2021.0104] [Reference Citation Analysis]
335 Liu SY, Wong VW, Wong SK, Wong GL, Lai CM, Lam CC, Shu SS, Chan HL, Ng EK. A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. Sci Rep 2021;11:5416. [PMID: 33686111 DOI: 10.1038/s41598-021-83782-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
336 Johansson L, Hockings PD, Johnsson E, Dronamraju N, Maaske J, Garcia-Sanchez R, Wilding JPH. Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. Diabetes Obes Metab 2020;22:1094-101. [PMID: 32072735 DOI: 10.1111/dom.14004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
337 Sasson A, Kristoferson E, Batista R, McClung JA, Abraham NG, Peterson SJ. The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and systemic complications of NAFLD. Arch Biochem Biophys 2021;697:108679. [PMID: 33248947 DOI: 10.1016/j.abb.2020.108679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
338 Tamaki N, Kurosaki M, Takahashi Y, Itakura Y, Kirino S, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Loomba R, Izumi N. Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. Int J Mol Sci 2020;22:E40. [PMID: 33375190 DOI: 10.3390/ijms22010040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
339 Pirola CJ, Sookoian S. Editorial: surviving your genes-the role of PNPLA3 variation in end-stage liver disease. Aliment Pharmacol Ther 2018;48:773-5. [PMID: 30246305 DOI: 10.1111/apt.14901] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
340 Petrov PD, García-Mediavilla MV, Guzmán C, Porras D, Nistal E, Martínez-Flórez S, Castell JV, González-Gallego J, Sánchez-Campos S, Jover R. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2019;63:e1900487. [PMID: 31322321 DOI: 10.1002/mnfr.201900487] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
341 Xu J, Shen J, Yuan R, Jia B, Zhang Y, Wang S, Zhang Y, Liu M, Wang T. Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-alcoholic Fatty Liver Disease. Front Pharmacol 2021;12:796207. [PMID: 35002729 DOI: 10.3389/fphar.2021.796207] [Reference Citation Analysis]
342 Cusi K. A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions.Liver Int. 2020;40 Suppl 1:82-88. [PMID: 32077613 DOI: 10.1111/liv.14350] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
343 Ting YW, Kong AS, Zain SM, Chan WK, Tan HL, Mohamed Z, Pung YF, Mohamed R. Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort. Clin Mol Hepatol 2021;27:486-98. [PMID: 33618508 DOI: 10.3350/cmh.2020.0162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
344 Zhou M, Yang N, Xing X, Chang D, Li J, Deng J, Chen Y, Hu C, Zhang R, Lu X, Zhao Y, He Y. Obesity interacts with hyperuricemia on the severity of non-alcoholic fatty liver disease. BMC Gastroenterol 2021;21:43. [PMID: 33509116 DOI: 10.1186/s12876-021-01615-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
345 Tanaka Y, Ikeda T, Ogawa H, Kamisako T. Ezetimibe Markedly Reduces Hepatic Triglycerides and Cholesterol in Rats Fed on Fish Oil by Increasing the Expression of Cholesterol Efflux Transporters. J Pharmacol Exp Ther 2020;374:175-83. [DOI: 10.1124/jpet.120.265660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
346 Enomoto H, Aizawa N, Hasegawa K, Ikeda N, Sakai Y, Yoh K, Takata R, Yuri Y, Kishino K, Shimono Y, Ishii N, Takashima T, Nishimura T, Nishikawa H, Iwata Y, Iijima H, Nishiguchi S. Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients. Int J Mol Sci 2020;21:E3089. [PMID: 32349377 DOI: 10.3390/ijms21093089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
347 Valdecantos MP, Ruiz L, Pardo V, Castro-Sanchez L, García-Monzón C, Lanzón B, Rupérez J, Barbas C, Naylor J, Trevaskis JL, Grimsby J, Rondinone CM, Valverde ÁM. Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy. Sci Rep 2018;8:16461. [PMID: 30405191 DOI: 10.1038/s41598-018-33949-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
348 Koo DJ, Lee MY, Jung I, Moon SJ, Kwon H, Park SE, Rhee EJ, Lee WY. Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study. PLoS One 2021;16:e0255535. [PMID: 34432804 DOI: 10.1371/journal.pone.0255535] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
349 Singh SP, Anirvan P, Khandelwal R, Satapathy SK. Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille? J Clin Transl Hepatol 2021;9:931-8. [PMID: 34966656 DOI: 10.14218/JCTH.2021.00174] [Reference Citation Analysis]
350 Samji NS, Snell PD, Singal AK, Satapathy SK. Racial Disparities in Diagnosis and Prognosis of Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2020;16:66-72. [PMID: 32922753 DOI: 10.1002/cld.948] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
351 Nascimbeni F, Pellegrini E, Lugari S, Mondelli A, Bursi S, Onfiani G, Carubbi F, Lonardo A. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. Atherosclerosis 2019;284:66-74. [DOI: 10.1016/j.atherosclerosis.2019.02.028] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
352 Bahrami M, Cheraghpour M, Jafarirad S, Alavinejad P, Asadi F, Hekmatdoost A, Mohammadi M, Yari Z. The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial. Complement Ther Med 2020;52:102452. [PMID: 32951715 DOI: 10.1016/j.ctim.2020.102452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
353 Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci 2021;22:2350. [PMID: 33652942 DOI: 10.3390/ijms22052350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
354 Torres-Peña JD, Martín-Piedra L, Fuentes-Jiménez F. Statins in Non-alcoholic Steatohepatitis. Front Cardiovasc Med 2021;8:777131. [PMID: 34901236 DOI: 10.3389/fcvm.2021.777131] [Reference Citation Analysis]
355 Hadefi A, Verset L, Pezzullo M, Rosewick N, Degré D, Gustot T, Moreno C, Devière J, Trépo E. Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study. Endosc Int Open 2021;9:E1792-800. [PMID: 34790547 DOI: 10.1055/a-1550-7668] [Reference Citation Analysis]
356 Robinson A, Wong RJ. Applications and Limitations of Noninvasive Methods for Evaluating Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2020;15:157-61. [PMID: 32395243 DOI: 10.1002/cld.878] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
357 Kothari S, Dhami-Shah H, Shah SR. Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol 2019;9:723-30. [PMID: 31889754 DOI: 10.1016/j.jceh.2019.06.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
358 Karlas T, Blank V, Böhlig A. Diagnostic Value of Ultrasound in Fatty Liver Disease. Ultraschall Med 2021;42:128-53. [PMID: 33622003 DOI: 10.1055/a-1352-4313] [Reference Citation Analysis]
359 Curcic IB, Berkovic MC, Kuna L, Roguljic H, Smolic R, Varzic SC, Jukic LV, Smolic M. Obesity Paradox in Chronic Liver Diseases: Product of Bias or a Real Thing? J Clin Transl Hepatol. 2019;7:275-279. [PMID: 31608220 DOI: 10.14218/jcth.2019.00029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
360 Idilman IS, Low HM, Gidener T, Philbrick K, Mounajjed T, Li J, Allen AM, Yin M, Venkatesh SK. Association between Visceral Adipose Tissue and Non-Alcoholic Steatohepatitis Histology in Patients with Known or Suspected Non-Alcoholic Fatty Liver Disease. J Clin Med 2021;10:2565. [PMID: 34200525 DOI: 10.3390/jcm10122565] [Reference Citation Analysis]
361 Galarregui C, Marin-Alejandre BA, Perez-Diaz-Del-Campo N, Cantero I, Monreal JI, Elorz M, Benito-Boillos A, Herrero JI, Tur JA, Martínez JA, Zulet MA, Abete I. Predictive Value of Serum Ferritin in Combination with Alanine Aminotransferase and Glucose Levels for Noninvasive Assessment of NAFLD: Fatty Liver in Obesity (FLiO) Study. Diagnostics (Basel) 2020;10:E917. [PMID: 33171699 DOI: 10.3390/diagnostics10110917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
362 Altamirano J, Qi Q, Choudhry S, Abdallah M, Singal AK, Humar A, Bataller R, Borhani AA, Duarte-Rojo A. Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. Transl Gastroenterol Hepatol. 2020;5:31. [PMID: 32258535 DOI: 10.21037/tgh.2019.11.14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
363 Chang J, Koseki M, Saga A, Kanno K, Higo T, Okuzaki D, Okada T, Inui H, Tanaka K, Asaji M, Zhu Y, Kamada Y, Ono M, Saibara T, Ichi I, Ohama T, Nishida M, Yamashita S, Sakata Y. Dietary Oxysterol, 7-Ketocholesterol Accelerates Hepatic Lipid Accumulation and Macrophage Infiltration in Obese Mice. Front Endocrinol (Lausanne) 2020;11:614692. [PMID: 33776901 DOI: 10.3389/fendo.2020.614692] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
364 Kahl S, Pützer J, Roden M. Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. Semin Liver Dis 2021. [PMID: 34289506 DOI: 10.1055/s-0041-1732354] [Reference Citation Analysis]
365 Jirapinyo P, Mccarty TR, Dolan RD, Shah R, Thompson CC. Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
366 Khanna S, Wilkins JT, Ning H, Allen NB, Lewis CE, Carr JJ, Lloyd-jones D, Vanwagner LB, Hirata MH. Lipoprotein Levels in Early Adulthood and NAFLD in Midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Journal of Nutrition and Metabolism 2022;2022:1-9. [DOI: 10.1155/2022/1727711] [Reference Citation Analysis]
367 Sridharan K, Sivaramakrishnan G, Sequeira RP, Elamin A. Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Postgrad Med J 2018;94:556-65. [PMID: 30341231 DOI: 10.1136/postgradmedj-2018-135967] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
368 Tobari M, Hashimoto E, Taniai M, Ikarashi Y, Kodama K, Kogiso T, Tokushige K, Takayoshi N, Hashimoto N. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign. J Gastroenterol Hepatol. 2019;34:1404-1410. [PMID: 30590868 DOI: 10.1111/jgh.14585] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
369 Fallatah HI, Al-Dabbagh A, Hiejazi MT, Hanbazazah SAA, Hussein AO, Al-Sahafi MA, Akbar HO. Prevalence and Clinical Characteristics of NAFLD in Chronic Liver Disease Patients from King Abdulaziz University Hospital, Jeddah. Saudi J Med Med Sci 2020;8:118-24. [PMID: 32587493 DOI: 10.4103/sjmms.sjmms_272_19] [Reference Citation Analysis]
370 Wu WK, Chen YH, Lee PC, Yang PJ, Chang CC, Liu KL, Hsu CC, Huang CC, Chuang HL, Sheen LY, Liu CJ, Wu MS. Mining Gut Microbiota From Bariatric Surgery for MAFLD. Front Endocrinol (Lausanne) 2021;12:612946. [PMID: 33897617 DOI: 10.3389/fendo.2021.612946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
371 Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018;14:99-114. [DOI: 10.1038/nrendo.2017.173] [Cited by in Crossref: 142] [Cited by in F6Publishing: 122] [Article Influence: 28.4] [Reference Citation Analysis]
372 Lima RVC, Stefano JT, Malta FM, Pinho JRR, Carrilho FJ, Arrese M, Oliveira CP. Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients. Biomedicines 2021;9:1751. [PMID: 34944567 DOI: 10.3390/biomedicines9121751] [Reference Citation Analysis]
373 Romano J, Forster E. Hepatocellular Carcinoma in a Patient With Hepatic Steatosis. ACG Case Rep J 2020;7:e00378. [PMID: 32607378 DOI: 10.14309/crj.0000000000000378] [Reference Citation Analysis]
374 Wai JW, Fu C, Wong VW. Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. J Gastroenterol 2020;55:731-41. [PMID: 32451628 DOI: 10.1007/s00535-020-01686-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
375 Birerdinc A, Younossi ZM. Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Ann Hepatol 2018;17:11-3. [PMID: 29311407 DOI: 10.5604/01.3001.0010.7530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
376 Tokuhara D. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents. Front Nutr 2021;8:700058. [PMID: 34250000 DOI: 10.3389/fnut.2021.700058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Pedroso JAB, Camporez JP, Belpiede LT, Pinto RS, Cipolla-Neto J, Donato J Jr. Evaluation of Hepatic Steatosis in Rodents by Time-Domain Nuclear Magnetic Resonance. Diagnostics (Basel) 2019;9:E198. [PMID: 31756971 DOI: 10.3390/diagnostics9040198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
378 Lee M, Kim KJ, Chung TH, Bae J, Lee YH, Lee BW, Cha BS, Yun M, Kang ES. Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes. Diabetes Obes Metab 2021;23:1041-51. [PMID: 33394549 DOI: 10.1111/dom.14310] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
379 Pan CS, Stanley TL. Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. Front Endocrinol (Lausanne) 2020;11:70. [PMID: 32153507 DOI: 10.3389/fendo.2020.00070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
380 Karjoo S. Is There an Association of Vascular Disease and Atherosclerosis in Children and Adolescents With Obesity and Non-alcoholic Fatty Liver Disease? Front Pediatr 2018;6:345. [PMID: 30505829 DOI: 10.3389/fped.2018.00345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
381 Lee DH, Sung SU, Lee YK, Lim IH, Jang H, Joo SK, Park JH, Chang MS, So YH, Kim W; Innovative Target Exploration of NAFLD (ITEN) Consortium. A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2022. [PMID: 35005800 DOI: 10.1111/apt.16766] [Reference Citation Analysis]
382 Zhai M, Liu Z, Long J, Zhou Q, Yang L, Zhou Q, Liu S, Dai Y. The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017. Sci Rep 2021;11:5195. [PMID: 33664363 DOI: 10.1038/s41598-021-84577-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
383 Manka P, Zeller A, Syn W. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 2019;79:903-27. [DOI: 10.1007/s40265-019-01126-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
384 Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol 2021;36:1497-507. [PMID: 33217052 DOI: 10.1111/jgh.15353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
385 Sharma M, Kulkarni A, Kumar P, Nori VB, Jagtap N, Gupta R, Reddy DN, Rao PN. Difference in lifestyle and metabolic profile of non-alcoholic fatty liver disease with raised alanine amino-transferases between obese and non-overweight subjects. Sci Rep 2020;10:15232. [PMID: 32943747 DOI: 10.1038/s41598-020-72306-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
386 Mori S, Arima N, Ito M, Fujiyama S, Kamo Y, Ueki Y. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS One 2018;13:e0203084. [PMID: 30142184 DOI: 10.1371/journal.pone.0203084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
387 Becerril S, Rodríguez A, Catalán V, Ramírez B, Unamuno X, Gómez-Ambrosi J, Frühbeck G. iNOS Gene Ablation Prevents Liver Fibrosis in Leptin-Deficient ob/ob Mice. Genes (Basel) 2019;10:E184. [PMID: 30818874 DOI: 10.3390/genes10030184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
388 Lyu J, Imachi H, Fukunaga K, Sato S, Kobayashi T, Dong T, Saheki T, Matsumoto M, Iwama H, Zhang H, Murao K. Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes. Mol Metab 2020;34:16-26. [PMID: 32180556 DOI: 10.1016/j.molmet.2019.12.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
389 McHenry S, Tirath A, Tsai R, Sharma Y, Flores AG, Davidson NO, Fowler KJ, Ciorba MA, Deepak P. Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. Inflamm Bowel Dis 2020;26:1917-25. [PMID: 31907542 DOI: 10.1093/ibd/izz324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
390 Betanzos-Robledo L, Cantoral A, Peterson KE, Hu H, Hernández-Ávila M, Perng W, Jansen E, Ettinger AS, Mercado-García A, Solano-González M, Sánchez B, Téllez-Rojo MM. Association between cumulative childhood blood lead exposure and hepatic steatosis in young Mexican adults. Environ Res 2021;196:110980. [PMID: 33691159 DOI: 10.1016/j.envres.2021.110980] [Reference Citation Analysis]
391 Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, Ma Z, Bruno MJ, de Knegt RJ, Cao W, Peppelenbosch MP, Ghanbari M, Li Z, Pan Q. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00208-1. [PMID: 33618024 DOI: 10.1016/j.cgh.2021.02.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
392 Kucukoglu O, Sowa JP, Mazzolini GD, Syn WK, Canbay A. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. J Hepatol. 2021;74:442-457. [PMID: 33161047 DOI: 10.1016/j.jhep.2020.10.030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
393 Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database. Hepatology 2018;68:2230-8. [PMID: 29774589 DOI: 10.1002/hep.30094] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 10.3] [Reference Citation Analysis]
394 Park H, Lee SJ. Working hours and nonalcoholic fatty liver disease according to sleep duration. Chronobiol Int 2019;36:1671-80. [PMID: 31581841 DOI: 10.1080/07420528.2019.1670671] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
395 Saoi M, Sasaki K, Sagawa H, Abe K, Kogiso T, Tokushige K, Hashimoto E, Ohashi Y, Britz-McKibbin P. High Throughput Screening of Serum γ-Glutamyl Dipeptides for Risk Assessment of Nonalcoholic Steatohepatitis with Impaired Glutathione Salvage Pathway. J Proteome Res 2020;19:2689-99. [PMID: 31483669 DOI: 10.1021/acs.jproteome.9b00405] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
396 Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:484-95. [PMID: 34131333 DOI: 10.1038/s41574-021-00507-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
397 Aitharaju V, De Silvestri A, Barr RG. Assessment of chronic liver disease by multiparametric ultrasound: results from a private practice outpatient facility. Abdom Radiol (NY) 2021. [PMID: 34304291 DOI: 10.1007/s00261-021-03225-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
398 Clifford SM, Murphy DJ. Non-alcoholic fatty liver disease and coronary atherosclerosis-does myocardial glucose metabolism provide the missing link? J Nucl Cardiol 2021;28:621-3. [DOI: 10.1007/s12350-019-01783-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
399 Kutaiba N, Richmond D, Morey M, Brennan D, Rotella JA, Ardalan Z, Goodwin M. Incidental hepatic steatosis on unenhanced computed tomography performed for suspected renal colic: Gaps in reporting and documentation. J Med Imaging Radiat Oncol 2019;63:431-8. [PMID: 30874372 DOI: 10.1111/1754-9485.12873] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
400 Fu S, Yu M, Tan Y, Liu D. Role of histone deacetylase on nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2021;15:353-61. [PMID: 33213187 DOI: 10.1080/17474124.2021.1854089] [Reference Citation Analysis]
401 Imajo K, Honda Y, Yoneda M, Saito S, Nakajima A. Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. J Med Ultrason (2001) 2020;47:535-48. [PMID: 33108553 DOI: 10.1007/s10396-020-01059-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
402 Zhao Q, Liu J, Deng H, Ma R, Liao JY, Liang H, Hu J, Li J, Guo Z, Cai J, Xu X, Gao Z, Su S. Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS Output. Cell 2020;183:76-93.e22. [PMID: 32931733 DOI: 10.1016/j.cell.2020.08.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 18.0] [Reference Citation Analysis]
403 Katsiki N, Gastaldelli A, Mikhailidis DP. Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A “non-invasive alternative” to liver biopsy? Metabolism 2019;101:154010. [DOI: 10.1016/j.metabol.2019.154010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
404 Sharif A, Abbas Z, Ahmed S, Ali Samjo S, Baqai K. Effect of Non-alcoholic Fatty Liver Disease on Transaminase Levels and Transient Elastography in Patients with Chronic Hepatitis B. Cureus 2019;11:e5995. [PMID: 31807383 DOI: 10.7759/cureus.5995] [Reference Citation Analysis]
405 Karamfilova V, Gateva A, Alexiev A, Zheleva N, Velikova T, Ivanova-Boyanova R, Ivanova R, Cherkezov N, Kamenov Z, Mateva L. The association between retinol-binding protein 4 and prediabetes in obese patients with nonalcoholic fatty liver disease. Arch Physiol Biochem 2019;:1-6. [PMID: 31588816 DOI: 10.1080/13813455.2019.1673429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
406 Yurtdaş G, Akbulut G, Baran M, Yılmaz C. The effects of Mediterranean diet on hepatic steatosis, oxidative stress, and inflammation in adolescents with non-alcoholic fatty liver disease: A randomized controlled trial. Pediatr Obes 2021;:e12872. [PMID: 34881510 DOI: 10.1111/ijpo.12872] [Reference Citation Analysis]
407 Ducatman A, LaPier J, Fuoco R, DeWitt JC. Official health communications are failing PFAS-contaminated communities. Environ Health 2022;21:51. [PMID: 35538533 DOI: 10.1186/s12940-022-00857-9] [Reference Citation Analysis]
408 Tincopa MA. Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00177. [PMID: 33102798 DOI: 10.1002/edm2.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
409 Zhang S, Fu J, Zhang Q, Liu L, Meng G, Yao Z, Wu H, Bao X, Gu Y, Lu M, Sun S, Wang X, Zhou M, Jia Q, Song K, Xiang H, Wu Y, Niu K. Association between nut consumption and non-alcoholic fatty liver disease in adults. Liver Int 2019;39:1732-41. [PMID: 31162803 DOI: 10.1111/liv.14164] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
410 de Brito E Silva MB, Tustumi F, de Miranda Neto AA, Dantas ACB, Santo MA, Cecconello I. Gastric Bypass Compared with Sleeve Gastrectomy for Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis. Obes Surg 2021;31:2762-72. [PMID: 33846949 DOI: 10.1007/s11695-021-05412-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
411 Kriss M, Golden-Mason L, Kaplan J, Mirshahi F, Setiawan VW, Sanyal AJ, Rosen HR. Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development. PLoS One 2020;15:e0236353. [PMID: 32730345 DOI: 10.1371/journal.pone.0236353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
412 Babu AF, Csader S, Lok J, Gómez-Gallego C, Hanhineva K, El-Nezami H, Schwab U. Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis. Nutrients 2021;13:3135. [PMID: 34579012 DOI: 10.3390/nu13093135] [Reference Citation Analysis]
413 Park H, Yoon EL, Kim M, Lee J, Kim JH, Cho S, Jun DW, Nah EH. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era. Hepatol Res 2021. [PMID: 34841632 DOI: 10.1111/hepr.13737] [Reference Citation Analysis]
414 Vyhmeister R, Enestvedt CK. The Changing Liver Transplant Recipient: From Hepatitis C to Nonalcoholic Steatohepatitis and Alcohol. Clin Liver Dis 2021;25:137-55. [PMID: 33978575 DOI: 10.1016/j.cld.2020.08.012] [Reference Citation Analysis]
415 He XL, He YM, Zhang D, Li HS, Zhang Q, Yuan SS, Zhang Z, Wang YY, Liu CH, Fan CH, Li YH, Zheng M, Yang HJ, Zhou P. Efficacy and Mechanism of a Chinese Classic Prescription of Yueju in Treating Nonalcoholic Steatohepatitis and Protecting Hepatocytes from Apoptosis. Evid Based Complement Alternat Med 2020;2020:8888040. [PMID: 33178326 DOI: 10.1155/2020/8888040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
416 Viveiros K. The Role of Life Style Modifications in Comprehensive Non-Alcoholic Fatty Liver Disease Treatment. Clin Liver Dis (Hoboken) 2021;17:11-4. [PMID: 33552479 DOI: 10.1002/cld.1007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
417 Wang Y, Zhang Y, Yang J, Li H, Wang J, Geng W. Lactobacillus plantarum MA2 Ameliorates Methionine and Choline-Deficient Diet Induced Non-Alcoholic Fatty Liver Disease in Rats by Improving the Intestinal Microecology and Mucosal Barrier. Foods 2021;10:3126. [PMID: 34945677 DOI: 10.3390/foods10123126] [Reference Citation Analysis]
418 Schwimmer JB, Ugalde-nicalo P, Vos MB. Low Free Sugar Diet in Adolescents With Nonalcoholic Fatty Liver Disease—Reply. JAMA 2019;321:2469. [DOI: 10.1001/jama.2019.5153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
419 Li M, Cao D, Liu Y, Jin L, Zeng N, Wang L, Zhao K, Lv H, Zhang M, Zhang P, Yang Z, Zhang Z. Alterations in the Liver Fat Fraction Features Examined by Magnetic Resonance Imaging Following Bariatric Surgery: a Self-Controlled Observational Study. OBES SURG 2020;30:1917-28. [DOI: 10.1007/s11695-020-04415-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
420 Spinosa M, Stine JG. Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State? Curr Pharm Des 2020;26:1036-44. [PMID: 32003679 DOI: 10.2174/1381612826666200131101553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
421 Milic J, Menozzi V, Schepis F, Malagoli A, Besutti G, Franconi I, Raimondi A, Carli F, Mussini C, Sebastiani G, Guaraldi G. Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. AIDS 2020;34:1915-21. [PMID: 33009010 DOI: 10.1097/QAD.0000000000002650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
422 Liu H, Shi ZH. Dynamic expression of adiponectin signaling pathway molecules in a rat model of non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2018; 26(28): 1645-1650 [DOI: 10.11569/wcjd.v26.i28.1645] [Reference Citation Analysis]
423 Ding C, Tang Y, Zhu W, Huang P, Lian P, Ran J, Huang X. Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis. Acta Diabetol. [DOI: 10.1007/s00592-021-01830-7] [Reference Citation Analysis]
424 Kelly N, Wattacheril J. Nonalcoholic Fatty Liver Disease: Evidence-Based Management and Early Recognition of Nonalcoholic Steatohepatitis. The Journal for Nurse Practitioners 2019;15:622-6. [DOI: 10.1016/j.nurpra.2019.06.008] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
425 Estep M, Mehta R, Bratthauer G, Alaparthi L, Monge F, Ali S, Abdelatif D, Younoszai Z, Stepanova M, Goodman ZD, Younossi ZM. Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis. BMC Gastroenterol 2019;19:27. [PMID: 30744560 DOI: 10.1186/s12876-019-0951-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
426 Fiorucci S, Biagioli M, Distrutti E. Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacol Res 2018;134:289-98. [PMID: 30021122 DOI: 10.1016/j.phrs.2018.07.014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
427 Um YJ, Chang Y, Jung H, Cho IY, Shin JH, Shin H, Wild SH, Byrne CD, Ryu S. Decrease in Sleep Duration and Poor Sleep Quality over Time Is Associated with an Increased Risk of Incident Non-Alcoholic Fatty Liver Disease. JPM 2022;12:92. [DOI: 10.3390/jpm12010092] [Reference Citation Analysis]
428 Kim HP, Idowu MO, Mospan AR, Allmon AG, Roden M, Newsome P, Lok AS, Thuluvath PJ, Taunk J, Fried MW, Sanyal AJ, Barritt AS 4th; TARGET-NASH Investigators. Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Aliment Pharmacol Ther 2021;54:1472-80. [PMID: 34694013 DOI: 10.1111/apt.16674] [Reference Citation Analysis]
429 Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2021;161:1657-69. [PMID: 34602251 DOI: 10.1053/j.gastro.2021.07.049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
430 Chalasani S, Mathur K, Shammas N, Orman E, Vuppalanchi R, Lammert C. Hepatic steatosis is highly prevalent but is not correlated with stiffness in autoimmune hepatitis. Medicine (Baltimore) 2020;99:e22805. [PMID: 33080756 DOI: 10.1097/MD.0000000000022805] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
431 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
432 Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases.Transl Gastroenterol Hepatol. 2020;5:16. [PMID: 32258520 DOI: 10.21037/tgh.2019.09.08] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 30.5] [Reference Citation Analysis]
433 Guillaume M, Moal V, Delabaudiere C, Zuberbuhler F, Robic MA, Lannes A, Metivier S, Oberti F, Gourdy P, Fouchard-Hubert I, Selves J, Michalak S, Peron JM, Cales P, Bureau C, Boursier J. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. Aliment Pharmacol Ther 2019;50:1214-22. [PMID: 31617224 DOI: 10.1111/apt.15529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
434 Chianelli D, Rucker PV, Roland J, Tully DC, Nelson J, Liu X, Bursulaya B, Hernandez ED, Wu J, Prashad M, Schlama T, Liu Y, Chu A, Schmeits J, Huang DJ, Hill R, Bao D, Zoll J, Kim Y, Groessl T, McNamara P, Liu B, Richmond W, Sancho-Martinez I, Phimister A, Seidel HM, Badman MK, Joseph SB, Laffitte B, Molteni V. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem 2020;63:3868-80. [PMID: 31940200 DOI: 10.1021/acs.jmedchem.9b01621] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
435 Lee S, Kim KW, Lee J, Park T, Koo K, Song GW, Lee SG. Visceral Fat Area Is an Independent Risk Factor for Overweight or Obese Nonalcoholic Fatty Liver Disease in Potential Living Liver Donors. Transplant Proc 2022:S0041-1345(22)00091-4. [PMID: 35256204 DOI: 10.1016/j.transproceed.2021.10.032] [Reference Citation Analysis]
436 Tong XF, Wang QY, Zhao XY, Sun YM, Wu XN, Yang LL, Lu ZZ, Ou XJ, Jia JD, You H. Histological assessment based on liver biopsy: the value and challenges in NASH drug development. Acta Pharmacol Sin 2022. [PMID: 35165400 DOI: 10.1038/s41401-022-00874-x] [Reference Citation Analysis]
437 Cannella R, Dasyam N, Seo SH, Furlan A, Borhani AA. Performance of morphologic criteria for the diagnosis of cirrhosis in patients with non-alcoholic steatohepatitis compared to other etiologies of chronic liver disease: effect of level of training and experience. Abdom Radiol (NY) 2021;46:960-8. [PMID: 32902660 DOI: 10.1007/s00261-020-02719-9] [Reference Citation Analysis]
438 Malespin MH, Barritt AS 4th, Watkins SE, Schoen C, Tincopa MA, Corbin KD, Mospan AR, Munoz B, Trinh HN, Weiss LM, Reddy KR, Loomba R, Kemmer N, Lok AS. Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00073-2. [PMID: 33486083 DOI: 10.1016/j.cgh.2021.01.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
439 Murag S, Ahmed A, Kim D. Recent Epidemiology of Nonalcoholic Fatty Liver Disease. Gut Liver 2021;15:206-16. [PMID: 32921636 DOI: 10.5009/gnl20127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
440 Heredia NI, Thrift AP, Balakrishnan M. Perceived Barriers to Weight Loss among Hispanic Patients with Non-alcoholic Fatty Liver Disease. Hisp Health Care Int 2021;:15404153211043885. [PMID: 34658280 DOI: 10.1177/15404153211043885] [Reference Citation Analysis]
441 Shao C, Ye J, Li F, Feng S, Wang W, Zhong B. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease. Digestive and Liver Disease 2019;51:1392-9. [DOI: 10.1016/j.dld.2019.02.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
442 Sanai FM, Abaalkhail F, Hasan F, Farooqi MH, Nahdi NA, Younossi ZM. Management of nonalcoholic fatty liver disease in the Middle East. World J Gastroenterol 2020; 26(25): 3528-3541 [PMID: 32742124 DOI: 10.3748/wjg.v26.i25.3528] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
443 Huang H, Wang J, Xu L, Miao M, Xu C. Association between High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. Int J Endocrinol 2021;2021:6676526. [PMID: 34194492 DOI: 10.1155/2021/6676526] [Reference Citation Analysis]
444 Cunha GM, Villela-Nogueira CA, Bergman A, Lobo Lopes FPP. Abbreviated mpMRI protocol for diffuse liver disease: a practical approach for evaluation and follow-up of NAFLD. Abdom Radiol (NY) 2018;43:2340-50. [PMID: 29450605 DOI: 10.1007/s00261-018-1504-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
445 Pinyopornpanish K, Khoudari G, Saleh MA, Angkurawaranon C, Pinyopornpanish K, Mansoor E, Dasarathy S, McCullough A. Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study. BMC Gastroenterol 2021;21:394. [PMID: 34674650 DOI: 10.1186/s12876-021-01978-0] [Reference Citation Analysis]
446 Francque S, Vonghia L. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. Adv Ther 2019;36:1052-74. [PMID: 30888594 DOI: 10.1007/s12325-019-00898-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
447 Chartampilas E. Imaging of nonalcoholic fatty liver disease and its clinical utility. Hormones (Athens) 2018;17:69-81. [PMID: 29858854 DOI: 10.1007/s42000-018-0012-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
448 Guo W, Lu J, Qin P, Li X, Zhu W, Wu J, Xu N, Zhang Q. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults. Lipids Health Dis 2020;19:218. [PMID: 33028338 DOI: 10.1186/s12944-020-01393-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
449 Thompson RB, Chow K, Mager D, Pagano JJ, Grenier J. Simultaneous proton density fat-fraction and R 2 imaging with water-specific T1 mapping (PROFIT1 ): application in liver. Magn Reson Med 2021;85:223-38. [PMID: 32754942 DOI: 10.1002/mrm.28434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
450 Dokmak A, Lizaola-Mayo B, Trivedi HD. The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective. Am J Med 2021;134:23-9. [PMID: 32931760 DOI: 10.1016/j.amjmed.2020.08.010] [Reference Citation Analysis]
451 Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med 2020;152:116-41. [PMID: 32156524 DOI: 10.1016/j.freeradbiomed.2020.02.025] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 45.0] [Reference Citation Analysis]
452 Mahmoudi L, Asadi S, Al-Mousavi Z, Niknam R. A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease. Clin Nutr 2021;40:2999-3005. [PMID: 33341312 DOI: 10.1016/j.clnu.2020.11.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
453 Małecki P, Mania A, Tracz J, Łuczak M, Mazur-Melewska K, Figlerowicz M. Adipocytokines as Risk Factors for Development of Nonalcoholic Fatty Liver Disease in Children. J Clin Exp Hepatol 2021;11:646-53. [PMID: 34866842 DOI: 10.1016/j.jceh.2021.03.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
454 Kim MN, Ahn SH. Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma? Authors' reply. Aliment Pharmacol Ther 2022;55:481-2. [DOI: 10.1111/apt.16765] [Reference Citation Analysis]
455 Wang Q, Xie W, Liu L, Wang P, Pan CQ. Serum markers for predicting advanced fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease. Medicine (Baltimore) 2021;100:e25327. [PMID: 33950921 DOI: 10.1097/MD.0000000000025327] [Reference Citation Analysis]
456 Sabirin F, Lim SM, Neoh CF, Ramasamy K. Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease in vivo: A Systematic Review. Front Nutr 2022;9:844374. [DOI: 10.3389/fnut.2022.844374] [Reference Citation Analysis]
457 Alkayyali T, Qutranji L, Kaya E, Bakir A, Yilmaz Y. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. Acta Diabetol 2020;57:613-8. [PMID: 31897769 DOI: 10.1007/s00592-019-01467-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
458 Ajmera V, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab 2021;50:101167. [PMID: 33460786 DOI: 10.1016/j.molmet.2021.101167] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
459 Kang MK, Park JG. Low Skeletal Muscle Mass Is a Risk Factor for Subclinical Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2021;11:854. [PMID: 34068776 DOI: 10.3390/diagnostics11050854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
460 Mertens J, Van Gaal LF, Francque SM, De Block C. NAFLD in type 1 diabetes: overrated or underappreciated? Ther Adv Endocrinol Metab 2021;12:20420188211055557. [PMID: 34840719 DOI: 10.1177/20420188211055557] [Reference Citation Analysis]
461 Tada T, Kumada T, Toyoda H, Nakamura S, Shibata Y, Yasuda S, Watanuki Y, Tsujii K, Fukuda N, Fujioka M, Takeshima K, Niwa F, Ogawa S, Hashinokuchi S, Kataoka S, Ichikawa H, Iijima H. Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imaging-determined proton density fat fraction. Hepatol Res 2020;50:1319-27. [PMID: 32876367 DOI: 10.1111/hepr.13563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
462 Polyzos SA, Mantzoros CS. Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism 2020;111S:154318. [PMID: 32707055 DOI: 10.1016/j.metabol.2020.154318] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
463 Cantoral A, Montoya A, Luna-Villa L, Roldán-Valadez EA, Hernández-Ávila M, Kershenobich D, Perng W, Peterson KE, Hu H, Rivera JA, Téllez-Rojo MM. Overweight and obesity status from the prenatal period to adolescence and its association with non-alcoholic fatty liver disease in young adults: cohort study. BJOG 2020;127:1200-9. [PMID: 32145139 DOI: 10.1111/1471-0528.16199] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
464 Jia S, Zhao Y, Liu J, Guo X, Chen M, Zhou S, Zhou J. Magnetic Resonance Imaging-Proton Density Fat Fraction vs. Transient Elastography-Controlled Attenuation Parameter in Diagnosing Non-alcoholic Fatty Liver Disease in Children and Adolescents: A Meta-Analysis of Diagnostic Accuracy. Front Pediatr 2022;9:784221. [DOI: 10.3389/fped.2021.784221] [Reference Citation Analysis]
465 Dietrich CF, Shi L, Löwe A, Dong Y, Potthoff A, Sparchez Z, Teufel A, Guth S, Koch J, Barr RG, Cui XW. Conventional ultrasound for diagnosis of hepatic steatosis is better than believed. Z Gastroenterol 2021. [PMID: 34171931 DOI: 10.1055/a-1491-1771] [Reference Citation Analysis]
466 Clermont-Dejean NM, Schwenger KJP, Salazar E, Colombo FF, Lu Z, Lou W, Gramlich L, Whittaker S, Armstrong D, Jurewitsch B, Raman M, Duerksen DR, McHattie JD, Murthy S, Allard JP. Home parenteral nutrition patients on mixed oil lipid emulsion have a higher rate of hospitalizations compare to those on soybean oil- a prospective 2-year cohort study. Clin Nutr 2021;40:4616-23. [PMID: 34229267 DOI: 10.1016/j.clnu.2021.06.012] [Reference Citation Analysis]
467 Majeed M, Majeed S, Nagabhushanam K, Lawrence L, Mundkur L. Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice. Sci Rep 2020;10:7440. [PMID: 32366854 DOI: 10.1038/s41598-020-64293-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
468 Sarkar M, Grab J, Dodge JL, Gunderson EP, Rubin J, Irani RA, Cedars M, Terrault N. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. J Hepatol 2020;73:516-22. [PMID: 32531415 DOI: 10.1016/j.jhep.2020.03.049] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
469 Diniz AB, Antunes MM, Lacerda VAS, Nakagaki BN, Freitas Lopes MA, Castro-Oliveira HM, Mattos MS, Mafra K, de Miranda CDM, de Oliveira Costa KM, Lopes ME, Alvarenga DM, Carvalho-Gontijo R, Marchesi SC, Lacerda DR, de Araújo AM, de Carvalho É, David BA, Santos MM, Lima CX, Silva Gomes JA, Minto Fontes Cal TC, de Souza BR, Couto CA, Faria LC, Teixeira Vidigal PV, Matos Ferreira AV, Radhakrishnnan S, Ricci M, Oliveira AG, Rezende RM, Menezes GB. Imaging and immunometabolic phenotyping uncover changes in the hepatic immune response in the early phases of NAFLD. JHEP Rep 2020;2:100117. [PMID: 32695965 DOI: 10.1016/j.jhepr.2020.100117] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
470 Bredin C, Naimimohasses S, Norris S, Wright C, Hancock N, Hart K, Moore JB. Development and relative validation of a short food frequency questionnaire for assessing dietary intakes of non-alcoholic fatty liver disease patients. Eur J Nutr 2020;59:571-80. [PMID: 30805696 DOI: 10.1007/s00394-019-01926-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
471 Orabi D, Berger NA, Brown JM. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers (Basel) 2021;13:3473. [PMID: 34298687 DOI: 10.3390/cancers13143473] [Reference Citation Analysis]
472 Lardi LL, Lul RM, Port GZ, Coral GP, Peres A, Dornelles GP, Branco F, Fernandes S, Leães CG, Mattos AA, Buss C, Tovo CV. Fibromax and inflamatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease. Minerva Gastroenterol (Torino) 2022;68:85-90. [PMID: 32700499 DOI: 10.23736/S2724-5985.20.02746-4] [Reference Citation Analysis]
473 Rudolph B, Bjorklund N, Ovchinsky N, Kogan-Liberman D, Perez A, Liszewski M, Levin TL, Ewart M, Liu Q, Xue X, Viswanathan S, Strickler HD. Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design. Contemp Clin Trials 2018;75:51-8. [PMID: 30401631 DOI: 10.1016/j.cct.2018.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
474 Ding R, Lu W, Zhou X, Huang D, Wang Y, Li X, Yan L, Lin W, Song S, Zhang Z, Chen L. A Novel Non-invasive Model Based on GPR for the Prediction of Liver Fibrosis in Patients With Chronic Hepatitis B. Front Med (Lausanne) 2021;8:727706. [PMID: 34631748 DOI: 10.3389/fmed.2021.727706] [Reference Citation Analysis]
475 Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, Farrell K, Sunny NE, Kalavalapalli S, Pettus J, Ciaraldi TP, Mudaliar S, Henry RR. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21:812-821. [PMID: 30447037 DOI: 10.1111/dom.13584] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
476 Sarwar R, Pierce N, Koppe S. Obesity and nonalcoholic fatty liver disease: current perspectives. Diabetes Metab Syndr Obes 2018;11:533-42. [PMID: 30288073 DOI: 10.2147/DMSO.S146339] [Cited by in Crossref: 62] [Cited by in F6Publishing: 41] [Article Influence: 15.5] [Reference Citation Analysis]
477 Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H. Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy. Antioxidants (Basel) 2021;10:174. [PMID: 33530432 DOI: 10.3390/antiox10020174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
478 Kenđel Jovanović G, Mrakovcic-Sutic I, Pavičić Žeželj S, Benjak Horvat I, Šuša L, Rahelić D, Klobučar Majanović S. Metabolic and Hepatic Effects of Energy-Reduced Anti-Inflammatory Diet in Younger Adults with Obesity. Can J Gastroenterol Hepatol 2021;2021:6649142. [PMID: 33628758 DOI: 10.1155/2021/6649142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
479 Kockerling D, Nathwani R, Forlano R, Manousou P, Mullish BH, Dhar A. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25(8): 888-908 [PMID: 30833797 DOI: 10.3748/wjg.v25.i8.888] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
480 Bertot LC, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Chin J, Huang Y, Adams LA. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. Liver Int. 2018;38:1793-1802. [PMID: 29575516 DOI: 10.1111/liv.13739] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
481 Jiang ZG, Tapper EB. Cost Saving or Cost Effective? Unanswered Questions in the Screening of Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun 2019;3:1293-5. [PMID: 31592491 DOI: 10.1002/hep4.1386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
482 Mantovani A, Dauriz M, Gatti D, Viapiana O, Zoppini G, Lippi G, Byrne CD, Bonnet F, Bonora E, Targher G. Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. Aliment Pharmacol Ther 2019;49:375-88. [PMID: 30600540 DOI: 10.1111/apt.15087] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
483 Noureddin M, Ntanios F, Malhotra D, Hoover K, Emir B, McLeod E, Alkhouri N. Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning. Hepatol Commun 2022. [PMID: 35365931 DOI: 10.1002/hep4.1935] [Reference Citation Analysis]
484 Kozłowska-Petriczko K, Wunsch E, Petriczko J, Syn WK, Milkiewicz P. Diagnostic Accuracy of Non-Imaging and Ultrasound-Based Assessment of Hepatic Steatosis Using Controlled Attenuation Parameter (CAP) as Reference. J Clin Med 2021;10:1507. [PMID: 33916626 DOI: 10.3390/jcm10071507] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
485 Herrington GJ, Peterson JJ, Cheng L, Allington BM, Jensen RD, Healy HS, Correia MLG. The use of very low‐calorie diets in subjects with obesity complicated with nonalcoholic fatty liver disease: A scoping review. Obesity Science & Practice. [DOI: 10.1002/osp4.589] [Reference Citation Analysis]
486 Hartley A, Santos Ferreira DL, Anderson EL, Lawlor DA. Metabolic profiling of adolescent non-alcoholic fatty liver disease. Wellcome Open Res 2018;3:166. [PMID: 30687796 DOI: 10.12688/wellcomeopenres.14974.2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
487 Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol 2020;5:996-1007. [PMID: 32805205 DOI: 10.1016/S2468-1253(20)30216-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
488 Bannaga AS, Metzger J, Kyrou I, Voigtländer T, Book T, Melgarejo J, Latosinska A, Pejchinovski M, Staessen JA, Mischak H, Manns MP, Arasaradnam RP. Discovery, validation and sequencing of urinary peptides for diagnosis of liver fibrosis-A multicentre study. EBioMedicine 2020;62:103083. [PMID: 33160210 DOI: 10.1016/j.ebiom.2020.103083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
489 Chen C, Li H, Song J, Zhang C, Li M, Mao Y, Liu A, Du J, Drew PD. Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease. PPAR Research 2022;2022:1-7. [DOI: 10.1155/2022/4709300] [Reference Citation Analysis]
490 Chondronikola M, Sarkar S. Total-body PET Imaging: A New Frontier for the Assessment of Metabolic Disease and Obesity. PET Clin 2021;16:75-87. [PMID: 33160928 DOI: 10.1016/j.cpet.2020.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
491 Adler E, Brandman D. Treatment of Fatty Liver Disease-Time to Implement Common Sense Measures. JAMA Intern Med 2019. [PMID: 31260055 DOI: 10.1001/jamainternmed.2019.2244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
492 Armstrong MJ, Mellinger JL, Trivedi PJ. Alcohol Consumption in Patients with Non-alcoholic Fatty Liver Disease: Convenient vs. Inconvenient Truths. Am J Gastroenterol 2018;113:1437-9. [PMID: 30166633 DOI: 10.1038/s41395-018-0237-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
493 Guo W, Tian W, Lin L, Xu X. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. Diabetes Research and Clinical Practice 2020;170:108487. [DOI: 10.1016/j.diabres.2020.108487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
494 Sawaf B, Ali AH, Jaafar RF, Kanso M, Mukherji D, Khalife MJ, Faraj W. Spectrum of liver diseases in patients referred for Fibroscan: A single center experience in the Middle East. Ann Med Surg (Lond) 2020;57:166-70. [PMID: 32774848 DOI: 10.1016/j.amsu.2020.07.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
495 Panunzi S, Maltese S, Verrastro O, Labbate L, De Gaetano A, Pompili M, Capristo E, Bornstein SR, Mingrone G. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. Diabetes Obes Metab. 2021;23:980-990. [PMID: 33368954 DOI: 10.1111/dom.14304] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
496 Likhitsup A, Dundulis J, Ansari S, El-Halawany H, Michelson R, Hutton C, Kennedy K, Helzberg JH, Chhabra R. Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department. Ann Gastroenterol. 2019;32:283-286. [PMID: 31040626 DOI: 10.20524/aog.2019.0371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
497 Tamargo JA, Sherman KE, Campa A, Martinez SS, Li T, Hernandez J, Teeman C, Mandler RN, Chen J, Ehman RL, Baum MK. Food insecurity is associated with magnetic resonance-determined nonalcoholic fatty liver and liver fibrosis in low-income, middle-aged adults with and without HIV. Am J Clin Nutr 2021;113:593-601. [PMID: 33515016 DOI: 10.1093/ajcn/nqaa362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
498 Rudolph B. Diagnostic and Treatment Dilemmas in Pediatric NAFLD. Clin Liver Dis (Hoboken) 2021;18:37-9. [PMID: 34484703 DOI: 10.1002/cld.1085] [Reference Citation Analysis]
499 Qi R, Jiang R, Xiao H, Wang Z, He S, Wang L, Wang Y. Ginsenoside Rg1 protects against d-galactose induced fatty liver disease in a mouse model via FOXO1 transcriptional factor. Life Sci 2020;254:117776. [PMID: 32437790 DOI: 10.1016/j.lfs.2020.117776] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
500 Mantovani A, Turino T, Lando MG, Gjini K, Byrne CD, Zusi C, Ravaioli F, Colecchia A, Maffeis C, Salvagno G, Lippi G, Bonora E, Targher G. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab. 2019;. [PMID: 31786361 DOI: 10.1016/j.diabet.2019.11.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
501 Cholongitas E, Pavlopoulou I, Papatheodoridi M, Markakis GE, Bouras E, Haidich AB, Papatheodoridis G. Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. Ann Gastroenterol 2021;34:404-14. [PMID: 33948067 DOI: 10.20524/aog.2021.0604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
502 Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021;110:921-37. [PMID: 32696080 DOI: 10.1007/s00392-020-01709-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
503 Lin SZ, Chen YW, Fan JG. Non‐alcoholic fatty liver disease to metabolic dysfunction‐associated fatty liver disease : Conceptual changes for clinicians, researchers and patients. J Dig Dis 2020;21:604-9. [DOI: 10.1111/1751-2980.12944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
504 Lee GH, Phyo WW, Loo WM, Kwok R, Ahmed T, Shabbir A, So J, Koh CJ, Hartono JL, Muthiah M, Lim K, Tan PS, Lee YM, Lim SG, Dan YY. Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population. World J Hepatol 2020; 12(12): 1228-1238 [PMID: 33442450 DOI: 10.4254/wjh.v12.i12.1228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
505 Mutlu B, Puigserver P. Controversies surrounding peripheral cannabinoid receptor 1 in fatty liver disease. J Clin Invest 2021;131:e154147. [PMID: 34779413 DOI: 10.1172/JCI154147] [Reference Citation Analysis]
506 Orlandi P, Solini A, Banchi M, Brunetto MR, Cioni D, Ghiadoni L, Bocci G. Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. Pharmaceuticals (Basel) 2021;14:995. [PMID: 34681219 DOI: 10.3390/ph14100995] [Reference Citation Analysis]
507 Ferraioli G, Berzigotti A, Barr RG, Choi BI, Cui XW, Dong Y, Gilja OH, Lee JY, Lee DH, Moriyasu F, Piscaglia F, Sugimoto K, Wong GL, Wong VW, Dietrich CF. Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. Ultrasound Med Biol 2021;47:2803-20. [PMID: 34284932 DOI: 10.1016/j.ultrasmedbio.2021.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
508 Leone A, Battezzati A, Bedogni G, Vignati L, Vanzulli A, De Amicis R, Foppiani A, Bertoli S. Sex- and Age-Related Differences in the Contribution of Ultrasound-Measured Visceral and Subcutaneous Abdominal Fat to Fatty Liver Index in Overweight and Obese Caucasian Adults. Nutrients 2019;11:E3008. [PMID: 31835303 DOI: 10.3390/nu11123008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
509 Younossi ZM, Ong JP, Takahashi H, Yilmaz Y, Eguchi Y, El Kassas M, Buti M, Diago M, Zheng MH, Fan JG, Yu ML, Wai-Sun Wong V, Alswat K, Chan WK, Mendez-Sanchez N, Burra P, Bugianesi E, Duseja AK, George J, Papatheodoridis GV, Saeed H, Castera L, Arrese M, Kugelmas M, Romero-Gomez M, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00719-9. [PMID: 34229038 DOI: 10.1016/j.cgh.2021.06.048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
510 Shah RA, Kowdley KV. Obeticholic acid for the treatment of nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2020;14:311-321. [PMID: 32241197 DOI: 10.1080/17474124.2020.1748498] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
511 Šamadan L, Jeličić M, Vince A, Papić N. Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for Recurrent Clostridioides difficile Infection. Antibiotics (Basel) 2021;10:780. [PMID: 34198964 DOI: 10.3390/antibiotics10070780] [Reference Citation Analysis]
512 Huang S, Mu F, Li F, Wang W, Chen H, Lei L, Ma Y, Ding Y, Wang J. A Network-Based Approach to Explore the Mechanism and Bioactive Compounds of Erzhi Pill against Metabolic Dysfunction-Associated Fatty Liver Disease. J Diabetes Res 2020;2020:7867245. [PMID: 32724826 DOI: 10.1155/2020/7867245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
513 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
514 Haam JH, Kim YS, Cho DY, Chun H, Choi SW, Lee YK, Lim SW, Koo HS, Kim MJ. Elevated levels of urine isocitrate, hydroxymethylglutarate, and formiminoglutamate are associated with arterial stiffness in Korean adults. Sci Rep 2021;11:10180. [PMID: 33986342 DOI: 10.1038/s41598-021-89639-w] [Reference Citation Analysis]
515 Luo Y, Wadhawan S, Greenfield A, Decato BE, Oseini AM, Collen R, Shevell DE, Thompson J, Jarai G, Charles ED, Sanyal AJ. SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH. Hepatol Commun 2021;5:760-73. [PMID: 34027267 DOI: 10.1002/hep4.1670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
516 Li C, Cui L, Wang X, Yan Z, Wang S, Zheng Y. Using intestinal flora to distinguish non-alcoholic steatohepatitis from non-alcoholic fatty liver. J Int Med Res 2020;48:300060520978122. [PMID: 33327816 DOI: 10.1177/0300060520978122] [Reference Citation Analysis]
517 Saha P, Talukdar AD, Nath R, Sarker SD, Nahar L, Sahu J, Choudhury MD. Role of Natural Phenolics in Hepatoprotection: A Mechanistic Review and Analysis of Regulatory Network of Associated Genes. Front Pharmacol 2019;10:509. [PMID: 31178720 DOI: 10.3389/fphar.2019.00509] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
518 Ma Z, Wang Y, Xu C, Ai F, Huang L, Wang J, Peng J, Zhou Y, Yin M, Zhang S, Yang X. Obesity-Related Genetic Variants and Hyperuricemia Risk in Chinese Men. Front Endocrinol (Lausanne) 2019;10:230. [PMID: 31031707 DOI: 10.3389/fendo.2019.00230] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
519 Wong VW, Irles M, Wong GL, Shili S, Chan AW, Merrouche W, Shu SS, Foucher J, Le Bail B, Chan WK, Chan HL, de Ledinghen V. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut 2019;68:2057-64. [PMID: 30658997 DOI: 10.1136/gutjnl-2018-317334] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 16.0] [Reference Citation Analysis]
520 Keleidari B, Mahmoudieh M, Gorgi K, Sheikhbahaei E, Shahabi S. Hepatic Failure After Bariatric Surgery: A Systematic Review. Hepat Mon 2019;In Press. [DOI: 10.5812/hepatmon.86078] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
521 Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00821-1. [PMID: 34329774 DOI: 10.1016/j.cgh.2021.07.039] [Reference Citation Analysis]
522 Méndez-sánchez N, Chavez-tapia NC, Almeda-valdes P, Uribe M. The Management of Incidental Fatty Liver Found on Imaging. What Do We Need to do?: . American Journal of Gastroenterology 2018;113:1274-6. [DOI: 10.1038/s41395-018-0047-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
523 Maharjan S, Bonilla D, Sindurakar P, Li H, Li W, Duarte S, Zarrinpar A, Zhang YS. 3D human nonalcoholic hepatic steatosis and fibrosis models. Bio-des Manuf 2021;4:157-70. [DOI: 10.1007/s42242-020-00121-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
524 Moore MP, Cunningham RP, Davis RAH, Deemer SE, Roberts BM, Plaisance EP, Rector RS. A dietary ketone ester mitigates histological outcomes of NAFLD and markers of fibrosis in high-fat diet fed mice. Am J Physiol Gastrointest Liver Physiol 2021;320:G564-72. [PMID: 33501889 DOI: 10.1152/ajpgi.00259.2020] [Reference Citation Analysis]
525 Hashida R, Nakano D, Yamamura S, Kawaguchi T, Tsutsumi T, Matsuse H, Takahashi H, Gerber L, Younossi ZM, Torimura T. Association between Activity and Brain-Derived Neurotrophic Factor in Patients with Non-Alcoholic Fatty Liver Disease: A Data-Mining Analysis. Life (Basel) 2021;11:799. [PMID: 34440543 DOI: 10.3390/life11080799] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
526 Davis TME. Diabetes and metabolic dysfunction-associated fatty liver disease. Metabolism 2021;123:154868. [PMID: 34400217 DOI: 10.1016/j.metabol.2021.154868] [Reference Citation Analysis]
527 Jamwal R, de la Monte SM, Ogasawara K, Adusumalli S, Barlock BB, Akhlaghi F. Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver. Mol Pharm 2018;15:2621-32. [PMID: 29792708 DOI: 10.1021/acs.molpharmaceut.8b00159] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
528 Pirola CJ, Sookoian S. Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity. World J Gastroenterol 2018; 24(15): 1601-1615 [PMID: 29686467 DOI: 10.3748/wjg.v24.i15.1601] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 29] [Article Influence: 9.5] [Reference Citation Analysis]
529 Li H, Guo M, An Z, Meng J, Jiang J, Song J, Wu W. Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China. Int J Environ Res Public Health 2020;17:E1818. [PMID: 32168920 DOI: 10.3390/ijerph17061818] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
530 Vespasiani-Gentilucci U, Gallo P, Dell’Unto C, Volpentesta M, Antonelli-Incalzi R, Picardi A. Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables. World J Gastroenterol 2018; 24(43): 4835-4845 [PMID: 30487694 DOI: 10.3748/wjg.v24.i43.4835] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
531 Cigrovski Berkovic M, Virovic-Jukic L, Bilic-Curcic I, Mrzljak A. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World J Gastroenterol 2020; 26(21): 2740-2757 [PMID: 32550751 DOI: 10.3748/wjg.v26.i21.2740] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
532 Seif El-Din SH, Salem MB, El-Lakkany NM, Hammam OA, Nasr SM, Okasha H, Ahmed LA, Saleh S, Botros SS. Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. Hum Exp Toxicol 2021;40:1496-509. [PMID: 33678036 DOI: 10.1177/0960327121999445] [Reference Citation Analysis]
533 Mantovani A, Zusi C. The dawn of a new era for nonalcoholic fatty liver disease? Hepatobiliary Surg Nutr 2019;8:629-31. [PMID: 31929991 DOI: 10.21037/hbsn.2019.09.15] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
534 Pinyopornpanish K, Al-Yaman W, Butler RS, Carey W, McCullough A, Romero-Marrero C. Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis. Am J Gastroenterol 2021. [PMID: 34212895 DOI: 10.14309/ajg.0000000000001347] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
535 Srivastava RAK. Life-style-induced metabolic derangement and epigenetic changes promote diabetes and oxidative stress leading to NASH and atherosclerosis severity. J Diabetes Metab Disord 2018;17:381-91. [PMID: 30918873 DOI: 10.1007/s40200-018-0378-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
536 Samala N, Desai A, Vilar-Gomez E, Smith ER, Gawrieh S, Kettler CD, Pike F, Chalasani N. Decreased Quality of Life Is Significantly Associated With Body Composition in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020;18:2980-2988.e4. [PMID: 32360826 DOI: 10.1016/j.cgh.2020.04.046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
537 Sofogianni A, Filippidis A, Chrysavgis L, Tziomalos K, Cholongitas E. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. World J Hepatol 2020; 12(8): 493-505 [PMID: 32952876 DOI: 10.4254/wjh.v12.i8.493] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
538 Lenga L, Lange M, Arendt CT, Yel I, Booz C, Durden J, Leithner D, Vogl TJ, Albrecht MH, Martin SS. Can Dual-energy CT-based Virtual Monoenergetic Imaging Improve the Assessment of Hypodense Liver Metastases in Patients With Hepatic Steatosis? Acad Radiol 2021;28:769-77. [PMID: 32446765 DOI: 10.1016/j.acra.2020.03.044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
539 Zhang Z, Dai W, Weng S, Luo M, Fu J, Zadroga JA, Spolitu S, Peng D. The association of serum total bile acid with non-alcoholic fatty liver disease in Chinese adults: a cross sectional study. Lipids Health Dis 2020;19:18. [PMID: 32019569 DOI: 10.1186/s12944-020-1201-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
540 Marin-Alejandre BA, Abete I, Cantero I, Riezu-Boj JI, Milagro FI, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano JI, Huarte-Muniesa MP, Tur JA, Martínez JA, Zulet MA. Association between Sleep Disturbances and Liver Status in Obese Subjects with Nonalcoholic Fatty Liver Disease: A Comparison with Healthy Controls. Nutrients 2019;11:E322. [PMID: 30717355 DOI: 10.3390/nu11020322] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
541 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
542 Kim Y. Emerging Treatment Options for Sarcopenia in Chronic Liver Disease. Life (Basel) 2021;11:250. [PMID: 33803020 DOI: 10.3390/life11030250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
543 Małecki P, Figlerowicz M, Kemnitz P, Mazur-Melewska K, Służewski W, Mania A. Estimation of the risk of fibrosis in children with nonalcoholic fatty liver disease. Clin Exp Hepatol 2020;6:220-7. [PMID: 33145428 DOI: 10.5114/ceh.2020.99515] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
544 Hong Y, Dufendach K, Wang Y, Thoma F, Kilic A. Impact of hepatic steatosis on outcomes after left ventricular assist device implantation. J Card Surg 2021;36:2277-83. [PMID: 33783048 DOI: 10.1111/jocs.15536] [Reference Citation Analysis]
545 Dobbie LJ, Kassab M, Davison AS, Grace P, Cuthbertson DJ, Hydes TJ. Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care. J Clin Med 2021;10:5755. [PMID: 34945051 DOI: 10.3390/jcm10245755] [Reference Citation Analysis]
546 Willis SA, Bawden SJ, Malaikah S, Sargeant JA, Stensel DJ, Aithal GP, King JA. The role of hepatic lipid composition in obesity-related metabolic disease. Liver Int 2021. [PMID: 34547171 DOI: 10.1111/liv.15059] [Reference Citation Analysis]
547 Rinella M, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol 2021:S0168-8278(21)02177-2. [PMID: 34793868 DOI: 10.1016/j.jhep.2021.10.029] [Reference Citation Analysis]
548 Zhang NP, Liu XJ, Xie L, Shen XZ, Wu J. Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. Lab Invest. 2019;99:749-763. [PMID: 30700851 DOI: 10.1038/s41374-018-0177-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
549 Wang C, Chuang H, Liao K, Yu M, Dai C, Chang W, Tsai C, Chiang H, Huang P. Urinary thiodiglycolic acid is associated with increased risk of non-alcoholic fatty liver disease in children living near a petrochemical complex. Environment International 2019;131:104978. [DOI: 10.1016/j.envint.2019.104978] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
550 Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, Chien N, Trinh S, Henry L, Stave CD, Hosaka T, Cheung RC, Nguyen MH. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739-752. [PMID: 32413340 DOI: 10.1016/s2468-1253(20)30077-7] [Cited by in Crossref: 85] [Cited by in F6Publishing: 38] [Article Influence: 42.5] [Reference Citation Analysis]
551 Fujii H, Kawada N, Japan Study Group Of Nafld Jsg-Nafld. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E3863. [PMID: 32485838 DOI: 10.3390/ijms21113863] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
552 Huang P, Tu B, Liao HJ, Huang FZ, Li ZZ, Zhu KY, Dai F, Liu HZ, Zhang TY, Sun CZ. Elevation of plasma tRNA fragments as a promising biomarker for liver fibrosis in nonalcoholic fatty liver disease. Sci Rep 2021;11:5886. [PMID: 33723340 DOI: 10.1038/s41598-021-85421-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
553 Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020;17:40-52. [PMID: 31641249 DOI: 10.1038/s41575-019-0212-0] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 22.7] [Reference Citation Analysis]
554 Xu J, Wang R, You S, Zhang L, Zheng P, Ji G, Liu B. Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern: Study protocol for a multicenter randomized controlled trial. Trials 2020;21:512. [PMID: 32522273 DOI: 10.1186/s13063-020-04362-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
555 Sanguankeo A. Comment on: gastric bypass specifically impairs liver parameters as compared with sleeve gastrectomy, independently of evolution of metabolic disorders. Surg Obes Relat Dis 2019;15:513. [PMID: 30709749 DOI: 10.1016/j.soard.2019.01.006] [Reference Citation Analysis]
556 Li Q, Li JF, Mao XR. Application of artificial intelligence in liver diseases: From diagnosis to treatment. Artif Intell Gastroenterol 2021; 2(5): 133-140 [DOI: 10.35712/aig.v2.i5.133] [Reference Citation Analysis]
557 Ozaki A, Yoneda M, Kessoku T, Iwaki M, Kobayashi T, Honda Y, Ogawa Y, Imajo K, Sakai E, Taguri M, Yamanaka T, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). Contemp Clin Trials Commun 2020;17:100516. [PMID: 31956725 DOI: 10.1016/j.conctc.2019.100516] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
558 Ebadi M, Ip S, Bhanji RA, Montano-Loza AJ. Effect of Coffee Consumption on Non-Alcoholic Fatty Liver Disease Incidence, Prevalence and Risk of Significant Liver Fibrosis: Systematic Review with Meta-Analysis of Observational Studies. Nutrients 2021;13:3042. [PMID: 34578919 DOI: 10.3390/nu13093042] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
559 León-Mimila P, Villamil-Ramírez H, Li XS, Shih DM, Hui ST, Ocampo-Medina E, López-Contreras B, Morán-Ramos S, Olivares-Arevalo M, Grandini-Rosales P, Macías-Kauffer L, González-González I, Hernández-Pando R, Gómez-Pérez F, Campos-Pérez F, Aguilar-Salinas C, Larrieta-Carrasco E, Villarreal-Molina T, Wang Z, Lusis AJ, Hazen SL, Huertas-Vazquez A, Canizales-Quinteros S. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. Diabetes Metab 2021;47:101183. [PMID: 32791310 DOI: 10.1016/j.diabet.2020.07.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
560 Shi L, Guo S, Zhang S, Gao X, Liu A, Wang Q, Zhang T, Zhang Y, Wen A. Glycyrrhetinic acid attenuates disturbed vitamin a metabolism in non-alcoholic fatty liver disease through AKR1B10. Eur J Pharmacol 2020;883:173167. [PMID: 32485245 DOI: 10.1016/j.ejphar.2020.173167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
561 Perakakis N, Joshi A, Peradze N, Stefanakis K, Li G, Feigh M, Veidal SS, Rosen G, Fleming M, Mantzoros CS. The Selective Peroxisome Proliferator-Activated Receptor Gamma Modulator CHS-131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis. Hepatol Commun 2020;4:1302-15. [PMID: 32923834 DOI: 10.1002/hep4.1558] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
562 Ni M, Zhang B, Zhao J, Feng Q, Peng J, Hu Y, Zhao Y. Biological mechanisms and related natural modulators of liver X receptor in nonalcoholic fatty liver disease. Biomedicine & Pharmacotherapy 2019;113:108778. [DOI: 10.1016/j.biopha.2019.108778] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
563 Ciećko-Michalska I, Szczepanek M, Tobiasz-Adamczyk B, Mach T. Non-alcoholic fatty liver disease in Poland: how and at what stage is diagnosed, and how is treated. A survey study. Prz Gastroenterol 2019;14:173-7. [PMID: 31649787 DOI: 10.5114/pg.2019.88165] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
564 Mejia JC, Pasko J. Primary Liver Cancers: Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Clin North Am 2020;100:535-49. [PMID: 32402299 DOI: 10.1016/j.suc.2020.02.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
565 Chuah KH, Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Liver stiffness measurement in non-alcoholic fatty liver disease: Two is better than one. J Gastroenterol Hepatol 2020;35:1404-11. [PMID: 31907981 DOI: 10.1111/jgh.14978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
566 Hanayama M, Yamamoto Y, Utsunomiya H, Yoshida O, Liu S, Mogi M, Matsuura B, Takeshita E, Ikeda Y, Hiasa Y. The mechanism of increased intestinal palmitic acid absorption and its impact on hepatic stellate cell activation in nonalcoholic steatohepatitis. Sci Rep 2021;11:13380. [PMID: 34183709 DOI: 10.1038/s41598-021-92790-z] [Reference Citation Analysis]
567 Banini BA, Sanyal AJ. NAFLD-related HCC. Adv Cancer Res 2021;149:143-69. [PMID: 33579423 DOI: 10.1016/bs.acr.2020.11.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
568 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
569 Aboubakr A, Stroud A, Kumar S, Newberry C. Dietary Approaches for Management of Non-Alcoholic Fatty Liver Disease: A Clinician's Guide. Curr Gastroenterol Rep 2021;23:21. [PMID: 34654976 DOI: 10.1007/s11894-021-00827-0] [Reference Citation Analysis]
570 Wong RJ, Tran T, Kaufman H, Niles J, Gish R. Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis. PLoS One 2019;14:e0220612. [PMID: 31369606 DOI: 10.1371/journal.pone.0220612] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
571 Properzi C, O'Sullivan TA, Sherriff JL, Ching HL, Jeffrey GP, Buckley RF, Tibballs J, MacQuillan GC, Garas G, Adams LA. Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial. Hepatology. 2018;68:1741-1754. [PMID: 29729189 DOI: 10.1002/hep.30076] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 17.5] [Reference Citation Analysis]
572 Kumar J, Memon RS, Shahid I, Rizwan T, Zaman M, Menezes RG, Kumar S, Siddiqi TJ, Usman MS. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. Dig Liver Dis 2021;53:44-51. [PMID: 32912770 DOI: 10.1016/j.dld.2020.08.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
573 Yao VJH, Sun M, Rahman AA, Samuel Z, Chan J, Zheng E, Yao AC. Comparative analysis of metabolic risk factors for progression of non-alcoholic fatty liver disease. Clin Exp Hepatol 2021;7:241-7. [PMID: 34295993 DOI: 10.5114/ceh.2021.107567] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
574 Lu S, Wang Y, Liu J. TNF-α signaling in non-alcoholic steatohepatitis and targeted therapies. J Genet Genomics 2021:S1673-8527(21)00337-4. [PMID: 34757037 DOI: 10.1016/j.jgg.2021.09.009] [Reference Citation Analysis]
575 Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Toyoda H, Kumada T, Fujishiro M. Serum Nutritional Markers as Prognostic Factors for Hepatic and Extrahepatic Carcinogenesis in Japanese Patients with Nonalcoholic Fatty Liver Disease. Nutr Cancer 2020;72:884-91. [PMID: 31433263 DOI: 10.1080/01635581.2019.1653474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
576 Liu B, Xue J, Zhang M, Wang M, Ma T, Zhao M, Gu Q, Qin S. Hydrogen inhalation alleviates nonalcoholic fatty liver disease in metabolic syndrome rats. Mol Med Rep 2020;22:2860-8. [PMID: 32945408 DOI: 10.3892/mmr.2020.11364] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
577 Ascher Bartlett JM, Mittal N. Approach to Pediatric Obesity and Nonalcoholic Fatty Liver Disease. Pediatr Ann 2021;50:e474-7. [PMID: 34757877 DOI: 10.3928/19382359-20211019-02] [Reference Citation Analysis]
578 Park H, Park K, Kim M, Park H, Hwang H. Association between serum uric acid level and non-alcoholic fatty liver disease in Koreans. Asian Biomedicine 2022;16:15-22. [DOI: 10.2478/abm-2022-0003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
579 Li J, Liu M, Li Y, Sun DD, Shu Z, Tan Q, Guo S, Xie R, Gao L, Ru H, Zang Y, Liu H, Li J, Zhou Y. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem 2020;63:12748-72. [PMID: 32991173 DOI: 10.1021/acs.jmedchem.0c01065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
580 Chuah K, Chan W. Quantification of Liver Fat in NAFLD: Available Modalities and Clinical Significance. Curr Hepatology Rep 2019;18:492-502. [DOI: 10.1007/s11901-019-00493-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
581 Burhans MS, Balu N, Schmidt KA, Cromer G, Utzschneider KM, Schur EA, Holte SE, Randolph TW, Kratz M. Impact of the Analytical Approach on the Reliability of MRI-Based Assessment of Hepatic Fat Content. Curr Dev Nutr 2020;4:nzaa171. [PMID: 33381677 DOI: 10.1093/cdn/nzaa171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
582 Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.Arch Med Res. 2021;52:25-37. [PMID: 33334622 DOI: 10.1016/j.arcmed.2020.11.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
583 Castellana M, Biacchi E, Procino F, Casanueva FF, Trimboli P. Very-low-calorie ketogenic diet for the management of obesity, overweight and related disorders. Minerva Endocrinol 2021;46. [DOI: 10.23736/s2724-6507.20.03356-8] [Reference Citation Analysis]
584 Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S. Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig Liver Dis. 2021;53:79-85. [PMID: 33144054 DOI: 10.1016/j.dld.2020.10.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
585 Qin S, Wang S, Wang X, Wang J. Non-alcoholic fatty liver disease and the risk of urolithiasis: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12092. [PMID: 30170429 DOI: 10.1097/MD.0000000000012092] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
586 Congly SE, Shaheen AA, Swain MG. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting. PLoS One 2021;16:e0251741. [PMID: 34019560 DOI: 10.1371/journal.pone.0251741] [Reference Citation Analysis]
587 Kalopitas G, Antza C, Doundoulakis I, Siargkas A, Kouroumalis E, Germanidis G, Samara M, Chourdakis M. Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Nutrition 2021;83:111092. [PMID: 33418491 DOI: 10.1016/j.nut.2020.111092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
588 Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int 2021;41:1290-3. [PMID: 33590934 DOI: 10.1111/liv.14828] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
589 Fassio E, Barreyro FJ, Pérez MS, Dávila D, Landeira G, Gualano G, Ruffillo G. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations? WJH 2022; 14(2):354-71. [DOI: 10.4254/wjh.v14.i2.354] [Reference Citation Analysis]
590 Prasoppokakorn T, Chan WK, Wong VWS, Pitisuttithum P, Mahadeva S, Nik Mustapha NR, Wong GLH, Leung HHW, Sripongpun P, Treeprasertsuk S. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease . World J Gastroenterol 2022; 28(15): 1563-1573 [DOI: 10.3748/wjg.v28.i15.1563] [Reference Citation Analysis]
591 Suliman I, Abdelgelil N, Kassamali F, Hassanein TI. The Effects of Hepatic Steatosis on the Natural History of HBV Infection. Clin Liver Dis. 2019;23:433-450. [PMID: 31266618 DOI: 10.1016/j.cld.2019.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
592 Houttu V, Boulund U, Grefhorst A, Soeters MR, Pinto-Sietsma SJ, Nieuwdorp M, Holleboom AG. The role of the gut microbiome and exercise in non-alcoholic fatty liver disease. Therap Adv Gastroenterol 2020;13:1756284820941745. [PMID: 32973925 DOI: 10.1177/1756284820941745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
593 Zhai Z, Niu KM, Liu H, Lin C, Tu Y, Liu Y, Cai L, Ouyang K, Liu J. Policosanol alleviates hepatic lipid accumulation by regulating bile acids metabolism in C57BL6/mice through AMPK-FXR-TGR5 cross-talk. J Food Sci 2021. [PMID: 34730235 DOI: 10.1111/1750-3841.15951] [Reference Citation Analysis]
594 Jung CY, Ryu GW, Kim HW, Ahn SH, Kim SU, Kim BS. Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease. Diabetologia 2021. [PMID: 34932136 DOI: 10.1007/s00125-021-05627-9] [Reference Citation Analysis]
595 Xiao MW, Lin SX, Shen ZH, Luo WW, Wang XY. Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract 2019;2019:1484598. [PMID: 31885541 DOI: 10.1155/2019/1484598] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
596 Wang L, Wang Y, Liu S, Zhai X, Zhou G, Lu F, Zhao J. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol 2019;54:1096-105. [PMID: 31134334 DOI: 10.1007/s00535-019-01594-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
597 Compaoré NI, Coulibaly A, Koura M, Somda KS, Somé CC, Zombré NMS, Bougouma A. [Metabolic hepatic steatosis associated with obesity in adults living in Burkina Faso]. Pan Afr Med J 2021;38:266. [PMID: 34122693 DOI: 10.11604/pamj.2021.38.266.22253] [Reference Citation Analysis]
598 Seymour KA, Abdelmalek MF. The role of bariatric surgery in the management of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2021;37:208-15. [PMID: 33769376 DOI: 10.1097/MOG.0000000000000721] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
599 Orkin S, Yodoshi T, Sun Q, Fei L, Meryum S, Arce-Clachar AC, Bramlage K, Beck AF, Mouzaki M. Can Baseline Characteristics be Used to Predict Liver Disease Outcomes in Pediatric Nonalcoholic Fatty Liver Disease? Obesity (Silver Spring) 2021;29:171-6. [PMID: 33185977 DOI: 10.1002/oby.22999] [Reference Citation Analysis]
600 Green CH, Syn WK. Non-nutritive sweeteners and their association with the metabolic syndrome and non-alcoholic fatty liver disease: a review of the literature. Eur J Nutr 2019;58:1785-800. [PMID: 31119399 DOI: 10.1007/s00394-019-01996-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
601 Moein H, Arteaga EJ, Sarkar S. Using Telehealth for Diagnosis and Management of Non‐Alcoholic Fatty Liver Disease. Clinical Liver Disease 2022;19:171-5. [DOI: 10.1002/cld.1191] [Reference Citation Analysis]
602 Rashed ZE, Grasselli E, Khalifeh H, Canesi L, Demori I. Brown-Algae Polysaccharides as Active Constituents against Nonalcoholic Fatty Liver Disease. Planta Med 2020. [PMID: 33142346 DOI: 10.1055/a-1273-3159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
603 Perazzo H, Cardoso SW, Yanavich C, Nunes EP, Morata M, Gorni N, da Silva PS, Cardoso C, Almeida C, Luz P, Veloso VG, Grinsztejn B. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy. J Int AIDS Soc. 2018;21:e25201. [PMID: 30394678 DOI: 10.1002/jia2.25201] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
604 Barbara M, Scott A, Alkhouri N. New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr 2018;7:372-81. [PMID: 30498712 DOI: 10.21037/hbsn.2018.08.05] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
605 Castellana M, Donghia R, Lampignano L, Castellana F, Zupo R, Sardone R, Pergola G, Giannelli G. Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma. J Clin Med 2021;10:4638. [PMID: 34682759 DOI: 10.3390/jcm10204638] [Reference Citation Analysis]
606 Seike T, Mizukoshi E, Yamada K, Okada H, Kitahara M, Yamashita T, Arai K, Terashima T, Iida N, Fushimi K, Yamashita T, Sakai Y, Honda M, Harada K, Kaneko S. Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients. J Gastroenterol 2020;55:701-11. [PMID: 32124081 DOI: 10.1007/s00535-020-01679-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
607 [DOI: 10.1101/2020.09.23.20200535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
608 Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Transplantation. 2019;103:22-27. [PMID: 30335697 DOI: 10.1097/tp.0000000000002484] [Cited by in Crossref: 120] [Cited by in F6Publishing: 57] [Article Influence: 40.0] [Reference Citation Analysis]
609 Mohammadi M, Abbasalipourkabir R, Ziamajidi N. Fish oil and chicoric acid combination protects better against palmitate-induced lipid accumulation via regulating AMPK-mediated SREBP-1/FAS and PPARα/UCP2 pathways. Arch Physiol Biochem 2020;:1-9. [PMID: 32654534 DOI: 10.1080/13813455.2020.1789881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
610 Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022;28:310-31. [PMID: 35110952 DOI: 10.3748/wjg.v28.i3.310] [Reference Citation Analysis]
611 Lou J, Li C, Li ZS, Zhang T, Chen ZN, Bian H. Hepatic CD147 knockout modulates liver steatosis and up-regulates autophagy in high-fat-diet-induced NAFLD mice. Biochem Biophys Res Commun 2020;524:1010-7. [PMID: 32063360 DOI: 10.1016/j.bbrc.2020.01.164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
612 Yabiku K. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Front Endocrinol (Lausanne) 2021;12:768850. [PMID: 34950104 DOI: 10.3389/fendo.2021.768850] [Reference Citation Analysis]
613 Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
614 Mizuno K, Haga H, Okumoto K, Hoshikawa K, Katsumi T, Nishina T, Saito T, Katagiri H, Ueno Y. Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver. PLoS One 2021;16:e0249556. [PMID: 33852613 DOI: 10.1371/journal.pone.0249556] [Reference Citation Analysis]
615 Kim H, Lee DS, An TH, Park HJ, Kim WK, Bae KH, Oh KJ. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int J Mol Sci 2021;22:4495. [PMID: 33925827 DOI: 10.3390/ijms22094495] [Reference Citation Analysis]
616 Bettini S, Bordigato E, Milan G, Dal Pra' C, Favaretto F, Belligoli A, Sanna M, Serra R, Foletto M, Prevedello L, Busetto L, Fassina G, Vettor R, Fabris R. SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy. Obes Facts 2019;12:291-306. [PMID: 31104052 DOI: 10.1159/000499717] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
617 Jacobo-Albavera L, Domínguez-Pérez M, Medina-Leyte DJ, González-Garrido A, Villarreal-Molina T. The Role of the ATP-Binding Cassette A1 (ABCA1) in Human Disease. Int J Mol Sci 2021;22:1593. [PMID: 33562440 DOI: 10.3390/ijms22041593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
618 Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:948-963. [PMID: 30819364 DOI: 10.1016/j.jacc.2018.11.050] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 40.0] [Reference Citation Analysis]
619 Méndez-Sánchez N, Díaz-Orozco LE. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD). Med Sci Monit 2021;27:e933860. [PMID: 34248137 DOI: 10.12659/MSM.933860] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
620 Paul S, Davis AM. Diagnosis and Management of Nonalcoholic Fatty Liver Disease. JAMA. 2018;320:2474-2475. [PMID: 30476962 DOI: 10.1001/jama.2018.17365] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
621 Shah RA, Alkhouri N, Kowdley KV. Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. Expert Opinion on Emerging Drugs 2020;25:251-60. [DOI: 10.1080/14728214.2020.1796968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
622 Iruarrizaga-lejarreta M, Arretxe E, Alonso C. Using metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitis. Expert Review of Precision Medicine and Drug Development 2019;4:283-97. [DOI: 10.1080/23808993.2019.1685379] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
623 Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, Park H, Kim KI, Kim SH, Rim KS, Hwang SG. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol. 2019;25:52-64. [PMID: 30360031 DOI: 10.3350/cmh.2018.0040] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
624 Fujii H, Fukumoto S, Enomoto M, Uchida-Kobayashi S, Kimura T, Tamori A, Nadatani Y, Takashima S, Nishimoto N, Kawada N. The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases. Sci Rep 2021;11:13844. [PMID: 34226630 DOI: 10.1038/s41598-021-93435-x] [Reference Citation Analysis]
625 Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, Anvari M, Hong D. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019;17:1040-1060.e11. [PMID: 30326299 DOI: 10.1016/j.cgh.2018.10.017] [Cited by in Crossref: 99] [Cited by in F6Publishing: 90] [Article Influence: 24.8] [Reference Citation Analysis]
626 Harry S, Lai LL, Nik Mustapha NR, Abdul Aziz YF, Vijayananthan A, Rahmat K, Mahadeva S, Chan WK. Volumetric Liver Fat Fraction Determines Grade of Steatosis More Accurately Than Controlled Attenuation Parameter in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2020;18:945-953.e2. [DOI: 10.1016/j.cgh.2019.08.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
627 Mederacke YS, Kirstein MM, Großhennig A, Marhenke S, Metzler F, Manns MP, Vogel A, Mederacke I. The PNPLA3 rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis. Aliment Pharmacol Ther 2020;51:1160-8. [PMID: 32323349 DOI: 10.1111/apt.15722] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
628 Lake JE, Overton T, Naggie S, Sulkowski M, Loomba R, Kleiner DE, Price JC, Chew KW, Chung RT, Corey KE. Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31431-2. [PMID: 33069882 DOI: 10.1016/j.cgh.2020.10.018] [Reference Citation Analysis]
629 Pahk K, Lee SG, Joung C, Kim EO, Kwon HW, Kim DH, Hwang JI, Kim S, Kim WK. SP-1154, a novel synthetic TGF-β inhibitor, alleviates obesity and hepatic steatosis in high-fat diet-induced mice. Biomed Pharmacother 2022;145:112441. [PMID: 34813997 DOI: 10.1016/j.biopha.2021.112441] [Reference Citation Analysis]
630 Zeng J, Qin L, Jin Q, Yang R, Ning G, Su Q, Yang Z, Fan J. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. Hepatobiliary & Pancreatic Diseases International 2022. [DOI: 10.1016/j.hbpd.2022.01.006] [Reference Citation Analysis]
631 Cho EJ, Yu SJ, Jung GC, Kwak MS, Yang JI, Yim JY, Chung GE. Body weight gain rather than body weight variability associated with increased risk of nonalcoholic fatty liver disease. Sci Rep 2021;11:14428. [PMID: 34257374 DOI: 10.1038/s41598-021-93883-5] [Reference Citation Analysis]
632 Zhou R, Fan X, Schnabl B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res 2019;209:22-38. [PMID: 30853445 DOI: 10.1016/j.trsl.2019.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
633 Ha Y, Chon YE, Kim MN, Lee JH, Hwang SG. Gamma-Glutamyl Transpeptidase Dynamics as a Biomarker for Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease. J Gastroenterol Hepatol 2022. [PMID: 35467042 DOI: 10.1111/jgh.15871] [Reference Citation Analysis]
634 Zhang J, Tan J, Wang M, Wang Y, Dong M, Ma X, Sun B, Liu S, Zhao Z, Chen L, Liu K, Xin Y, Zhuang L. Lipid-induced DRAM recruits STOM to lysosomes and induces LMP to promote exosome release from hepatocytes in NAFLD. Sci Adv 2021;7:eabh1541. [PMID: 34731006 DOI: 10.1126/sciadv.abh1541] [Reference Citation Analysis]
635 Takeuchi M. Toxic AGEs (TAGE) theory: a new concept for preventing the development of diseases related to lifestyle. Diabetol Metab Syndr 2020;12:105. [PMID: 33292465 DOI: 10.1186/s13098-020-00614-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
636 Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, Urquhart B, Harvie R, Mckenzie C, Summers K, Reid G, Burton JP, Silverman M. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. Am J Gastroenterol 2020;115:1055-65. [DOI: 10.14309/ajg.0000000000000661] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis]
637 Lonardo A, Lugari S, Nascimbeni F. Non-alcoholic fatty liver disease (NAFLD) diagnosis and management-differentiating the essential from the ancillary and the present from the future. Hepatobiliary Surg Nutr 2020;9:374-8. [PMID: 32509834 DOI: 10.21037/hbsn.2019.11.12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
638 Lambrecht J, van Grunsven LA, Tacke F. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opin Pharmacother 2020;21:1637-50. [PMID: 32543284 DOI: 10.1080/14656566.2020.1774553] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
639 Yuan XX, Zhu HJ, Pan H, Chen S, Liu ZY, Li Y, Wang LJ, Lu L, Yang HB, Gong FY. Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients. World J Gastroenterol 2019; 25(14): 1741-1752 [PMID: 31011258 DOI: 10.3748/wjg.v25.i14.1741] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
640 Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 2020;158:1851-64. [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052] [Cited by in Crossref: 120] [Cited by in F6Publishing: 136] [Article Influence: 60.0] [Reference Citation Analysis]
641 Lin E, Huang X, Pei Z, Gross J, Popov V. Intragastric Balloon Improves Steatohepatitis and Fibrosis. ACG Case Rep J 2021;8:e00534. [PMID: 33490302 DOI: 10.14309/crj.0000000000000534] [Reference Citation Analysis]
642 Rom O, Liu Y, Finney AC, Ghrayeb A, Zhao Y, Shukha Y, Wang L, Rajanayake KK, Das S, Rashdan NA, Weissman N, Delgadillo L, Wen B, Garcia-Barrio MT, Aviram M, Kevil CG, Yurdagul A Jr, Pattillo CB, Zhang J, Sun D, Hayek T, Gottlieb E, Mor I, Chen YE. Induction of glutathione biosynthesis by glycine-based treatment mitigates atherosclerosis. Redox Biol 2022;52:102313. [PMID: 35447412 DOI: 10.1016/j.redox.2022.102313] [Reference Citation Analysis]
643 Xue J, Liang S, Ma J, Xiao Y. Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease. BMC Endocr Disord 2022;22:49. [PMID: 35216556 DOI: 10.1186/s12902-022-00967-y] [Reference Citation Analysis]
644 Petrelli A, Ravà L, Mascali A, Rapini N, Massoud M, Manca Bitti ML, Cianfarani S, Manco M. Estimated insulin sensitivity, cardiovascular risk, and hepatic steatosis after 12 years from the onset of T1D. Diabetes Metab Res Rev 2021;:e3479. [PMID: 34077603 DOI: 10.1002/dmrr.3479] [Reference Citation Analysis]
645 Stefan N. [New pharmacological treatment options for nonalcoholic fatty liver disease]. Internist (Berl) 2020;61:759-65. [PMID: 32409850 DOI: 10.1007/s00108-020-00801-4] [Reference Citation Analysis]
646 Kashiwagi K, Yamaguchi A, Shiba S, Taniki N, Inoue N, Takaishi H, Iwao Y, Kanai T. Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease. Alcohol 2020;89:1-7. [PMID: 32738385 DOI: 10.1016/j.alcohol.2020.07.010] [Reference Citation Analysis]
647 Foley PJ. Effect of low carbohydrate diets on insulin resistance and the metabolic syndrome. Curr Opin Endocrinol Diabetes Obes 2021;28:463-8. [PMID: 34468401 DOI: 10.1097/MED.0000000000000659] [Reference Citation Analysis]
648 Banaszczak M, Maciejewska D, Drozd A, Ryterska K, Milc DJ, Raszeja-Wyszomirska J, Wunsch E, González-Muniesa P, Stachowska E. 5-Lipooxygenase Derivatives as Serum Biomarkers of a Successful Dietary Intervention in Patients with NonAlcoholic Fatty Liver Disease. Medicina (Kaunas) 2020;56:E58. [PMID: 32028646 DOI: 10.3390/medicina56020058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
649 Moylan CA, Mavis AM, Jima D, Maguire R, Bashir M, Hyun J, Cabezas MN, Parish A, Niedzwiecki D, Diehl AM, Murphy SK, Abdelmalek MF, Hoyo C. Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children. Epigenetics 2022;:1-16. [PMID: 35188871 DOI: 10.1080/15592294.2022.2039850] [Reference Citation Analysis]
650 Varganova DL, Pavlov CS, Casazza G, Nikolova D, Gluud C; Cochrane Hepato-Biliary Group. Essential phospholipids for people with non-alcoholic fatty liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
651 Guo JY, Chen JC, Chen CY. Is there any useful surrogate to evaluate metabolic fatty liver disease? J Chin Med Assoc 2021;84:344-5. [PMID: 33742991 DOI: 10.1097/JCMA.0000000000000512] [Reference Citation Analysis]
652 Marques E, Pfohl M, Auclair A, Jamwal R, Barlock BJ, Sammoura FM, Goedken M, Akhlaghi F, Slitt AL. Perfluorooctanesulfonic acid (PFOS) administration shifts the hepatic proteome and augments dietary outcomes related to hepatic steatosis in mice. Toxicol Appl Pharmacol 2020;408:115250. [PMID: 32979393 DOI: 10.1016/j.taap.2020.115250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
653 Kositamongkol C, Charernboon T, Chaisathaphol T, Washirasaksiri C, Auesomwang C, Sitasuwan T, Charatcharoenwitthaya P, Phisalprapa P. Clinical predictive score for detecting nonalcoholic fatty liver disease with significant fibrosis in patients with metabolic syndrome. Medicine (Baltimore) 2021;100:e27640. [PMID: 34871234 DOI: 10.1097/MD.0000000000027640] [Reference Citation Analysis]
654 Goldman O, Ben-Assuli O, Rogowski O, Zeltser D, Shapira I, Berliner S, Zelber-Sagi S, Shenhar-Tsarfaty S. Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine. J Med Syst 2021;45:22. [PMID: 33426569 DOI: 10.1007/s10916-020-01693-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
655 Ledoux S, Coupaye M. Reply to the letter on "gastric bypass specifically impairs liver parameters compared with sleeve gastrectomy, independently of evolution of metabolic disorders". Surg Obes Relat Dis 2019;15:514. [PMID: 30803882 DOI: 10.1016/j.soard.2019.01.032] [Reference Citation Analysis]
656 Sargeant JA, Gray LJ, Bodicoat DH, Willis SA, Stensel DJ, Nimmo MA, Aithal GP, King JA. The effect of exercise training on intrahepatic triglyceride and hepatic insulin sensitivity: a systematic review and meta-analysis: Exercise, intrahepatic triglyceride and hepatic insulin sensitivity. Obesity Reviews 2018;19:1446-59. [DOI: 10.1111/obr.12719] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
657 Yang S, Cheng J, Zhang R, Sun H, Zhang H, Lyu S, Duan W. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. Hepatol Res 2021. [PMID: 34751487 DOI: 10.1111/hepr.13728] [Reference Citation Analysis]
658 Shi YW, Fan JG. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. Acta Pharmacol Sin 2021. [PMID: 34907360 DOI: 10.1038/s41401-021-00822-1] [Reference Citation Analysis]
659 Ikeda S, Sugihara T, Hoshino Y, Matsuki Y, Nagahara T, Okano JI, Kitao S, Fujioka Y, Yamamoto K, Isomoto H. Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease. Yonago Acta Med 2020;63:188-97. [PMID: 32884438 DOI: 10.33160/yam.2020.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
660 Seko Y, Yamaguchi K, Tochiki N, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, Umemura A, Moriguchi M, Itoh Y. The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease. Genes (Basel) 2021;12:628. [PMID: 33922278 DOI: 10.3390/genes12050628] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
661 Sui G, Jia L, Quan D, Zhao N, Yang G. Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults. Aging (Albany NY) 2021;13:21309-24. [PMID: 34473644 DOI: 10.18632/aging.203460] [Reference Citation Analysis]
662 García-Carretero R, Holgado-Cuadrado R, Barquero-Pérez Ó. Assessment of Classification Models and Relevant Features on Nonalcoholic Steatohepatitis Using Random Forest. Entropy (Basel) 2021;23:763. [PMID: 34204225 DOI: 10.3390/e23060763] [Reference Citation Analysis]
663 Papatheodoridi AM, Chrysavgis L, Koutsilieris M, Chatzigeorgiou A. The Role of Senescence in the Development of Nonalcoholic Fatty Liver Disease and Progression to Nonalcoholic Steatohepatitis. Hepatology. 2020;71:363-374. [PMID: 31230380 DOI: 10.1002/hep.30834] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 17.7] [Reference Citation Analysis]
664 Raikhelson KL, Kondrashina EA, Pazenko EV. [Mixed steatohepatitis: more questions than answers (Part 1)]. Ter Arkh 2020;92:91-6. [PMID: 33720580 DOI: 10.26442/00403660.2020.12.200470] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
665 Anand A, Shalimar, Jana M, Kandasamy D, Kumar B, Singh G, Jain V. Usefulness of Controlled Attenuation Parameter for Identification and Grading of Nonalcoholic Fatty Liver Disease in Adolescents with Obesity. Indian J Pediatr 2021. [PMID: 34324132 DOI: 10.1007/s12098-021-03842-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
666 Tsutsumi N, Nishimata S, Shimura M, Kashiwagi Y, Kawashima H. Hepcidin Levels and Pathological Characteristics in Children with Fatty Liver Disease. Pediatr Gastroenterol Hepatol Nutr 2021;24:295-305. [PMID: 34046333 DOI: 10.5223/pghn.2021.24.3.295] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
667 Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. Obesity (Silver Spring) 2021;29:1950-60. [PMID: 34553836 DOI: 10.1002/oby.23263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
668 Shiha G, Alswat K, Al Khatry M, Sharara AI, Örmeci N, Waked I, Benazzouz M, Al-Ali F, Hamed AE, Hamoudi W, Attia D, Derbala M, Sharaf-Eldin M, Al-Busafi SA, Zaky S, Bamakhrama K, Ibrahim N, Ajlouni Y, Sabbah M, Salama M, Anushiravani A, Afredj N, Barakat S, Hashim A, Fouad Y, Soliman R. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol 2021;6:57-64. [PMID: 33181119 DOI: 10.1016/S2468-1253(20)30213-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
669 Tada T, Kumada T, Toyoda H, Yasuda S, Sone Y, Hashinokuchi S, Ogawa S, Oguri T, Kamiyama N, Chuma M, Akita T, Tanaka J. Liver stiffness does not affect ultrasound‐guided attenuation coefficient measurement in the evaluation of hepatic steatosis. Hepatol Res 2020;50:190-8. [DOI: 10.1111/hepr.13442] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
670 Makri E, Kita M, Goulas A, Papaioannidou P, Efstathiadou ZA, Adamidou F, Polyzos SA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. Diabetes Metab Syndr 2020;14:1913-9. [PMID: 33011499 DOI: 10.1016/j.dsx.2020.09.030] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
671 Sjöstedt N, Neuhoff S, Brouwer KLR. Physiologically-Based Pharmacokinetic Model of Morphine and Morphine-3-Glucuronide in Nonalcoholic Steatohepatitis. Clin Pharmacol Ther 2021;109:676-87. [PMID: 32897538 DOI: 10.1002/cpt.2037] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
672 Schmitz SM, Kroh A, Ulmer TF, Andruszkow J, Luedde T, Brozat JF, Neumann UP, Alizai PH. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems. BMC Gastroenterol 2020;20:254. [PMID: 32758151 DOI: 10.1186/s12876-020-01400-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
673 Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:430-43. [PMID: 32791578 DOI: 10.3350/cmh.2020.0137] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
674 Chang WH, Mueller SH, Chung SC, Foster GR, Lai AG. Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost. J Transl Med 2022;20:2. [PMID: 34980174 DOI: 10.1186/s12967-021-03210-9] [Reference Citation Analysis]
675 Sekhon AK, Gollapalli A, Kaur D, Janssen B, Stevens ML, Valerio F, Sierra-Hoffman MA. A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH). Am J Case Rep 2021;22:e932961. [PMID: 34826302 DOI: 10.12659/AJCR.932961] [Reference Citation Analysis]
676 Cano R, Pérez JL, Dávila LA, Ortega Á, Gómez Y, Valero-Cedeño NJ, Parra H, Manzano A, Véliz Castro TI, Albornoz MPD, Cano G, Rojas-Quintero J, Chacín M, Bermúdez V. Role of Endocrine-Disrupting Chemicals in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review. Int J Mol Sci 2021;22:4807. [PMID: 34062716 DOI: 10.3390/ijms22094807] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
677 Zhang S, Wang Y, Wang Z, Wang H, Xue C, Li Q, Guan W, Yuan J. Rotating night shift work and non-alcoholic fatty liver disease among steelworkers in China: a cross-sectional survey. Occup Environ Med 2020;77:333-9. [PMID: 32019846 DOI: 10.1136/oemed-2019-106220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
678 Tran C, Kim JJ, Feld JJ, Wong WW. Cost-effectiveness of obeticholic acid for the treatment of non-alcoholic steatohepatitis: An early economic evaluation. CanLivJ 2021;4:360-9. [DOI: 10.3138/canlivj-2021-0011] [Reference Citation Analysis]
679 Soresi M, Cabibi D, Giglio RV, Martorana S, Guercio G, Porcasi R, Terranova A, Lazzaro LA, Emma MR, Augello G, Cervello M, Pantuso G, Montalto G, Giannitrapani L. The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods.Biomed Res Int. 2020;2020:5023157. [PMID: 32420347 DOI: 10.1155/2020/5023157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
680 Stefan N. [New aspects of nonalcoholic steatohepatitis]. Internist (Berl) 2019;60:128-32. [PMID: 30645665 DOI: 10.1007/s00108-018-0550-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
681 Baikpour M, Ozturk A, Dhyani M, Mercaldo ND, Pierce TT, Grajo JR, Samir AE. Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Nonalcoholic Fatty Liver Disease. AJR Am J Roentgenol 2020;214:786-91. [PMID: 31939698 DOI: 10.2214/AJR.19.21963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
682 Ofosu A, Ramai D, Reddy M. Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. Ann Gastroenterol. 2018;31:288-295. [PMID: 29720854 DOI: 10.20524/aog.2018.0240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
683 Venkatesh SK, Torbenson MS. Liver fibrosis quantification. Abdom Radiol. [DOI: 10.1007/s00261-021-03396-y] [Reference Citation Analysis]
684 Wang YL, Zhou X, Li DL, Ye JM. Role of the mTOR-autophagy-ER stress pathway in high fructose-induced metabolic-associated fatty liver disease. Acta Pharmacol Sin 2021. [PMID: 33731774 DOI: 10.1038/s41401-021-00629-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
685 Yang D, Zhang X, Yue L, Hu H, Wei X, Guo Q, Zhang B, Fan X, Xin Y, Oh Y, Gu N. Thiamethoxam induces nonalcoholic fatty liver disease in mice via methionine metabolism disturb via nicotinamide N-methyltransferase overexpression. Chemosphere 2021;273:129727. [PMID: 33524747 DOI: 10.1016/j.chemosphere.2021.129727] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
686 He K, Li J, Xi W, Ge J, Sun J, Jing Z. Dapagliflozin for nonalcoholic fatty liver disease: a systematic review and meta-analysis. Diabetes Res Clin Pract 2022;:109791. [PMID: 35202771 DOI: 10.1016/j.diabres.2022.109791] [Reference Citation Analysis]
687 Wu CT, Chu TW, Jang JR. Current-Visit and Next-Visit Prediction for Fatty Liver Disease With a Large-Scale Dataset: Model Development and Performance Comparison. JMIR Med Inform 2021;9:e26398. [PMID: 34387552 DOI: 10.2196/26398] [Reference Citation Analysis]
688 Elalfy H, El-Maksoud MA, Abed S, El Aziz MA, Elsamanoudy AZ, Abo El-Khair SM, Mohamed MA, Elkashef W, Zalata K, Farag R, Arafa M. Clinicopathological impact of anti-smooth muscle antibodies in patients with non-alcoholic fatty liver disease. Br J Biomed Sci 2019;76:101-3. [PMID: 30700210 DOI: 10.1080/09674845.2019.1575532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
689 White CM, Lee JY. The impact of turmeric or its curcumin extract on nonalcoholic fatty liver disease: a systematic review of clinical trials. Pharm Pract (Granada) 2019;17:1350. [PMID: 31015871 DOI: 10.18549/PharmPract.2019.1.1350] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
690 Petrtýl J, Dvořák K, Stříteský J, Leníček M, Jirásková A, Šmíd V, Haluzík M, Brůha R, Vítek L. Association of Serum Bilirubin and Functional Variants of Heme Oxygenase 1 and Bilirubin UDP-Glucuronosyl Transferase Genes in Czech Adult Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants (Basel) 2021;10:2000. [PMID: 34943103 DOI: 10.3390/antiox10122000] [Reference Citation Analysis]
691 Radun R, Trauner M. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Semin Liver Dis 2021. [PMID: 34289507 DOI: 10.1055/s-0041-1731707] [Reference Citation Analysis]
692 Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067. [PMID: 32118201 DOI: 10.1016/j.jhepr.2020.100067] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 23.5] [Reference Citation Analysis]
693 Perez-Diaz-Del-Campo N, Marin-Alejandre BA, Cantero I, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Riezu-Boj JI, Milagro FI, Tur JA, Martinez JA, Abete I, Zulet MA. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study. Eur J Nutr 2021;60:3043-57. [PMID: 33474638 DOI: 10.1007/s00394-020-02476-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
694 Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17:e1003100. [PMID: 32353039 DOI: 10.1371/journal.pmed.1003100] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
695 Glass O, Filozof C, Noureddin M, Berner-Hansen M, Schabel E, Omokaro SO, Schattenberg JM, Barradas K, Miller V, Francque S, Abdelmalek MF; Liver Forum Standard of Care Working Group. Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. J Hepatol 2020;73:680-93. [PMID: 32353483 DOI: 10.1016/j.jhep.2020.04.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
696 Wilechansky RM, Pedley A, Massaro JM, Hoffmann U, Benjamin EJ, Long MT. Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis. Liver Int 2019;39:1535-44. [PMID: 31033142 DOI: 10.1111/liv.14125] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
697 Attia SL, Softic S, Mouzaki M. Evolving Role for Pharmacotherapy in NAFLD/NASH. Clin Transl Sci 2021;14:11-9. [PMID: 32583961 DOI: 10.1111/cts.12839] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
698 Hunter H, de Gracia Hahn D, Duret A, Im YR, Cheah Q, Dong J, Fairey M, Hjalmarsson C, Li A, Lim HK, McKeown L, Mitrofan CG, Rao R, Utukuri M, Rowe IA, Mann JP. Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver. Elife 2020;9:e56573. [PMID: 33063664 DOI: 10.7554/eLife.56573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
699 Bakhshimoghaddam F, Alizadeh M. Modulation of the gut microbiota represents a new management for non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr 2020;9:223-6. [PMID: 32355686 DOI: 10.21037/hbsn.2019.10.01] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
700 Alkhouri N, Lawitz E, Noureddin M. Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment. Hepatol Commun 2019;3:605-13. [PMID: 31061949 DOI: 10.1002/hep4.1342] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
701 Hoozemans J, de Brauw M, Nieuwdorp M, Gerdes V. Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review. Metabolites 2021;11:353. [PMID: 34072995 DOI: 10.3390/metabo11060353] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
702 Gautam CS, Sharma J, Singla M, Tiwana IK, Singh H. Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls. touchREV Endocrinol 2021;17:33-6. [PMID: 35118444 DOI: 10.17925/EE.2021.17.1.33] [Reference Citation Analysis]
703 Devasthale P, Cheng D. Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH). J Med Chem 2018;61:9879-88. [PMID: 29986142 DOI: 10.1021/acs.jmedchem.8b00864] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
704 Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(39): 5919-5943 [PMID: 33132645 DOI: 10.3748/wjg.v26.i39.5919] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
705 Kim TH, Lee Y, Lee YS, Gim JA, Ko E, Yim SY, Jung YK, Kang S, Kim MY, Kim H, Kim BH, Kim JH, Seo YS, Yim HJ, Yeon JE, Um SH, Byun KS. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. Sci Rep 2021;11:14639. [PMID: 34282172 DOI: 10.1038/s41598-021-94115-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
706 Chen LZ, Ding HY, Liu SS, Liu Q, Jiang XJ, Xin YN, Xuan SY. Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China. Lipids Health Dis 2019;18:45. [PMID: 30738435 DOI: 10.1186/s12944-019-0992-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
707 Takata N, Ishii KA, Takayama H, Nagashimada M, Kamoshita K, Tanaka T, Kikuchi A, Takeshita Y, Matsumoto Y, Ota T, Yamamoto Y, Yamagoe S, Seki A, Sakai Y, Kaneko S, Takamura T. LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH. Sci Rep 2021;11:555. [PMID: 33436955 DOI: 10.1038/s41598-020-80689-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
708 Głuszyńska P, Lemancewicz D, Dzięcioł JB, Razak Hady H. Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review. J Clin Med 2021;10:5721. [PMID: 34945016 DOI: 10.3390/jcm10245721] [Reference Citation Analysis]
709 Zou ZY, Zeng J, Ren TY, Shi YW, Yang RX, Fan JG. Efficacy of Intragastric Balloons in the Markers of Metabolic Dysfunction-associated Fatty Liver Disease: Results from Meta-analyses. J Clin Transl Hepatol 2021;9:353-63. [PMID: 34221921 DOI: 10.14218/JCTH.2020.00183] [Reference Citation Analysis]
710 Lee DH. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) 2020;35:243-59. [PMID: 32615709 DOI: 10.3803/EnM.2020.35.2.243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
711 Marin-Alejandre BA, Abete I, Cantero I, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano JI, Huarte-Muniesa MP, Tur JA, Martinez JA, Zulet MA. The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. Nutrients 2019;11:E2543. [PMID: 31652512 DOI: 10.3390/nu11102543] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
712 Sales RC, Medeiros PC, Spreafico F, de Velasco PC, Gonçalves FKA, Martín-Hernández R, Mantilla-Escalante DC, Gil-Zamorano J, Peres WAF, de Souza SAL, Dávalos A, Tavares do Carmo MG. Olive Oil, Palm Oil, and Hybrid Palm Oil Distinctly Modulate Liver Transcriptome and Induce NAFLD in Mice Fed a High-Fat Diet. Int J Mol Sci 2018;20:E8. [PMID: 30577497 DOI: 10.3390/ijms20010008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
713 de Gregorio E, Colell A, Morales A, Marí M. Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease. Int J Mol Sci 2020;21:E3858. [PMID: 32485811 DOI: 10.3390/ijms21113858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
714 Iritani S, Akuta N, Kawamura Y, Kajiwara A, Kasuya K, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saito S, Suzuki F, Arase Y, Ikeda K, Suzuki Y, Kumada H. Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. BMC Gastroenterol 2020;20:368. [PMID: 33148171 DOI: 10.1186/s12876-020-01509-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
715 Pais R, Maurel T. Natural History of NAFLD. J Clin Med 2021;10:1161. [PMID: 33802047 DOI: 10.3390/jcm10061161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
716 Shan MY, Dai Y, Ren XD, Zheng J, Zhang KB, Chen B, Yan J, Xu ZH. Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis. J Integr Med 2021;19:545-54. [PMID: 34686466 DOI: 10.1016/j.joim.2021.09.003] [Reference Citation Analysis]
717 Ali H, Kazmi M, Choi C, Hashemipour R, Singh I, Pyrsopoulos NT. In-Hospital Outcomes of Patients With Non-Alcoholic Fatty Liver Disease Who Underwent Percutaneous Coronary Intervention: A Nationwide Inpatient Sample Analysis. Cureus 2021;13:e17338. [PMID: 34430188 DOI: 10.7759/cureus.17338] [Reference Citation Analysis]
718 Finotti M, Romano M, Auricchio P, Scopelliti M, Brizzolari M, Grossi U, Piccino M, Benvenuti S, Morana G, Cillo U, Zanus G. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. J Pers Med 2021;11:499. [PMID: 34199535 DOI: 10.3390/jpm11060499] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
719 Sampson CM, Dimet AL, Neelakantan H, Ogunseye KO, Stevenson HL, Hommel JD, Watowich SJ. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Sci Rep 2021;11:5637. [PMID: 33707534 DOI: 10.1038/s41598-021-85051-6] [Reference Citation Analysis]
720 Wang N, Wang Y, Chen X, Zhang W, Chen Y, Xia F, Wan H, Li Q, Jiang B, Hu B, Lu Y. Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes. Front Endocrinol (Lausanne) 2019;10:926. [PMID: 32063885 DOI: 10.3389/fendo.2019.00926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
721 Ferraioli G, Kumar V, Ozturk A, Nam K, de Korte CL, Barr RG. US Attenuation for Liver Fat Quantification: An AIUM-RSNA QIBA Pulse-Echo Quantitative Ultrasound Initiative. Radiology 2022;:210736. [PMID: 35076304 DOI: 10.1148/radiol.210736] [Reference Citation Analysis]
722 Castillo-Leon E, Cioffi CE, Vos MB. Perspectives on youth-onset nonalcoholic fatty liver disease. Endocrinol Diabetes Metab 2020;3:e00184. [PMID: 33102800 DOI: 10.1002/edm2.184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
723 Yao J, Liang X, Liu Y, Zheng M. Neddylation: A Versatile Pathway Takes on Chronic Liver Diseases. Front Med (Lausanne) 2020;7:586881. [PMID: 33195347 DOI: 10.3389/fmed.2020.586881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
724 Sirli R, Sporea I. Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use? Can J Gastroenterol Hepatol 2021;2021:6662760. [PMID: 33834008 DOI: 10.1155/2021/6662760] [Reference Citation Analysis]
725 Xie M, Tang H, Li F, Wu S, Dong Y, Yang Y, Baker JS, Ma J. Mediating Roles of hsCRP, TNF-α and Adiponectin on the Associations between Body Fat and Fatty Liver Disease among Overweight and Obese Adults. Biology (Basel) 2021;10:895. [PMID: 34571772 DOI: 10.3390/biology10090895] [Reference Citation Analysis]
726 Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9:E2648. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
727 Pereira ENGDS, Paula DP, Araujo BP, Fonseca MJMD, Diniz MFHS, Daliry A, Griep RH. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. World J Gastroenterol 2021; 27(29): 4913-4928 [PMID: 34447235 DOI: 10.3748/wjg.v27.i29.4913] [Reference Citation Analysis]
728 Umbro I, Baratta F, Angelico F, Del Ben M. Nonalcoholic Fatty Liver Disease and the Kidney: A Review. Biomedicines 2021;9:1370. [PMID: 34680486 DOI: 10.3390/biomedicines9101370] [Reference Citation Analysis]
729 Soto-Angona Ó, Anmella G, Valdés-Florido MJ, De Uribe-Viloria N, Carvalho AF, Penninx BWJH, Berk M. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. BMC Med 2020;18:261. [PMID: 32998725 DOI: 10.1186/s12916-020-01713-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
730 Xie J, Huang H, Chen Y, Xu L, Xu C. Skipping breakfast is associated with an increased long-term cardiovascular mortality in metabolic dysfunction-associated fatty liver disease (MAFLD) but not MAFLD-free individuals. Aliment Pharmacol Ther 2022;55:212-24. [PMID: 34877669 DOI: 10.1111/apt.16727] [Reference Citation Analysis]
731 Harrison SA, Baum SJ, Gunn NT, Younes ZH, Kohli A, Patil R, Koziel MJ, Chera H, Zhao J, Chakravarthy MV. Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2021. [PMID: 34382947 DOI: 10.14309/ajg.0000000000001375] [Reference Citation Analysis]
732 Chen S, Che S, Li S, Ruan Z. The combined impact of decabromodiphenyl ether and high fat exposure on non-alcoholic fatty liver disease in vivo and in vitro. Toxicology 2021;464:153015. [PMID: 34757160 DOI: 10.1016/j.tox.2021.153015] [Reference Citation Analysis]
733 Liu L, Xie S, Teng Y, Deng Z, Chen K, Liu H, Huo R, Liang X, Guo P, Yang D, Ma L, Xiang B, Li L, Zhong J. Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. Front Oncol 2022;11:783339. [DOI: 10.3389/fonc.2021.783339] [Reference Citation Analysis]
734 García-Carretero R, Barquero-Pérez O, Mora-Jiménez I, Soguero-Ruiz C, Goya-Esteban R, Rodríguez-Castro C, Ramos-López J. [Prevalence and clinical features of non-alcoholic steatohepatitis in a hypertensive population]. Hipertens Riesgo Vasc 2019;36:130-6. [PMID: 30655210 DOI: 10.1016/j.hipert.2018.10.001] [Reference Citation Analysis]
735 Chen YL, Li H, Li S, Xu Z, Tian S, Wu J, Liang XY, Li X, Liu ZL, Xiao J, Wei JY, Ma CY, Wu KN, Ran L, Kong LQ. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol 2021;21:212. [PMID: 33971822 DOI: 10.1186/s12876-021-01782-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
736 Lee MCM, Kachura JJ, Vlachou PA, Dzulynsky R, Di Tomaso A, Samawi H, Baxter N, Brezden-Masley C. Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer. Curr Oncol 2021;28:3030-40. [PMID: 34436031 DOI: 10.3390/curroncol28040265] [Reference Citation Analysis]
737 Arora A, Kumar A, Prasad N, Duseja A, Acharya SK, Agarwal SK, Aggarwal R, Anand AC, Bhalla AK, Choudhary NS, Chawla YK, Dhiman RK, Dixit VK, Gopalakrishnan N, Gupta A, Hegde UN, Jasuja S, Jha V, Kher V, Kumar A, Madan K, Maiwall R, Mathur RP, Nayak SL, Pandey G, Pandey R, Puri P, Rai RR, Raju SB, Rana DS, Rao PN, Rathi M, Saraswat VA, Saxena S, Shalimar, Sharma P, Singh SP, Singal AK, Soin AS, Taneja S, Varughese S. INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease. J Clin Exp Hepatol 2021;11:354-86. [PMID: 33994718 DOI: 10.1016/j.jceh.2020.09.005] [Reference Citation Analysis]
738 Alswat KA, Fallatah HI, Al-Judaibi B, Elsiesy HA, Al-Hamoudi WK, Qutub AN, Alturaify N, Al-Osaimi A. Position statement on the diagnosis and management of non-alcoholic fatty liver disease. Saudi Med J 2019;40:531-40. [PMID: 31219486 DOI: 10.15537/smj.2019.6.23980] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
739 Kalogirou MS, Patoulias D, Haidich AB, Akriviadis E, Sinakos E. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 2021;45:101568. [PMID: 33309563 DOI: 10.1016/j.clinre.2020.10.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
740 Khoudari G, Singh A, Noureddin M, Fritze D, Lopez R, Asaad I, Lawitz E, Poordad F, Kowdley KV, Alkhouri N. Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. World J Hepatol 2019; 11(10): 710-718 [PMID: 31749901 DOI: 10.4254/wjh.v11.i10.710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
741 Lominadze Z, Kallwitz ER. Misconception: You Can't Have Liver Disease With Normal Liver Chemistries. Clin Liver Dis (Hoboken) 2018;12:96-9. [PMID: 30988921 DOI: 10.1002/cld.742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
742 Ye FZ, Liu WY, Zheng KI, Pan XY, Ma HL, Wang XD, Chen YP, Zheng MH. Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2020;32:80-6. [PMID: 31625959 DOI: 10.1097/MEG.0000000000001483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
743 Charatcharoenwitthaya P, Kuljiratitikal K, Aksornchanya O, Chaiyasoot K, Bandidniyamanon W, Charatcharoenwitthaya N. Moderate-Intensity Aerobic vs Resistance Exercise and Dietary Modification in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial. Clin Transl Gastroenterol 2021;12:e00316. [PMID: 33939383 DOI: 10.14309/ctg.0000000000000316] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
744 Jun JH, Lee SK, Kim SY, Cho DH, Song TJ, Park DH, Lee SS, Seo DW, Kim MH. Comparison between groove carcinoma and groove pancreatitis. Pancreatology. 2018;18:805-811. [PMID: 30224296 DOI: 10.1016/j.pan.2018.08.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
745 Sanyal A, Charles ED, Neuschwander-tetri BA, Loomba R, Harrison SA, Abdelmalek MF, Lawitz EJ, Halegoua-demarzio D, Kundu S, Noviello S, Luo Y, Christian R. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet 2018;392:2705-17. [DOI: 10.1016/s0140-6736(18)31785-9] [Cited by in Crossref: 156] [Cited by in F6Publishing: 88] [Article Influence: 39.0] [Reference Citation Analysis]
746 Bril F, McPhaul MJ, Kalavalapalli S, Lomonaco R, Barb D, Gray ME, Shiffman D, Rowland CM, Cusi K. Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. J Clin Endocrinol Metab 2021:dgab417. [PMID: 34190318 DOI: 10.1210/clinem/dgab417] [Reference Citation Analysis]
747 Yang YJ, Bang CS, Choi JH, Lee JJ, Shin SP, Suk KT, Baik GH, Kim DJ. Alcohol consumption is associated with the risk of developing colorectal neoplasia: Propensity score matching analysis. Sci Rep 2019;9:8253. [PMID: 31164696 DOI: 10.1038/s41598-019-44719-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
748 Erman H, Beydogan E, Cetin SI, Boyuk B. Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome. Mediators Inflamm 2020;2020:3534042. [PMID: 32317862 DOI: 10.1155/2020/3534042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
749 Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. Life (Basel) 2021;11:143. [PMID: 33672864 DOI: 10.3390/life11020143] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
750 Mandala A, Janssen RC, Palle S, Short KR, Friedman JE. Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms. Nutrients 2020;12:E3166. [PMID: 33081177 DOI: 10.3390/nu12103166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
751 Ferro D, Baratta F, Pastori D, Cocomello N, Colantoni A, Angelico F, Del Ben M. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients 2020;12:E2762. [PMID: 32927776 DOI: 10.3390/nu12092762] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
752 Liebe R, Esposito I, Bock HH, Vom Dahl S, Stindt J, Baumann U, Luedde T, Keitel V. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol 2021;74:1455-71. [PMID: 33577920 DOI: 10.1016/j.jhep.2021.01.045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
753 Arnouk J, Rachakonda VP, Jaiyeola D, Behari J. Differential Outcomes and Clinical Challenges of NAFLD With Extreme Obesity. Hepatol Commun 2020;4:1419-29. [PMID: 33024913 DOI: 10.1002/hep4.1572] [Reference Citation Analysis]
754 Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. J Am Coll Cardiol 2022;79:180-91. [PMID: 35027111 DOI: 10.1016/j.jacc.2021.11.007] [Reference Citation Analysis]
755 Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Rep 2020;2:100192. [PMID: 33163950 DOI: 10.1016/j.jhepr.2020.100192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
756 Shanahan W, Bagwe I, Brassill MJ, O'Regan P. Reduced and more appropriate referrals of patients with type 2 diabetes using liver stiffness measurement compared to FIB-4. Ir J Med Sci 2022. [PMID: 35486350 DOI: 10.1007/s11845-022-03019-5] [Reference Citation Analysis]
757 Casler K, Trees K, Bosak K. Providing Care for Fatty Liver Disease Patients: Primary Care Nurse Practitioners' Knowledge, Actions, and Preparedness. Gastroenterol Nurs 2020;43:E184-9. [PMID: 32889968 DOI: 10.1097/SGA.0000000000000487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
758 Younossi Z, Stepanova M, Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Schall RA, McColgan B, Subramanian GM, Myers RP, Muir A, Afdhal NH, Bosch J, Goodman Z. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.